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Chronic obstructive pulmonary disease (COPD) is a common, preventable and 
treatable disease. It is characterized by persistent respiratory symptoms and air-
flow limitation that is due to airway and/or alveolar abnormalities usually caused by 
significant exposure to noxious particles or gases.1 Tobacco smoking is the main 
risk factor for COPD, but other environmental exposures, such as air pollution and 
biomass fuel exposure, may also contribute. Furthermore, host factors, such as 
genetic factors and accelerated aging, predispose individuals to develop COPD.1 
Both the prevalence and burden of COPD is rising worldwide. COPD accounts 
for 6% of all deaths globally and is projected to become the third leading cause 
of morbidity and mortality worldwide by 2030.2 In the Netherlands, the prevalence 
of COPD is estimated to be around 2% across all ages. However, as COPD is 
strongly related to age, estimated prevalences rise up to more than 10% in those 
aged 40 years and older. As a result of the ageing population and changes in 
demographics, the prevalence of COPD in the Netherlands is expected to increase 
by 36% between 2010 and 2040. COPD already accounts for more than 6,000 
deaths and 22,000 hospital admissions each year, thereby representing a substan-
tial and growing burden for individual patients and for the Dutch society in terms of 
healthcare organisation and costs.3 
Diagnosis of COPD is based on clinical symptoms (dyspnoea, cough and sputum 
production are the most common symptoms) and patient characteristics (age > 
40 years, history of exposure to risk factors), in combination with spirometry.2 
Traditionally, disease severity was solely based on the degree of persistent airflow 
obstruction (obtained by spirometry) and classified according to the global initiative 
for chronic obstructive lung disease (GOLD) classification. However, more recent 
evidence shows that lung function alone does not correlate well with patient’s ex-
perience of disease severity and quality of life.2,4 Although the degree of persistent 
airflow obstruction remains the cornerstone of diagnosis, GOLD guidelines now 
recommend that disease severity is determined by a combined assessment of 
airflow obstruction, exacerbation frequency and symptom burden (Figure 1).1 
Furthermore, several extra-pulmonary symptoms (e.g. limited functional status 
and exercise capacity, poor nutritional status, co-morbidity) negatively influence 
quality of life and prognosis in individual patients. Many of these extra-pulmonary 
symptoms of COPD can also be seen as characteristics of older, geriatric patients 
in general. Therefore, they can accumulate in older patients with COPD, ultimately 
leading to a vicious circle of deteriorating health status and poor prognosis.5-7
Acute exacerbations in COPD, defined as an acute worsening of respiratory 
symptoms that result in additional therapy, play a key role. These exacerbations 
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represent a major burden for individual patients, are the most frequent reason for 
hospital admission and death among patients with COPD, and negatively influence 
quality of life and exercise capacity, often leading to readmissions, further decline 
of health status and high mortality rates.7-10 In patients who lack sufficient recovery 
during hospital stay, and in patients with frequent exacerbations and hospital read-
missions, pulmonary rehabilitation is recommended.9
Pulmonary rehabilitation after hospital admission for acute exacerbations (i.e. 
postacute pulmonary rehabilitation) has proven to be an effective treatment with 
positive effects on quality of life, exercise capacity, hospital readmissions and mor-
tality.9 However, despite proven benefits, many older patients with COPD do not 
receive postacute pulmonary rehabilitation in daily practice.11 Several reasons for 
this underuse have emerged. First, many physicians do not recommend postacute 
pulmonary rehabilitation to their older patients; this lack of referral can be related 
to the more impaired clinical and functional status of these older patients, who are 
more likely to present with frailty, higher burden of co-morbidities, and disability. 
Secondly, patients that are referred are less likely to participate, also mainly due 
to poor health status and other age-related problems.12 This is also caused by 
(temporary) care dependency after hospital admission which requires a specific 
setting for rehabilitation, including support and training of activities of daily living 
and a fluent transition from hospital admission to rehabilitation setting. Finally, in 
many older patients hospitalised for an acute exacerbation of COPD, palliative care 
methods and advance care planning are indicated because of their poor quality of 
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13 However, palliative care is still scarcely received by patients 
with severe COPD, and integration of palliative care into (postacute) pulmonary 
rehabilitation is recommended but not yet implemented in practice.14
To summarise, COPD is a significant and growing problem among older adults. Ex-
acerbations play a key role in terms of quality of life, prognosis and costs. Although 
postacute rehabilitation is effective and recommended, older patients with more 
advanced COPD often have additional specific age-related problems and needs 
that render referral and uptake of pulmonary rehabilitation difficult. Therefore, 
there is a need for specifically designed postacute rehabilitation programs for older 
patients with COPD.  
Geriatric rehabilitation
Geriatric rehabilitation can be an interesting option for older patients hospitalised 
for an acute exacerbation of COPD. Geriatric rehabilitation has emerged as a rela-
tively young but important and evolving field of interest in both clinical practice and 
scientific research. Geriatric rehabilitation is defined as “evaluative, diagnostic and 
therapeutic interventions whose purpose is to restore functional ability or enhance 
residual functional capability in older people with disabling impairments”.15 In the 
Netherlands, geriatric rehabilitation is provided as a form of postacute rehabilita-
tion, offered at skilled nursing facilities, usually situated in nursing homes, and 
organised as structured-care pathways in close collaboration with several medical 
departments of adjacent hospital(s). Geriatric rehabilitation does not differ from 
rehabilitation medicine in its approach and aims, but patients admitted for geriatric 
rehabilitation generally have specific characteristics, problems and needs as-
sociated with ageing. For example, they often have complex health issues due 
to co-morbidities, and may suffer from limited functional status, sarcopenia and 
cognitive problems. Furthermore, loneliness due to loss of social role or work and 
spiritual questions, including advance care planning, are common. In this sense, 
geriatric rehabilitation operates at the cross-roads of geriatric medicine, rehabilita-
tion medicine and palliative care.16 
Geriatric rehabilitation can improve outcomes related to function, nursing home 
admissions, and mortality.16 However, until now, evidence of this could only be 
acquired from two types of geriatric rehabilitation programs, i.e. general and or-
thopaedic geriatric rehabilitation.16 Studies on the effectiveness of rehabilitation 
programs specifically designed for geriatric patients in other clinical specialties 
(e.g. pulmonary, cardiac or stroke) are still lacking. This indicates the need and 
importance for the development, implementation and evaluation of other types of 
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geriatric rehabilitation programs, since they may have the potential to change clini-
cal practice in the future.16
In view of the ageing populations worldwide, appropriate rehabilitation programs 
for older patients are needed. On the other hand, increasing healthcare costs 
also call for appropriate and cost-effective use of rehabilitation resources.17,18 This 
implies screening or case finding of patients (e.g. with COPD) who are most likely 
to benefit from geriatric rehabilitation, and selecting the most appropriate setting for 
each patient, since the goal is to provide the right type of care, at the right moment, 
in the right setting, to the right patient. 
Palliative care in COPD
In many older patients with more advanced COPD, optimal pharmacologic therapy 
produces only moderate or incomplete relief from symptoms, resulting in signifi-
cantly impaired quality of life.19 Considering the poor quality of life and prognosis 
in these patients, palliative care is indicated and should start early in the disease 
trajectory, combined with active and restorative treatments, such as rehabilitation 
(Figure 2).13 In fact, it is advocated that integration of palliative care into pulmonary 
rehabilitation, and vice versa, is warranted.20,21 However, in daily practice such 
integration can be challenging since rehabilitation medicine and palliative care are 
usually organised as two separate domains in health care. In geriatric rehabilita-
tion, however, rehabilitation and palliative care methods are already combined.16
Adequate symptom management is considered to be a key part of palliative care 
and is also important to achieve optimal effect of rehabilitation. Patients with ad-
vanced COPD suffer from many symptoms, of which dyspnoea, cough and sputum 
production are the most commonly known. Recent literature indicated that pain 
is also a significant, but largely unrecognised, underestimated and undertreated 
symptom in patients with COPD.22,23 Furthermore, in patients with COPD, other 
symptoms, like dyspnoea, anxiety, depression and insomnia, seem to be associated 
with pain.24 These multiple concurrent symptoms can cluster and aggravate each 
other, causing what has been called the ‘vicious COPD circle’.23 In this concept, 
pain was described as “tying up the body”, which makes breathing difficult, thereby 
leading to more breathlessness and pain. Pain also induced anxiety, depression 
and insomnia, causing more pain and psychological problems.23 In COPD, pain 
is also related to diminished quality of life.25 Subsequently, pain might negatively 
influence outcomes of postacute pulmonary rehabilitation in COPD. On the other 
hand, postacute pulmonary rehabilitation can also be seen as a possible non-
pharmacological intervention to reduce pain in COPD, as it might counteract the 
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pain-related vicious circles in COPD.23 As pain management is preferably under-
taken using multi-domain strategies (e.g. psychological, physical, behavioural and 
pharmacological), it might be a separate goal in postacute pulmonary rehabilitation 
by means of improving muscle strength, exercise capacity and coping. However, 
studies on this topic are lacking, as are investigations on the eff ect of integrating 
standard pain assessment and treatment into rehabilitation programs. 
Figure 2. Care models illustrating three diff erent concepts of palliative care versus curative 



























































Model adapted from Lanken et al13. The third (C), individually integrated model is recommend-
ed as the preferred approach, in which patients receive palliative care (blue line) when they 
become symptomatic, concurrently with curative and restorative treatment, such as rehabilita-
tion (black line), in an individualised manner, based on their symptoms and disease trajectory. 
The red circle indicates the position of geriatric rehabilitation within this model.
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The GR_COPD program
In view of the above issues related to COPD in older patients, geriatric rehabilita-
tion and palliative care, the GR_COPD program was developed and implemented 
as a structured-care pathway in clinical practice (Figure 3). This new program 
offers multidisciplinary patient-centred rehabilitation that integrates palliative care 
methods, to older patients with COPD who have been hospitalised for an acute 
exacerbation. The program aims to counteract or stabilise the gradual decline in 
health status, achieve sustainable improvements in functional status, quality of life 
and self-management, and prevent hospital readmissions. As the feasibility and 
effectiveness of such a program for this specific group (i.e. older patients with 
advanced COPD) in this specific setting (geriatric rehabilitation) are unknown, 
research was needed. After describing the specific characteristics of the program, 
the feasibility of the program had to be established, the outcome measurements 
to be used in these patients had to be determined, and the effectiveness of the 
GR_COPD program had to be investigated. 
Aims and outline of this thesis
The primary aim of this thesis was to investigate the feasibility and effectiveness of 
the GR_COPD program; a geriatric rehabilitation program that integrated palliative 
care aspects, for older patients with advanced COPD hospitalized for an acute 
exacerbation. Therefore,  four studies, that included two different study populations 
and a systematic review and meta-analysis of the literature, were developed and 
executed. 
Part one of this thesis focusses on the GR_COPD program itself, the feasibility 
study, and the GR_COPD study that examined the effectiveness of the GR_COPD 
program. In chapter 2 the characteristics of the GR_COPD program are described, 
illustrated by three case studies of patients that were admitted to the GR_COPD 
program. The three cases that are presented illustrate why integration of reha-
bilitation and palliative care methods is needed and how this can be implemented 
into clinical practice. Chapter 3 presents the results of the feasibility study. The 
feasibility study consisted of a retrospective real-life case series of patients receiv-
ing the GR_COPD program. Aim of this study was to investigate feasibility in terms 
of patient characteristics, suitability, safety and preliminary evaluation of patient 
response to the GR_COPD program. Furthermore, defining a suitable, valid and 
reliable outcome measure that is also sensitive to change in response to the pro-
gram, in this specific group and setting, was needed. Therefore, chapter 4 presents 
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Figure 3. Flowchart of the GR_COPD program
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Abbreviations: SNF, skilled nursing facility; ADL, activities of daily living; CA, comprehensive 
assessment
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results from the feasibility study that investigated the responsiveness of the clinical 
COPD questionnaire (CCQ) in this specific group and setting. After completion of 
the feasibility study, the subsequent GR_COPD study was developed and aimed 
to investigate the effectiveness of the GR_COPD program on health status, as 
measured with the CCQ, as primary outcome. Results of the GR_COPD study, 
a real-life prospective cohort study with a follow-up period of three months, are 
presented in chapter 5.  
Part two of this thesis focuses on the palliative care aspects in COPD, with a more 
specific focus on symptom burden in general, and pain in patients with COPD, 
in particular. Chapter 6 presents the results of the systematic review and meta-
analysis study on pain in COPD, that aimed to systematically investigate published 
reports on the prevalence of pain, the characteristics of pain and factors related 
to pain, in patients with COPD. Chapter 7 provides the results of cross-sectional 
data from the GR_COPD study, that investigated the prevalence of pain and its 
characteristics and relationships in patients with COPD, hospitalized for an acute 
exacerbation and indicated for the GR_COPD program. 
In chapter 8, the summary and general discussion of this thesis, the main findings 
emerging from this work are presented and are placed into a broader perspective. 
Methodological considerations of the four studies are addressed and interpreted in 
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2Geriatric Rehabilitation for patients with advanced COPD:  programme characteristics and 
case studies 
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Considering the worldwide ageing population, there is a growing need for rehabili-
tation programmes especially designed for geriatric patients. The authors devel-
oped and implemented a post-acute geriatric rehabilitation programme in a skilled 
nursing facility for patients with advanced chronic obstructive pulmonary disease 
(COPD); the GR-COPD programme. This paper describes the characteristics of 
the programme and presents three case studies to illustrate its possible benefits 
for individual patients. The case studies show that integration of rehabilitation and 
palliative care components is essential, as patients with advanced COPD admitted 
to the hospital for an acute exacerbation often suffer from high symptom burden, 
deteriorating quality of life, and poor prognosis. Development and implementation 
of a post-acute GR-COPD programme is feasible and can offer substantial benefits 
for patients with advanced COPD admitted to the hospital for an acute exacerba-
tion.
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Background
Considering the worldwide ageing population with increasing numbers of frail older 
people with chronic diseases, there is a growing need for rehabilitation programmes 
specifically designed for geriatric patients. Geriatric patients often have specific 
problems and needs associated with ageing: multiple comorbidities and polyphar-
macy, cognitive dysfunction, frailty and the need to talk about end of life decisions. 
Due to this complexity, disabilities in geriatric patients are often multicausal.1 Geri-
atric rehabilitation (GR) has emerged as a promising field of interest and has been 
defined as “evaluative, diagnostic and therapeutic interventions whose purpose 
is to restore functional ability or enhance residual functional capability in elderly 
people with disabling impairments”.2 
In a recent systematic review on the effects of inpatient GR programs Bachmann 
et al concluded that GR has the potential to improve outcomes related to func-
tion, admission to nursing homes and mortality in elderly patients.1 Interestingly, 
they found only two types of GR programs in their meta-analysis: general and 
orthopaedic (for hip fracture). They found no study in any other clinical specialty, 
such as pulmonary, cardiac or stroke that was specifically designed for geriatric 
patients. This emphasizes the need for development and research for other types 
of GR programmes. 
One of the fields in which development of disease specific programmes for geriatric 
patients can be meaningful is that of progressive organ failure such as chronic 
obstructive pulmonary disease (COPD).  COPD is a progressive airway disease 
with rising prevalence, morbidity and mortality rates worldwide.3  The prevalence of 
advanced COPD worldwide ranges from 0.1 to 0.7% in the general population and 
is strongly related to age.4 In the Netherlands, 18% of all COPD patients suffer from 
severe COPD, i.e. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
stage III disease, to very severe COPD, i.e. GOLD stage IV disease (Table 1). It is 
expected that the prevalences of advanced COPD, i.e. GOLD stages III and IV, will 
rise by 30% and 120%, respectively in the next decade.5 
Health status is severely impaired in advanced COPD. Patients have high symptom 
burden, deteriorating functional capacity, declining quality of life, and poor progno-
sis.6,7 Pulmonary rehabilitation (PR) has emerged as a recommended standard of 
care for patients with symptomatic COPD and is effective in all stages of COPD.8 
PR after an acute exacerbation is a highly effective and safe by means of reduc-
ing the risk of readmission and mortality.9 However, in geriatric patients suffering 
from severe or end-stage COPD, training capacity is often limited and patients 
experience too many restrictions in daily functioning to undertake such an intensive 
programme.
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Poor health status and prognosis in advanced COPD also call for implementation 
of palliative care methods. Palliative care should start early in the disease trajec-
tory (when patients become symptomatic) and should be combined with active 
treatment and life-prolonging care.10 This recommendation is supported by the 
Official American Thoracic Society.11 However, although the palliative care needs 
of patients with severe or end-stage COPD are increasingly being recognized, pal-
liative care is still scarcely received by patients with advanced COPD.12 This might 
be due to the difficult disease trajectory of severe COPD, a phenomenon that was 
recently described as ‘prognostic paralysis’.13
Integration of rehabilitation and palliative care has been recognized as an inter-
esting option for patients with advanced COPD.14 Rehabilitation and palliative 
care programmes already show many common characteristics. They are both 
integrated, patient-centred, and multidisciplinary programs primarily focused on 
symptom control, functional capacity, quality of life, and participation. In patients 
with progressive disease, incorporation of rehabilitation into palliative care, and 
vice versa, can offer a strong model for collaboration. Such collaboration can also 
facilitate the gradual transition from curative management to palliative care.15 This 
approach is in line with the model presented by the American Thoracic Society in 
which patients receive palliative care concurrently with curative/restorative care 
(including rehabilitation) in an individualized manner.11
However, the implementation of such collaboration and integration in daily practice 
remains challenging. The authors proposed that a post-acute GR programme for 
patients with severe or end-stage COPD (a GR-COPD programme) could be a 
solution to the problems, as GR already combines rehabilitation and palliative care 
aspects. The paper describes the characteristics of this GR-COPD programme. To 
illustrate the methodology of the programme and its possible benefits for patients, 
three case studies are reported.
Table 1. GOLD staging of COPD
Stage Severity FEV1 % predicted#
I Mild COPD >80%
II Moderate COPD 50-80%
III Severe COPD 30-50%
IV Very severe COPD <30%
#: Recommended simplified spirometry thresholds from the Global Initiative for Chronic Ob-
structive Lung Disease (GOLD).19 All values are based on post-bronchodilator FEV1.
Abbreviations: FEV1: Forced expiratory volume in the first second as % of predicted value. 
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Geriatric Rehabilitation in Dutch nursing homes
In the Netherlands, GR is provided at skilled nursing facilities (SNF), usually 
situated in nursing homes. An SNF offers post-acute restorative treatment with a 
multidisciplinary patient-centred approach in a therapeutic environment. GR does 
not differ from rehabilitation medicine in its approach. However, patients admit-
ted to GR programmes do have different characteristics that those admitted for 
standard rehabilitation do not: higher age, substantial comorbidity and frailty. Due 
to their comorbidity and frailty, patients’ training capacity is sometimes severely 
limited, and they often suffer from concurrent diseases and complications interfer-
ing with the rehabilitation treatment. In this sense, GR operates at the intersection 
of geriatric medicine, rehabilitation medicine, and palliative care.
In the Netherlands, 55,000 patients are admitted for GR each year.16 Almost all of 
these (93%) are admitted to an SNF for GR after hospital admission.  Nearly half 
are admitted following a hip fracture or other orthopaedic surgery, 24% after stroke, 
and 31% after any other acute disabling disease or surgery, such as chronic or 
acute cardiopulmonary or neurological (other than stroke) diseases or abdominal 
surgery.16 
SNFs in the Netherlands offer an inpatient rehabilitation programme with an aver-
age length of admission (LoA) of 42 days and a maximum LoA of 3 months. On 
specific indication the inpatient rehabilitation programme can be prolonged for 
another 3 months (usually for stroke). Each patient receives a weekly average of 
18-22 hours of nursing care and 4 hours of individual therapy.16
SNFs have a specialized multidisciplinary team including an elderly care physi-
cian,17 a skilled nurse, a physiotherapist, a psychologist, an occupational therapist, 
a speech and language pathologist, a dietician, and social worker.
In the first week after admission to the SNF a comprehensive geriatric assessment 
(CGA) is conducted.18 This comprises a general medical assessment of disease 
severity, medication, and comorbidity; obtaining (hetero) anamnestic information 
on symptoms and functional capacity and psychosocial functioning; clinimetric 
tests; assessment of activities of daily living (ADL) status; assessment of health 
status; psychosocial screening; and intake by the social worker. Based on the 
CGA, an individual multidisciplinary GR programme is designed by the elderly care 
physician. Goal setting is tailored to the individual patient and the GR programme 
is evaluated weekly and adjusted as needed by the multidisciplinary team. The 
elderly care physician and the skilled nurse visit all patients weekly (family can be 
present) to evaluate their progress and adjust goals when needed.
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Characteristics of the GR-COPD programme
Patients with GOLD stage III or IV COPD who are admitted to the hospital with an 
acute exacerbation are signed up for the GR-COPD programme by a pulmonolo-
gist. GR-COPD is considered appropriate when patients suffer from high symptom 
burden and a substantial decline in functional capacity without sufficient recovery 
during their hospital stay. Furthermore, a multidisciplinary programme must be 
deemed necessary to achieve functional recovery (not only physiotherapy).
Two ‘standard’ GR-COPD treatment programmes were developed (Boxes 1 and 2). 
Differentiation between these two programmes is based on the patients’ medical 
history, health status before hospital admission, and training capacity. Both pro-
grammes are individually tailored to the patients’ needs and possibilities, based on 
the CGA.
Box 1. GR-COPD1
• Chronic obstructive pulmonary disease (COPD) Global Initiative for Chronic 
Obstructive Lung Disease (GOLD)19 stage III and IV
• History: stable course of health status
• Aim: restore patient to their pre-hospitalisation functional level
• Training capacity: relatively good
• Programme: focus on exercise and strength training (physiotherapy), opti-
mal pharmacological therapy, nutritional advice and patient education
Box 2. GR-COPD2
• Chronic obstructive pulmonary disease (COPD) Global Initiative for Chronic 
Obstructive Lung Disease (GOLD)19 stage III and IV
• History: frequent exacerbations and/or hospital admissions, gradual decline 
of health status, multiple disabling comorbidities
• Aim: to counteract or stabilize the gradual decline of health status and 
optimize quality of life
• Training capacity: limited
• Programme: rehabilitation and palliative care methods are integrated
Programme content
The GR-COPD programmes consists of several modules concerning different 
aspects of rehabilitation and palliative care: optimizing pulmonary medication 
use and inhalation techniques; chronic use of oxygen; smoking cessation; control 
of symptoms (mostly dyspnoea, cough, pain, fatigue, insomnia, and anorexia); 
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physiotherapy (endurance and strength training, inspiratory muscle training, relax-
ation techniques, breathing regulation skills and mucus evacuation techniques); 
occupational therapy (regulation of pace, use of walking aids); nutritional status 
and dietary supplementation; speech, breathing and swallowing techniques; psy-
chosocial intervention (mostly aimed at depression, anxiety or adverse coping 
strategies); self-management strategies and peer support contact; spiritual needs; 
advance care planning. During the last part of the programme, focus is on dis-
charge and strategies to maintain the attained physical and psychosocial levels 
of functioning. Patients follow a standardised daily programme and assignment 
to therapies is stringent. Patients who lack motivation or patients with prominent 
psychiatric or cognitive dysfunction are not included in the programme and are 
instead discharged back to their place of residence.
Case studies
Mrs A 
Mrs A was 69 years old when she was admitted to the SNF for the GR-COPD1 
programme. She had been diagnosed with COPD GOLD stage III in 2008 by her 
GP and had been unwilling to undergo further evaluation and treatment since. She 
was admitted to the hospital for 5 days because of progressive dyspnoea due to 
an acute viral infection. Her medical history showed no other chronic diseases or 
disabilities. She smoked 40 cigarettes per day. In the past few months her health 
status had declined significantly and she could walk only small distances, taking 
several pauses along the way. 
On admission to the GR-COPD ward she had a high symptom burden, with dys-
pnoea at rest, cough, and phlegm, all present during most days. Furthermore she 
suffered from impaired functional capacity, fatigue, impaired nutritional status, and 
anorexia. Table 2 shows the outcomes of several tests and questionnaires that 
were conducted in her CGA. 
An individual multidisciplinary rehabilitation programme was designed.  Primary 
interventions were to give education, to support smoking cessation, to analyse 
and to give advice concerning her diet and to restore functional capacity by means 
of lower- and upper-body exercise and strength training. During her stay Mrs A 
recovered very well and stopped smoking, and she could be discharged back 
home after 30 days. At discharge her functional- and exercise capacity, health- and 
nutritional status had all improved (Table 2). She continued physiotherapy twice a 
week. Three months after discharge she was seen by her pulmonologist. She was 
doing very well, maintaining her functional capacity with daily 1-hour walks and 
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physiotherapy once a week, and referred to herself as being ‘a different person’. 
Smoking cessation had been successful. She experienced no restrictions in daily 
functioning at all and her nutritional status had improved considerably. 
Mrs B
Mrs B, 82 years old, widowed, and living alone, had suffered from GOLD stage 
III COPD since 2005 and had a cardiac history including hypertension, an acute 
myocardial infarction in 2007, and a coronary artery bypass graft in 2008. She was 
admitted to the hospital owing to progressive dyspnoea and care dependency. In 
the past few weeks she had presented twice to the emergency care unit, once with 
atypical thoracic pain and once with a collapse without evident cause. She was 
apparently anxious, living alone, and feeling that she had lost control over her life. 
She was transferred to the SNF after 3 days of hospitalisation. 
During the first week an CGA was conducted (Table 2). Based on the CGA an 
individual GR-COPD2 programme was designed, the goals of which were: to 
optimize ADL independency; improve functional capacity, nutritional status and 
coping strategies; and restore her feelings of security and control. To achieve 
these goals the GR-COPD programme included the following rehabilitation and 
palliative care modules: physiotherapy (standard endurance and strength train-
ing, relaxation techniques and breathing regulation skills), occupational therapy 
(regulation of pace and advice concerning all ADL and a walking aid), analysis of 
diet and dietary supplementation, analyses of and intervention regarding a possible 
anxiety disorder and/or depression by a psychologist, and weekly conversations 
with the social worker concerning her feeling of insecurity and loss of control due 
to her progressive limitations and care dependency .
During her stay Mrs B showed good progress in daily functioning, her adaptation 
and coping strategies improved, and her symptoms diminished remarkably (Table 
2). Nevertheless, she remained very insecure, needing constant reassurance. 
The psychologist concluded that, although there was no specific anxiety disorder 
or depression present, Mrs B was indeed very frail in both her physical and her 
psychosocial functioning. The multidisciplinary team foresaw that, considering her 
frailty and the feeling of insecurity, discharge back home would probably cause a 
relapse. This was discussed with Mrs B and her children and it was concluded that 
moving to a residential care home was indicated. After 10 weeks of admission she 
was discharged back home and a few weeks later she was able to move to the 
residential care home of her choice. 
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Mr C 
Mr C, 60 years old, was admitted to the hospital with an acute exacerbation with-
out signs of infection. In the past few months he had been treated for several 
exacerbations by his GP and had been admitted to the hospital three times. His 
medical history showed, besides GOLD stage IV COPD, Dupeytren’s disease in 
both hands. Mr C was married and lived with his wife. 18 months prior to his most 
recent hospital admission he had followed the GR-COPD1 programme and after 
discharge had been stable for more than a year without exacerbations or hospital 
admissions. On admission to the GR-COPD ward he was mostly bed-bound and 
could walk only small distances in his room. He used oxygen 1 l/minute continu-
ously because of chronic respiratory failure. A CGA was conducted during the first 
days of admission (Table 2).
An individual GR-COPD2 programme was designed and included physiotherapy 
(endurance and strength training) and occupational therapy focusing on improving 
Mr C’s daily functioning so he would be able to function at home without help, 
Table 2. Comprehensive geriatric assessment on admission and discharge 
Mrs A Mrs  B Mr C
Admission Discharge Admission Discharge Admission
FEV1 32% 47% 21%
BMI 21.2 kg/m2 23.1 kg/m2 19.5 kg/m2 21.4 kg/m2 23.5 kg/m2
FFMI 12.8 kg/m2 13.3 kg/m2 14.2 kg/m2
HADS-A 4 14 8
HADS-D 5 15 3
CCQ 5.1 1.2 3.9 1.7 3.3
BI 18 20 20 20 14
6MWT 253 m 342 m 168 m 287 m 76 m
Abbreviations: FEV1: Forced expiratory volume in the first second as % of predicted; BMI: Body 
mass index , calculated as weight/height2 (kg/m2); FFMI: Fat-free Mass Index, was measured 
during hospital stay using the bioelectrical impedance analysis; HADS: Hospital Anxiety and 
Depression Score is a screening instrument for symptoms of anxiety and depression with two 
seven-item subscales, one for anxiety (HADS-A) and one for depression (HADS-D). A score 
of 8 points or higher on either subscale indicates a higher risk for the presence of a clinically 
relevant anxiety disorder or depression; CCQ: Clinical COPD Questionnaire is a 10-item, self-
administered questionnaire measure of health status. Higher scores indicate a worse health 
status. The minimal clinically important difference (MCID) of the CCQ total score is ±0.4;20 BI: 
Barthel Index , measures activities of daily living. Total score ranges from 0 to 20, with 20 rep-
resenting complete functional independence. Its MCID is +1.8;21 6MWT: the six-minute walking 
test is a widely used instrument to measure exercise capacity in patients with chronic obstruc-
tive pulmonary disease (COD). The MCID for the 6MWT in general for COPD patients is +54 
meter. In patients with severe COPD the MCID is +26m.22
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considering that he was alone at home most of the time because his wife still 
worked.  He was also treated by the dietician for losing weight and by the language 
and speech therapist regarding breathing and relaxation techniques, and he par-
ticipated in the education and peer support group run by the psychologist.
During the first month of his stay Mr C suffered from insomnia and recurrent tho-
racic pains. He described the pain as being unbearable and used Oramorph 2.5 
mg as needed with moderate effect. Long-acting morphine and promethazine were 
prescribed. There was no progress in his functional status and the physiotherapist 
reported that his exercise capacity was very limited, mostly due to deep desatura-
tion during exercise training, even though oxygen therapy was then temporarily 
enhanced. In fact, physiotherapy now seemed to have an adverse effect, leading 
to more exhaustion and pain.
All of this was discussed within the team and with Mr C, his wife and children. It was 
concluded that the aim of the programme should now be focussed on control of 
his symptoms of pain and insomnia. End-of-life care communication and advance 
care planning (do not attempt cardiopulmonary resuscitation, no more admissions 
to the hospital, discussion of the possibility of palliative sedation) seemed to lift a 
lot of weight from his shoulders and diminished his fear of dying from suffocation. 
During the weeks that followed Mr C’s insomnia improved and pain was sufficiently 
controlled with long-acting morphine, 15 mg twice a day. He had ‘good and bad 
days’, as he called them, and enjoyed visits from his grandchildren very much. 
After a few weeks, the elderly care physician was called one evening because Mr 
C experienced acute progression of dyspnoea and extreme anxiety. After physi-
cal examination, diminished unilateral breathing sounds were heard, indicating a 
possible pneumothorax on the left side, and palliative sedation was started with 
subcutaneous morphine and midazolam. On this Mr C became unconscious quickly 
and died the next morning in the presence of his wife and children.
Discussion and conclusion
These case studies show that a GR-COPD programme can offer substantial 
benefits and can integrate aspects of rehabilitation and palliative care. For some 
patients the focus is primarily on rehabilitation; restoring functional capacity and 
improving symptom burden, nutritional status and psychosocial functioning. The 
case of Mrs A demonstrates the possible effects on functional capacity and quality 
of life. In the case of Mrs B, adaptation to and acceptation of her loss of indepen-
dence had a crucial role. Without focusing on this part of the problem, the effects 
of the GR-COPD programme probably would not have lasted long and relapse 
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would have been expected.  In other patients, as for Mr C, rehabilitation cannot be 
the primary goal anymore and focus must primarily be on palliative care: symptom 
control, quality of life and advance care planning. 
As literature on this topic is very scarce, further research is essential. This should 
focus on defining appropriate outcome measurements to identity which patient 
outcomes can be achieved and sustained. Furthermore, there is a need to identify 
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Abstract
In view of the worldwide aging population, disease-specific geriatric rehabilita-
tion (GR) programs are needed. Therefore, we developed and implemented a 
postacute GR program for patients with advanced chronic obstructive pulmonary 
disease (COPD) (the GR-COPD program). The aim of this study is to investigate 
the feasibility of the GR-COPD program and to present clinical data on patient 
characteristics and course of functional capacity and health status. This is a natu-
ralistic prospective cohort study of patients with advanced COPD. A total of 61 pa-
tients entered the GR-COPD program and were eligible to participate in this study. 
All patients suffered from advanced COPD, and comorbidities were frequent. On 
admission, functional capacity and health status were severely limited but showed 
significant and clinically relevant improvement during the GR-COPD program. Pa-
tients with advanced COPD admitted to hospital for an acute exacerbation suffer 
from severely impaired functional capacity and poor health status. Development 
and implementation of a postacute GR program for these patients are feasible and 
likely to offer substantial improvements. Further research is essential and should 
focus on designing a controlled intervention trial to investigate the efficacy of the 
program.
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Introduction
Geriatric rehabilitation (GR) has emerged as a promising field of interest, showing 
that it has the potential to improve outcome measurements related to morbidity and 
mortality in elderly people.1 GR is usually organized as a form of integrated care and 
does not differ from rehabilitation medicine in its multidisciplinary, patient-centered 
approach. However, geriatric patients differ in many ways from younger patients 
that need rehabilitation. Besides having multimorbidity, their disabilities are usually 
multi-causal. Pre-existent functional limitations are not only caused by comorbidity 
but also by physiological conditions, such as sarcopenia.2 Furthermore, patients 
admitted for GR often suffer from concurrent diseases and complications interfer-
ing with the rehabilitation treatment. In this sense, GR operates at the crossroads 
of geriatric medicine and rehabilitation medicine.2 Considering the worldwide aging 
population, there is a growing need for programs designed for geriatric patients. 
However, studies on development, implementation and evaluation of disease-
specific GR programs (other than orthopedic and general), are lacking.1
One field in which development of disease-specific GR programs can be mean-
ingful is that of progressive organ failure, such as chronic obstructive pulmonary 
disease (COPD). Prevalence of COPD is rising worldwide and disease severity is 
strongly related to age.3 Patients with advanced COPD suffer from a high symptom 
burden, deteriorating functional capacity and declining quality of life; moreover, 
their prognosis is poor, especially after hospital admission for an acute exacerba-
tion.4-6
Pulmonary rehabilitation (PR) has emerged as a recommended standard of care for 
patients with symptomatic COPD and is effective in advanced and both stable and 
postacute COPD in reducing the risk for readmission and mortality and improving 
health related quality of life (HRQoL) and exercise capacity.7,8 Poor health status 
and prognosis in patients with advanced COPD also call for implementation of 
palliative care methods. Palliative care should start early in the disease trajectory 
(when patients become symptomatic) and should be combined with active treat-
ment and life-prolonging care.9
In clinical practice however, availability of PR programs is limited and patients 
with advanced COPD are often excluded from these programs because of their 
limited training capacity and frequent concurrent diseases and complications due 
to comorbidity, all interfering with the rehabilitation program. Furthermore, although 
the palliative care needs of patients advanced COPD are increasingly being recog-
nized, palliative care is still scarcely received by patients with advanced COPD.10 A 
disease specific GR program that is more adjusted to the needs and possibilities of 
this group of patients could be an interesting option. Besides offering an adjusted, 
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low intensity program, GR in the Netherlands is coordinated by an elderly care 
physician,  who is specialized in rehabilitation of frail, often elderly, patients with 
complex disabilities and multimorbidity.11 The importance of medical practitioners as 
an essential part of GR and their findings about causes, comorbidity and prognosis 
being incorporated into the rehabilitation plan, was recently stated.12 Furthermore, 
integration of rehabilitation medicine and palliative care is common practice in GR, 
and patients with advanced COPD might benefit from this integrated approach.13
Considering these facts, our group developed and implemented an postacute GR 
program for patients with advanced COPD (the GR-COPD program).14 Aim of the 
present study is to investigate feasibility of the program and to present clinical data 
on patient characteristics course of functional capacity and health status.
Methods
Design
This is a naturalistic prospective cohort study of patients with advanced COPD ad-
mitted to a postacute GR program in a skilled nursing facility (SNF). Baseline data 
(T0) were collected within 3 days after admission to the SNF. Patient and disease 
characteristics, functional capacity, nutritional status, psychosocial functioning and 
health status were registered. At discharge from the SNF (T1), functional capacity, 
nutritional status and health status were measured again. Data were collected from 
May 2009 until January 2011.
Setting and study population 
Patients with severe (Global Initiative for Chronic Obstructive Lung Disease 
(GOLD)15 stage 3) to very severe (GOLD stage 4) COPD, admitted to the hos-
pital for an acute exacerbation were selected for the GR-COPD program by a 
pulmonologist. Indication for the GR-COPD program was considered appropriate 
when patients suffered from high symptom burden and/or a substantial decline in 
functional capacity without sufficient recovery during hospital stay. Furthermore, 
a multidisciplinary approach was required to achieve improvement in functional 
capacity and health status instead of physical therapy alone and patients had to be 
motivated. Patients who lacked motivation, or patients with prominent psychiatric 
or cognitive dysfunction interfering with rehabilitation, were excluded from the pro-
gram. All patients admitted to the GR-COPD program were eligible to participate 
in this study. Data were collected from the patient’s file by the patient’s physician 
and transferred to an anonymous data file using Statistical Package for the Social 
Sciences software (SPSS 20; SPSS, Chicago, Illinois, USA).
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The GR-COPD program 
In the Netherlands, GR is organized as a form of integrated and transmural care 
and is provided at SNFs, usually situated in nursing homes.16 SNFs offer post-
acute restorative treatment with a multidisciplinary patient-centred approach in a 
therapeutic living environment.16 During the study period, GR was funded by the 
government’s Exceptional Medical Expenses Act (AWBZ), which offers a weekly 
average of 18–22 h of nursing care and 4 h of individual therapy. The SNF at 
which the current study was conducted has a multidisciplinary team that offers 
pulmonary, orthopedic, neurological and general GR. It is situated at a separate 
ward of the nursing home and has a capacity of 60 beds. On average, 350 patients 
are admitted to the GR ward each year with a mean length of admission (LOA) of 
39 days. The GR-COPD program was developed in 2009 by the multidisciplinary 
team of the SNF in close collaboration with the pulmonologist and physiotherapist 
from the pulmonary department of the local hospital. Development of the program 
was based on national and international guidelines on pulmonary rehabilitation 
and palliative care.9,17 The multidisciplinary team of the SNF consists of an elderly 
care physician, a skilled nurse, a physiotherapist, a psychologist, an occupational 
therapist, a speech and language pathologist, a dietician, and a social worker. Dur-
ing development and implementation each member of the team received specific 
training on pulmonary rehabilitation techniques within their own field of interest. A 
detailed description of the program has recently been published.14 The GR-COPD 
program contains several modules concerning different aspects of rehabilitation 
and palliative care: optimizing pulmonary medication use and inhalation techniques, 
support smoking cessation, adequate symptom control, physiotherapy (endurance 
and strength training, inspiratory muscle training, relaxation techniques, breathing 
regulation skills and mucus evacuation techniques), occupational therapy, analysis 
of nutritional status and dietary supplementation, analysis of speech, breathing and 
swallowing techniques,  psychosocial intervention (mostly aimed at depression, 
anxiety or adverse coping strategies), education focusing on self-management 
strategies, peer support contact and advance care planning. Goal setting is tai-
lored to the individual patient and the program is weekly evaluated and adjusted 
(as needed) by the multidisciplinary team and the pulmonologist, who makes 
monthly visits to all patients. All patients follow a standardized 6-week program 
and assignment to therapies is stringent. The program contains a minimum of 
six 40-min physiotherapy sessions per week, usually three endurance- and three 
strength training sessions. Group sessions are combined with individual training. 
Furthermore, training of breathing-, huffing- and relaxation techniques is offered 
once a week. Occupational therapy is given once or twice a week in 30- to 45-min 
sessions and analysis and evaluation of nutritional status is done by the dietician 
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every week. Patients participate in weekly group sessions, which are supervised 
by the psychologist, and are aimed at education of patients and relatives on self-
management strategies and peer support contact.
Measurements and instruments
The following patient and disease characteristics were registered: age, sex, 
marital status, disease severity (GOLD stage, forced expiratory volume in 1 s as 
percentage of predicted (FEV1 % pred)), long-term oxygen therapy (LTOT) (yes/
no), smoking status (smoker/nonsmoker), LOA during hospital stay and LOA during 
rehabilitation. Comorbidity was assessed using the modified Cumulative Illness 
Rating Scale (CIRS);18 The CIRS consists of 13 items (organ or disease systems) 
with a severity scale ranging from 0 to 4 for each item. Total score is the sum of all 
items (range 0 to 56), with scores > 10 indicating severe impairment.
Nutritional status was measured by the body mass index (BMI) and the fat-free 
mass index (FFMI). The BMI was calculated as weight/height2 (kg/m2) and was 
categorized in two groups: underweight (< 21 kg/m2) and no underweight (≥ 21 kg/
m2).19 The FFMI was measured during hospital stay using bioelectrical impedance 
analysis. Depletion was considered when the FFMI was ≤ 16 kg/m2 in men and ≤ 
15 kg/m2 in women.19
Functional capacity
The modified 20-point Barthel Index (BI) measures activities of daily living and is a 
valid, reliable and widely used instrument to assess improvement during rehabilita-
tion programs.20 The total score ranges from 0 to 20, with 20 representing complete 
functional independence. The minimal clinically important difference (MCID) for the 
BI is not well established for COPD patients. In stroke patients, the MCID of the BI 
is +1.85.21
The 6-minute walk test (6MWT) is a practical, easy to perform and widely used in-
strument to measure exercise capacity in COPD patients. The MCID for the 6MWT 
in patients with severe COPD is +26 (± 2) m.22
Peripheral muscle strength was measured as hand-grip force (HF) using a hand 
dynamometer. Total scores (right + left hand) are given in kilogram force, and 
normative data are age and sex dependent.23
Psychosocial functioning
The Hospital Anxiety and Depression Scale (HADS) is a valid and reliable screening 
instrument for symptoms of anxiety and depression. It has two 7-item subscales, 
one for anxiety and the other for depression. A score of 8 points or higher on either 
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subscale indicates a higher risk for the presence of a clinically relevant anxiety 
disorder or depression.24
Health status
Health status was measured using the Clinical COPD Questionnaire (CCQ).25 The 
CCQ is a validated and reliable 10-item, self-administered questionnaire. Items are 
scored on a Likert scale from 0 to 6. The final score is the sum of all items divided 
by 10; higher scores indicate a worse health status. The CCQ consists of the sub-
domains symptoms, functional status and mental status, and scores for these three 
domains can be calculated separately. The MCID of the CCQ total score is ±0.4.26
Statistical analysis
All data were processed using SPSS (SPSS 20.0). Descriptive analyses were used 
for general baseline patient characteristics, disease characteristics and data from 
measurements on admission. Categorical variables are described as frequencies, 
while continuous variables were tested for normality and are presented as mean 
and SD or median and interquartile range (IQR) in case of skewed data. Continu-
ous variables were compared between T0 and T1 using a paired samples t-test or 
Mann-Whitney test, as appropriate. We defined statistical significance at p ≤ 0.05 
(two-sided level of significance).
Results
General patient characteristics
Of the 63 consecutive patients who entered the program during the period from 
May 2009 until January 2011, 2 were excluded from this study because of a differ-
ent diagnosis (1 due to asthma and 1 due to small airway disease). One patient 
dropped out due to lack of motivation and was discharged back home. Two patients 
died during the program; in both patients it was concluded that rehabilitation was 
no longer feasible. For these patients end-of-life care communication and advance 
care planning (e.g. do not attempt cardiopulmonary resuscitation, no more admis-
sions to the hospital) had been performed and death was expected. Overall, 91% 
(n=53) of the patients were discharged back home after a median LOA of 35 days 
(IQR 21-61). Four patients were discharged to a residential care facility and one 
patient was discharged to a nursing home (Figure 1).
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Table 1 presents the patient and disease characteristics on admission to the GR-
COPD program (T0). All patients had advanced COPD (GOLD stage 3 (n=29) or 
GOLD stage 4 (n=32)), with a mean FEV1%pred of 32.9 (±10.8). Of these, 17 
(28%) patients were on LTOT. Comorbidity was prevalent, as 41% of the patients 
had a CIRS score ≥10, indicating severe impairment due to comorbidity. Organ 
and disease systems (except respiratory) showing the highest mean scores were: 
cardiac (0.97, 35% ≥ 2), musculoskeletal and integumentary (0.85, 33% ≥ 2) and 
endocrine-metabolic (0.75, 31% ≥ 2).




Patients entering the GR-COPD program 
between May 2009 and Jan 2011 
n=63 
 
Patients entering the study 
n=61 
Complete follow up  
n=58 
Lost to follow-up 
-lack of motivation; n=1 
-death; n=2 
Discharge: 
-back home; n=53 
-residential care facility; n=4 
-nursing home; n=1 
 
Patients excluded because 
of different diagnosis 
n=2 
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Measurements on admission
Table 2 presents the outcomes of all measurements on admission (T0) to and 
discharge from the GR-COPD program. Functional capacity was impaired; on 
admission the BI and the 6MWT showed care dependency and limited exercise 
capacity. Peripheral muscle strength showed that 25 patients (41%) had a HF 
below the normative value. Although the mean BMI was within normal range, 20 
patients (33%) had a BMI < 21 kg/m2 indicating underweight. Depletion of the FFMI 
was present in 44% (n=27) of all patients. HADS scores showed that 47% of the 
patients had a higher risk (score of ≥ 8) for anxiety and 43% for depression. The 
mean CCQ score was 3.5 (±0.9), indicating severely limited health status.
Course of functional capacity during the GR-COPD program
There was a significant and clinically relevant improvement of functional capacity 
during the GR-COPD program (Table 2, Figure 2). The median BI improved from 
17 (IQR 15-18) to 20 (IQR 17-20), and the mean 6MWT from 208 m (±119) to 274 
m (±122) at discharge. In 41 patients the BI improved 2 or more points (>MCID), in 
2 patients the BI on discharge was lower than on admission, and in 9 patients the 
BI did not change during the program. In 71.7% of the patients the 6MWT improved 
Table 1. Patient and disease characteristics on admission (baseline/T0) to the GR-COPD pro-
gram.*
Number of patients 61
Age in years (SD) 68.9 (9.9)
Sex: woman, n (%) 30 (49)
Living alone, n (%) 28 (46)
LOA-H in days (IQR) 8 (7-11)
LOA-SNF in days (IQR) 35 (21-61)
GOLD 3, n (%) 29 (48)
GOLD 4, n (%) 32 (52)
FEV1%pred (SD) 32.9 (10.8)
LTOT, n (%) 17 (28)
Comorbidity, CIRS (total score) (SD) 9.6 (4.3)
Smoker, n (%) 10 (16.5)
*Categorical variables are described as frequencies, while continuous variables are tested 
for normality and are presented as mean and SD or median and IQR in case of skewed data. 
Abbreviations: GR-COPD: geriatric rehabilitation program for patients with advanced chronic 
obstructive pulmonary disease; LOA-H: length of admission during hospital stay; LOA-SNF: 
length of admission during rehabilitation; IQR: interquartile range; GOLD: Global Initiative for 
Chronic Obstructive Lung Disease; FEV1%pred: forced expiratory volume in 1 s as percentage 
of predicted; LTOT: long-term oxygen therapy; CIRS: Cumulative Illness Rating Scale.
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≥ 26 m (>MCID). In 2 patients the 6MWT did not change and in 6 patients the 
6MWT decreased. The nutritional status measured by the mean BMI showed no 
significant improvement. However, the number of patients with underweight (BMI 
<21 kg/m2) decreased from 20 to 12 (p=0.007). Improvement in health status was 
also significant and clinically relevant: the mean score of the CCQ improved from 
3.5 (±0.9) on admission to 2.2 (±1.0) at discharge.
Discussion
Main findings
The main finding of this study is that, in patients with advanced COPD who suffered 
a recent exacerbation, comorbidity is frequent, functional capacity is impaired, and 
health status is severely limited. Furthermore, nutritional status is often impaired 
and many patients are at risk for an anxiety or depressive disorder. Neverthe-
Table 2. Outcomes of measurements on admission (T0) to and discharge from (T1) the GR-
COPD program.
Measurement T0 T1 p
Functional capacity
BI (IQR) 17 (15-18) 20 (17-20) <0.001b
6MWT (m) (SD) 208 (119) 274 (122) <0.001a
HF (kgf) (SD) 52.0 (17.0) 55.6 (17.5) <0.001a
HF < norm value, n (%) 25 (41) 18 (30) 0.024c
Nutritional status
BMI (kg/m2) (SD) 23.3 (4.7) 23.8 (4.0) 0.051a
BMI < 21kg/m2, n (%)                          20 (33) 12 (20) 0.007c
FFMI (kg/m2) (SD) 15.8 (2.3) - -
Psychosocial functioning
HADS_Anxiety 7.5 (4.2) - -
HADS_Depression 7.4 (4.6) - -
Health status
CCQ (SD) 3.5 (0.9) 2.2 (1.0) <0.001a
Categorical variables are described as frequencies, while continuous variables are tested for 
normality and are presented as mean and SD or median and IQR. Continuous variables were 
compared between T0 and T1 using a paired samples t-testa or Mann–Whitney testb, as appro-
priate. Categorical variables were compared between T0 and T1 using chi2-testsc. Abbrevia-
tions: GR-COPD: geriatric rehabilitation program for patients with advanced chronic obstruc-
tive pulmonary disease; BI: Barthel index; 6MWT: 6-minute walking test; HF: handgrip force; 
BMI: body mass index; FFMI: fat-free mass index; HADS: Hospital Anxiety and Depression 
Scale; CCQ: Clinical COPD Questionnaire.
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less, during the GR-COPD program, functional capacity and health status showed 
substantial and clinically relevant improvement. This implies that, although these 
patients are severely limited in training capacity, a postacute GR program is fea-
sible and is likely to offer substantial benefits.
Strength and limitations
To the best of our knowledge, this is the first study focusing on feasibility, patient 
characteristics and course of functional capacity in patients with advanced COPD, 
admitted to a postacute GR program. The current study was not designed as an 
intervention trial but as a naturalistic prospective cohort study. Therefore, a control 
group was not part of this study and the current study can also be seen as a pilot 
study. Further research is essential and should focus on designing a controlled 
intervention trial to investigate the efficacy of the program. Other limitations are 
possible population bias due to criteria used to select patients for the program and 
the fact that we were unable to collect information on patients that were selected 
Figure 2. Course of functional capacity and health status from admission (T0) to discharge (T1).
 
Abbreviations: 6MWT: six-minute walking test; CCQ: Clinical COPD questionnaire;
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for the program but refused to participate. Since these latter patients were dis-
charged back home from the hospital, health status and functional capacity of our 
population is probably worse than that of the initial population that was indicated 
for the program in the hospital. This could bias the generalizability of our results. 
We used the BI to measure functional capacity. However, the BI might not be the 
most suitable instrument to measure functional capacity and impairment in patients 
with COPD due to the ceiling effect and insensitivity to change at the upper level of 
the scale.27 Nevertheless, the BI is a widely used instrument and recent literature 
shows that it can be used in patients with COPD.28 Our results also show the ceiling 
effect of the BI, but improvement was still clinically relevant.
Few data are available on GR programs specifically designed for patients with ad-
vanced COPD. A recent systematic review on the efficacy of geriatric rehabilitation 
failed to identify one disease-specific program for geriatric patients that has been 
well evaluated, other than orthopedic and general geriatric rehabilitation.1 Studies 
on the effect of PR in elderly patients with COPD are scarce, but show positive 
outcomes of PR programs for relatively older COPD patients.29,30 However, com-
pared with our population, these studies included only stable COPD patients with 
less severe airflow obstruction and functional impairment. Furthermore, excluded 
from these latter studies were patients with comorbid diseases that are likely to 
limit exercise capacity. Studies on the effect of postacute PR programs in elderly 
COPD patients are also scarce. Puhan et al performed a systematic review to 
assess the effect of postacute PR on future hospital admissions, mortality, HRQoL 
and exercise capacity, in patients with COPD after a recent exacerbation.8 The 
authors concluded that postacute PR is a highly effective and safe intervention to 
reduce hospital admissions and mortality and to improve HRQoL. Of the nine stud-
ies that met their eligibility criteria, five investigated the effect of an inpatient PR 
program that followed immediately after hospital admission.31-35 Of these studies, 
one was conducted at an intensive care unit31 and one study included patients with 
less severe airflow limitation compared with our population.32 Three small stud-
ies reported positive effects on exercise capacity,33 health-care utilization,34 and 
HRQoL,35 of a postacute PR program in populations who were more similar to ours 
with regard to age, lung function and exercise capacity. However, in those studies 
comorbidity was not always measured,35 or patients with significant comorbidities 
were excluded from the PR program.33 Although there are differences between our 
population and the populations described in studies on the effect of postacute PR, 
these data are in line with our results, indicating that postacute rehabilitation in 
patients with advanced COPD is feasible, safe and can probably offer substantial 
benefits.
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A notable finding of the present study is that the mean age of the patients that 
entered the GR-COPD program was 68.9 years, which is relatively young consider-
ing that this is a GR program. However, indication for the GR-COPD program was 
based on disease severity and the presence of impaired functional capacity and 
health status with insufficient recovery during hospital stay. Age was not an inclu-
sion or exclusion criterion. This suggests that, in patients with COPD, advanced 
disease with limited functional capacity and health status can be present at a 
relatively young age. Nevertheless, 54% of the patients were aged ≥ 70 years and 
almost 20% of our population were aged ≥80 years.
Implications for future research
Although our results suggest that the GR-COPD program is effective in this specific 
group of patients, our study design did not include a control group and a randomized 
controlled trial is compulsory to confirm these findings. As literature on this topic is 
scarce, further research is essential. Studies should focus on defining appropriate 
outcome measurements to identity which patient outcomes can be achieved and 
sustained, and identify patient characteristics that can predict which patients with 
advanced COPD are most likely to benefit from an post-acute GR program.
Conclusions 
Patients with advanced COPD admitted to hospital for an acute exacerbation suffer 
from frequent comorbidities, severely impaired functional capacity and poor health 
status. Development and implementation of a postacute GR program for this group 
of patients is feasible and can probably offer substantial improvements.
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4Health status measured by the Clinical COPD Questionnaire (CCQ) improves following 
post-acute pulmonary 
rehabilitation in patients with 
advanced COPD: a prospective 
observational study









Aims: To evaluate outcomes of the clinical chronic obstructive pulmonary disease 
(COPD) questionnaire (CCQ) in patients with advanced COPD admitted for a post-
acute pulmonary rehabilitation (PR) program and to relate (change in) health status 
to lung function, degree of dyspnoea and (change in) functional capacity. Methods: 
This is a prospective observational study in patients with advanced COPD admitted 
for a post-acute PR program in a skilled nursing facility. Health status (CCQ) and 
functional capacity were measured before and after rehabilitation. Results: Health 
status measured by the CCQ was severely impaired and showed significant and 
clinically relevant improvement during the post-acute PR program. Moderate to 
strong correlations were found between CCQ scores and functional capacity on 
admission and at discharge. Moderate correlations were found between improve-
ment in CCQ scores and improvement in functional capacity. No correlation was 
found between CCQ scores and lung function (forced expiratory volume in 1 s % 
predicted). Conclusions: Health status measured by the CCQ improves following 
a post-acute PR program in patients with advanced COPD and correlates with 
improvement in functional capacity. These results suggest that the CCQ is sensi-
tive to change in response to PR in this specific group of patients.
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Introduction
In chronic obstructive pulmonary disease (COPD), health-related quality of life 
(HRQoL) is increasingly recognised as an important measurement that reflects the 
patient’s perspective of the impact of the disease on symptom burden, functional 
capacity and psychosocial functioning.1,2 Therefore, more traditional parameters 
of disease severity (such as lung function) should be supplemented with mea-
surements of HRQoL or health status. However, instruments to assess HRQoL or 
health status are often time-consuming and/or relatively difficult for the patients to 
comprehend. Furthermore, although instruments to measure HRQoL are widely 
used as important outcome measurements in research, their use in daily practice 
(especially in primary care) is limited. In 2003 van der Molen et al.3 developed 
and validated the Clinical COPD Questionnaire (CCQ). The CCQ is a simple and 
reliable 10-item tool that focuses not only on the clinical status of the airways, but 
also on functional limitations and psychosocial dysfunction. The CCQ consists of 
three separate domains (i.e., symptoms, functional state and mental state) and 
was originally developed to measure the clinical health status in patients with 
COPD. Treatment in clinical practice can be aimed at these subdomains, which 
elaborates on tailor-made medicine in patients with COPD. The CCQ can also be 
used to evaluate the adequacy of clinical management4 and to assess functional 
performance.5 In fact, the functional state domain of the CCQ is reported to be the 
best patient-reported outcome tool for assessing functional performance in patients 
with COPD in primary care.6 Furthermore, the CCQ can be used to measure the ef-
fect of integrated disease management interventions in primary care6 and to predict 
exacerbations7 and mortality2 in patients with mild to moderate COPD. However, 
little is known about the use of the CCQ in patients with advanced COPD, or its 
use as a primary outcome measure in pulmonary rehabilitation (PR). Therefore, 
the aim of the present study was to evaluate outcomes of the CCQ in patients 
with advanced COPD admitted for post-acute PR and to correlate (improvement 
in) health status measured by the CCQ to lung function, degree of dyspnoea and 
(improvement in) functional capacity.
Materials and methods
Design and setting
This is a prospective observational study designed to evaluate outcomes of the 
CCQ in patients with advanced COPD and to relate (improvement in) health status 
to lung function, degree of dyspnoea and (improvement in) functional capacity. The 
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study was conducted at a skilled nursing facility (SNF) that offers geriatric rehabili-
tation for patients with advanced COPD. Data were collected from the patients’ files 
by the patients’ physicians and transferred to an anonymous data file (SPPS 20). 
Given the fact that this observational study measured a form of structured usual 
care, no written informed consent was required.
Baseline measurements (T0) were collected and performed within 3 days after ad-
mission to the SNF; these consisted of patient and disease characteristics, health 
status (CCQ), degree of dyspnoea (modified Medical Research Council (mMRC) 
scale) and functional capacity (Barthel Index (BI) and the Six-Minute Walking Test 
(6MWT)). At discharge from the SNF (T1), health status and functional capacity 
were measured again. Data were collected from May 2009 until January 2011.
Participants
Patients with severe (Global Initiative for Chronic Obstructive Lung Disease 
(GOLD)8 stage 3) to very severe (GOLD stage 4) COPD, admitted to the hospital 
for an acute exacerbation, were indicated for the PR programme by a pulmonolo-
gist. PR was considered appropriate when patients suffered from high symptom 
burden and/or a substantial decline in health status and functional capacity without 
sufficient recovery during hospital stay. Furthermore, a multidisciplinary approach 
was required to achieve improvement in health status instead of physical therapy 
alone. Patients who lacked motivation or patients with prominent psychiatric or 
cognitive dysfunction interfering with PR were excluded from the programme. All 
patients admitted to the PR programme were eligible to participate in this study.
Pulmonary rehabilitation programme
The PR programme was offered at an SNF that offers geriatric rehabilitation. Ge-
riatric rehabilitation consists of post-acute restorative inpatient treatment with a 
multidisciplinary patient-centred approach in a therapeutic environment.9 Geriatric 
rehabilitation does not differ from rehabilitation medicine in its approach. However, 
patients admitted to geriatric rehabilitation programmes do have different charac-
teristics: higher age, substantial comorbidity and limited functional and training 
capacity.10 The SNF at which the present study was conducted has one ward with 
a multidisciplinary team that is specialised in post-acute care and rehabilitation for 
patients with advanced COPD.11 The PR programme contains several modules on 
different aspects of rehabilitation. Goal setting and duration of the programme is 
tailored to the individual patient, and the programme is evaluated weekly and ad-
justed (as needed) by the multidisciplinary team. All patients follow a standardised 
weekly programme that contains a minimum of five 40-min physiotherapy sessions, 
occupational therapy once or twice a week, analysis and evaluation of nutritional 
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status every week and weekly group sessions (education of patients and relatives, 
and peer support contact). Assignment to therapies is stringent. A detailed descrip-
tion of the PR programme was recently published.11
Health status and degree of dyspnoea
Health status was measured using the Dutch version of the CCQ.3 The CCQ is a 
validated and reliable 10-item, self-administered questionnaire. The CCQ consists 
of three subdomains: symptoms, functional state and mental state. Items are 
scored on a Likert scale (range 0–60). The final score is the sum of all items divided 
by 10; separate scores for all three domains can be calculated. Higher scores 
indicate a worse health status. The minimal clinically important difference (MCID) 
of the CCQ total score is − 0.4.12 Degree of dyspnoea was measured using the 
mMRC dyspnoea scale.7 The mMRC is an ordinal four-point scale (grades 0–4) 
based on degrees of various physical activities that precipitate dyspnoea. Grade 4 
represents the most severe category.
Functional capacity
Functional capacity was measured by the modified BI and the 6MWT. The BI mea-
sures activities of daily living and is a valid, reliable and widely used instrument to 
assess activities of daily living improvement during rehabilitation programmes.13 
The total score ranges from 0 to 20, with 20 representing complete functional 
independence. The MCID for the BI is not well established for COPD patients. In 
stroke patients the MCID of the BI was calculated at +1.85.14 The BI was assessed 
by a specialised nurse of the SNF.
The 6MWT is a practical, easy-to-perform and widely used instrument for measur-
ing exercise capacity in patients with COPD. The 6MWT is strongly predictive of 
survival in patients with COPD and an important outcome measure for PR.15,16 The 
MCID for the 6MWT in patients with severe COPD is +26 (±2) m.17 The 6MWT 
was assessed by a physiotherapist of the multidisciplinary team of the SNF in a 
standardised setting in accordance with international guidelines.15
Statistical analysis
All data were processed using SPSS (IBM SPSS Statistics for Windows, version 
20.0, IBM, Armonk, NY, USA). Descriptive analyses were used for measurements 
on admission (T0) and at discharge (T1). To compare the mean outcome measure-
ments on admission (T0) and discharge (T1), the paired sample t-test was used. 
In case of skewed data (BI), the nonparametric Wilcoxon test was used. To investi-
gate potential regression to the mean, a linear regression analysis was performed 
for change (T1 − T0) against baseline measurements (T0). Pearson’s correlation 
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coefficient was calculated to determine the strength of linear correlations between 
pairs of variables of interest. In case of skewed data or measurements at interval 
level, Spearman’s correlation coefficient was calculated. We defined statistical 
significance at P≤0.05 (two-sided level of significance).
Results
Study population
A total of 63 patients entered the programme during the specified period and 
were eligible to participate in this study. Of them, two were excluded because of 
a different diagnosis (one for asthma and one for small airway disease), two (5%) 
died during the rehabilitation programme and one dropped out because of lack of 
motivation. Patient and disease characteristics are presented in Table 1. Median 
length of admission to the SNF was 35 (21-61) days. The study population con-
sisted of 30 women and 31 men with a mean age of 68.9 (±9.9) years. All patients 
had advanced COPD (GOLD stage 3 or 4) with a mean forced expiratory volume 
in 1 s (FEV1) % predicted of 32.9 (±10.8); in addition, 17 patients (28%) were on 
long-term oxygen therapy.
Table 1. Patient and disease characteristics on admission (baseline/T0)
No. of patients 61
Age in years (SD) 68.9 (9.9)
Sex: woman, n (%) 30 (49)
Living alone, n (%) 28 (46)
LOA-H in days (IQR) 8 (7-11)
LOA-SNF in days (IQR) 35 (21-61)
GOLD 3, n (%) 29 (48)
GOLD 4, n (%) 32 (52)
FEV1 % of predicted (SD) 32.9 (10.8)
LTOT, n (%) 17 (28)
Smoker, n (%) 10 (16.5)
Categorical variables are described as frequencies, while continuous variables were tested for 
normality and are presented as mean (SD) or median (IQR) in case of skewed data.
Abbreviations: FEV1: forced expiratory volume in 1 s; GOLD: Global Initiative for Chronic Ob-
structive Lung Disease; IQR: interquartile range; LOA-H: length of admission during hospital 
stay; LOA-SNF: length of admission during rehabilitation; LTOT: long-term oxygen therapy.
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Health status, degree of dyspnoea and functional capacity on admission
On admission, the mean CCQ score was 3.5 (±0.9), indicating severely limited 
health status, and the mean score on the mMRC was 3.8 (±1.1). Functional capac-
ity was limited, as the median BI score (17 (interquartile range 15–18)) indicated 
care dependency and the mean 6MWT (208 (±119)m) indicated limited exercise 
capacity.
Course of health status and functional capacity during the PR programme
During the PR programme there was a significant and clinically relevant improve-
ment in health status (CCQ) and functional capacity (BI and 6MWT) (Table 2). The 
mean CCQ improved from 3.5 (±0.9, range 1.3–5.8) on admission to 2.2 (±1.0, 
range 0.6–4.4) at discharge. All three subdomains of the CCQ showed significant 
improvement: of all patients, 86.8% showed an improvement on the CCQ equal 
to the MCID or more; in two patients the CCQ score did not change; and in three 
patients the score increased, indicating a deterioration of health status during the 
programme.
On admission the median BI score was 17 (range 5–20), and 20 (range 11–20) at 
discharge. In 41 patients the BI improved two points or more, in 2 patients the BI 
at discharge was lower than on admission and in 9 patients the BI did not change 
during the programme. However, all these latter patients had a maximum score 
(19 or 20) on admission. The mean 6MWT improved from 208m (range 36–568 
m) on admission to 274m (range 61–634 m) at discharge. In 71.7% of the patients 
the 6MWT improved >26 m. In two patients the 6MWT did not change and in six 
patients the 6MWT decreased.


























Barthel Index (IQR) 61 17 (15-18) 58 20 (17-20) <0.001b
6MWT, meters (SD) 58 208 (119) 54 274 (122) <0.001a
Variables were tested for normality and are presented as mean (SD) or median (IQR) in case 
of skewed data.
Abbreviations: 6MWT: Six-Minute Walking Test; IQR: interquartile range.
aVariables were compared between T0 and T1 using a paired sample t-test, as appropriate.
bVariables were compared between T0 and T1 using a paired sample Wilcoxon test, as ap-
propriate.
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To investigate potential for regression to the mean, a linear regression analysis 
was performed for change (T1 − T0) against baseline measurements (T0). Figure 
1 shows the relation between improvement in CCQ (CCQ-delta) and CCQ at base-
line (CCQ-T0). Results from the linear regression model show a Y-intercept (b0) of 
0.36 and a gradient of the regression line (b1), representing the change in outcome 
variable (CCQ-delta) associated with one-unit change in the predictor (CCQ-T0) 
of − 0.473.
Relationship between health status, lung function, functional capacity 
and degree of dyspnoea on admission and discharge
To determine the correlation between health status as measured by the CCQ and 
lung function (FEV1%pred), functional capacity (6MWT and BI) and degree of dys-
pnoea (mMRC) on admission and at discharge, we calculated the correlation coef-
ficients between these variables (Table 3). On admission, there was a moderate to 
strong correlation between CCQ (CCQ total score and CCQ function domain score) 
and functional capacity measured by the 6MWT (CCQ total score: r = − 0.400, P 
= 0.002, CCQ function score: − 0.431, P = 0.001) and the BI (CCQ total score: r 
Figure 1. Scatterplot showing  the relation between improvement in CCQ (CCQ-delta) and 
CCQ at baseline (CCQ-T0) Y-intercept (B0) = 0.36o; gradient of regression line (b1) represent-
ing the change in outcome variable (CCQ-delta) associated with one unit change in the predic-
tor (CCQ-T0)= -0.473.














Abbreviations: CCQ: Clinical COPD questionnaire;
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Table 3. Correlations of CCQ score (total and subdomains) on admission (T0), discharge (T1) 
and change in CCQ scores (T1-T0) with measurements of functional capacity, degree of dys-
pnoea and lung function.












































































































































































Abbreviations: 6MWT: Six-Minute Walking Test; BI: Barthel Index; FEV1: forced expiratory volume in 1 s; 
mMRC: modified Medical Research Council.
aSpearman’s correlation coefficient was calculated for non-normally distributed (BI) and interval (mMRC) 
measurements. bPearson’s correlation coefficient was calculated for normally distributed measurements 
(6MWT, FEV1%pred). **Correlation is significant at the 0.01 level (two-tailed). *Correlation is significant at 
the 0.05 level (two-tailed).
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= − 0.481, P<0.001, CCQ function score: − 0.573, P<0.001). No correlation was 
found between the CCQ on admission (CCQ total score and CCQ separate domain 
scores) and lung function measured by the FEV1% of predicted. On admission, 
there was a moderate correlation between the mMRC dyspnoea scale and the 
CCQ total score and the CCQ function domain score. We found no significant 
correlation between the mMRC dyspnoea scale and the symptom domain of the 
CCQ. At discharge, we found a strong correlation between the CCQ total score and 
the CCQ function domain score and functional capacity measured by the 6MWT 
(CCQ total score: r = − 0.572, P<0.001) and the BI (CCQ total score: r = − 0.539, 
P<0.001). To determine whether patients with an improvement in CCQ of more 
than the MCID are the same as those with clinically relevant functional improve-
ments, we calculated the correlation coefficient between these variables. There 
was a moderate correlation between improvement in health status (CCQ-total 
score) and improvement in functional capacity (6MWT): r = − 0.432, P = 0.002. We 
found no significant correlation between improvement in CCQ and improvement 
in BI or between improvement in 6MWT and improvement in BI. Of the subjects 
with an improvement in the CCQ score equal to or greater than the MCID, 67.7 
and 73.9% also showed a clinically relevant improvement on the 6MWT and the 
BI, respectively. Overall, 45.3% of the subjects showed clinically relevant improve-
ments on all three outcome measurements (CCQ, 6MWT and BI). We found no 
correlation between baseline lung function (FEV1% of predicted) and improvement 
in health status or functional capacity.
Discussion
Main findings
The first main finding of this study is that health status measured by the CCQ 
is severely impaired in this group of patients. Second, health status measured 
by the CCQ showed substantial and clinically relevant improvement during the 
PR programme; this improvement correlates well with improvement in functional 
capacity, indicating that the CCQ is sensitive to change in response to PR.
Strengths and limitations of this study
This is the first study that describes the course of health status as measured by the 
CCQ in patients with advanced COPD during a post-acute PR programme, with 
follow-up of almost all patients and few missing data at follow-up. However, this 
study warrants some limitations. Our population might be biased because we did not 
collect information on patients who were selected for the PR programme but were 
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not motivated to participate. Patients who refused to participate were discharged 
from the hospital. The health status and functional capacity of our population may 
be even worse than that of the initial population that was indicated for PR in the 
hospital, because most patients who refused to participate were discharged home. 
Furthermore, part of the improvement in health status measured by the CCQ might 
be caused by the ‘in care effect’ of patients participating in a study. PR is expected 
to improve functional capacity, whereas improvement in the CCQ might partly be 
caused by participation in a study like the present one. Correlation between these 
two outcome measurements might therefore be overestimated. However, because 
of the observational design of the study and the fact that we solely measured a 
form of structured usual care, the ‘in care effect’ cannot be ruled out completely, but 
probably has limited influence on our results.
As the current study is an analysis of change between baseline and follow-up, a re-
gression to the mean effect should be considered as a possible cause of observed 
change. The results of the linear regression analysis show that, when adjusted for 
baseline, improvement in CCQ reduces from − 1.3 to − 0.5. This means that even 
after adjusting for regression to the mean there continues to be a significant and 
clinically relevant change.
To evaluate the use of the CCQ in this group of patients, comparison of the CCQ 
with another HRQoL instrument that is regularly used in this group of patients, 
namely, the Chronic Respiratory Questionnaire Self-Administered Standardized 
Format (CRQ-SAS),18 was initially included in the design of the study. However, 
during our study, compliance with the CRQ-SAS was very low, leading to very high 
rates of missing data (⩾50%), and we were therefore unable to present reliable 
results from the CRQ-SAS.
Nevertheless, this is still an interesting result, as it also confirms that HRQoL 
instruments such as the CRQ are often time-consuming and relatively difficult for 
patients to comprehend, leading to limited use, and usefulness, in daily practice. 
Compliance with the CCQ was, however, very good, leading tovery few missing 
data (<2% at baseline; 8% at follow-up).
The last limitation is the fact that we did not have a control group, and although 
our results suggest that the CCQ is a responsive instrument for measuring change 
in health status following a post-acute PR programme in patients with advanced 
COPD, a randomised controlled trial would serve well to further confirm these find-
ings.
Interpretation of findings in relation to previously published work
Literature on health status as measured by the CCQ in patients with advanced 
COPD is scarce. The CCQ was originally developed and validated by van der 
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Molen et al.3 and has since been validated for the Italian19 and Greek language20 in 
patients with stable COPD. Compared with our results, data from these latter stud-
ies show lower CCQ scores (total scores and separate domain scores). This can 
be explained by the fact that our population suffered from a recent exacerbation 
and that exacerbations have a negative effect on health status. Recently, Kocks et 
al.21 reported data from two randomised controlled COPD exacerbation trials on the 
day-to-day course of patient-reported health status (as measured with the CCQ) 
during exacerbations. They reported results from 210 COPD patients admitted to 
the hospital for an acute exacerbation (mean age 70.6 years, mean FEV1: 37% 
of predicted); the CCQ total score on admission to the hospital was 3.3 (±0.93). 
Although this score is similar to our results, the time at which the CCQ score was 
measured is different, as we measured the CCQ on admission to the SNF. In the 
study by Kocks et al., the CCQ total score improved rapidly during hospital stay, 
with a mean score of 2.3 on day 7. These results seem to confirm that our popula-
tion indeed consisted of those patients who failed to recover during hospital stay.
Our results show a substantial and clinically relevant improvement in health status 
during the PR programme. This suggests that the CCQ is sensitive to change in re-
sponse to PR in this group of patients. Literature on the responsiveness of the CCQ 
to interventions such as PR, or other forms of integrated care, is also scarce. The 
Picasso Bocholtz study6 evaluated the effect of Integrated Disease Management 
on health status as measured by the CCQ in 106 primary-care patients with mild to 
moderate COPD (mean age 64 years, mean FEV1 63% of predicted). At the start of 
the study, the mean CCQ total score was 1.5, with an overall improvement of − 0.4 
(P = 0.001) during follow-up. In the study by Damato et al.,19 the CCQ showed 
sensitiveness to change in 46 patients undergoing an inpatient PR programme; 
the CCQ total score improved from 2.0 at baseline to 1.3 after PR (P<0.001). Our 
data are in line with these studies, indicating that the CCQ is sensitive to change 
following interventions such as PR.
We found no correlation between CCQ total score at baseline and lung function 
(FEV1% of predicted). This is in line with a growing body of evidence showing 
that traditional measurements of disease severity (such as lung function) do not 
correlate well with HRQoL or health status.1,2 However, our results differ from those 
of van der Molen et al.3 and Damato et al.19 In both latter studies a significant 
correlation was found between the mean FEV1% of predicted and the mean CCQ 
total score (van der Molen et al.: r = − 0.38, P<0.01; Damato et al.: r = − 0.57, 
P<0.01). These correlation coefficients account for the total groups, including 
healthy smokers and subjects at risk. In COPD patients (GOLD stage 1–4), van 
der Molen et al. reported a correlation of r = − 0.49 (P<0.001). An explanation for 
these conflicting results can be that all our patients suffered from advanced COPD 
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and thus differed substantially from those in the other two studies. With disease 
progression, health status deteriorates and is probably relatively less influenced by 
the degree of airflow limitation. During the PR programme, we found no correlation 
between baseline lung function (FEV1% of predicted) and improvement in health 
status or functional capacity. This suggests that disease severity, as measured by 
the degree of airflow limitation, does not seem to predict which patients benefit 
most from the PR programme.
Implications for future research, policy and practice
In the present study, we evaluated the use of the CCQ in patients with advanced 
COPD admitted for post-acute PR. Considering our results, we recommend that 
the CCQ should be used as a (primary) outcome measure in an experimental 
study design to evaluate the effect of post-acute (inpatient/outpatient) PR on health 
status in patients with advanced COPD. Our study also confirms that the CCQ 
is a practical and easy-to-use instrument for assessing health status, not only in 
research but also in daily practice. Our study was conducted with patients who 
were recruited after hospital admission for an acute exacerbation and admitted for 
inpatient PR. Thus, our patients were not treated in primary care during this study. 
However, in primary care, patients with advanced COPD are a growing group, with 
a huge burden of disease and in great need of better care. Therefore, research 
should also focus on the course of health status measured by the CCQ in patients 
with advanced COPD in primary care and the clinical use of the CCQ in elaborating 
tailor-made medicine for this specific group of patients.
Conclusions
In patients with advanced COPD, health status measured by the CCQ improves 
after a post-acute PR programme. Moderate-to strong correlations were found 
between the CCQ scores and functional capacity, showing that the CCQ correlates 
well with other important outcome measurements of PR. These results suggest that 
the CCQ is sensitive to change in response to PR in this group of patients.
68 Chapter 4
References
 1. van der Molen T, Miravitlles M, Kocks JW. COPD management: role of symptom assess-
ment in routine clinical practice. International journal of chronic obstructive pulmonary 
disease. 2013;8:461-471.
 2. Sundh J, Janson C, Lisspers K, Montgomery S, Stallberg B. Clinical COPD Questionnaire 
score (CCQ) and mortality. International journal of chronic obstructive pulmonary disease. 
2012;7:833-842.
 3. van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. 
Development, validity and responsiveness of the Clinical COPD Questionnaire. Health and 
quality of life outcomes. 2003;1:13.
 4. Kocks JW, Kerstjens HA, Snijders SL, et al. Health status in routine clinical practice: validity 
of the clinical COPD questionnaire at the individual patient level. Health and quality of life 
outcomes. 2010;8:135.
 5. Kocks JW, Asijee GM, Tsiligianni IG, Kerstjens HA, van der Molen T. Functional status 
measurement in COPD: a review of available methods and their feasibility in primary 
care. Primary care respiratory journal : journal of the General Practice Airways Group. 
2011;20(3):269-275.
 6. Kruis AL, van Adrichem J, Erkelens MR, et al. Sustained effects of integrated COPD 
management on health status and exercise capacity in primary care patients. International 
journal of chronic obstructive pulmonary disease. 2010;5:407-413.
 7. Trappenburg JC, Touwen I, de Weert-van Oene GH, et al. Detecting exacerbations using 
the Clinical COPD Questionnaire. Health and quality of life outcomes. 2010;8:102.
 8. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a 
summary of the ATS/ERS position paper. The European respiratory journal. 2004;23(6):932-
946.
 9. Holstege MS, Zekveld IG, Caljouw MA, et al. Relationship of patient volume and service 
concentration with outcome in geriatric rehabilitation. Journal of the American Medical 
Directors Association. 2013;14(10):731-735.
 10. Wells JL, Seabrook JA, Stolee P, Borrie MJ, Knoefel F. State of the art in geriatric rehabilita-
tion. Part I: review of frailty and comprehensive geriatric assessment. Archives of physical 
medicine and rehabilitation. 2003;84(6):890-897.
 11. van Dam van Isselt EF, Groenewegen-Sipkema KH, Spruit-van Eijk M, Chavannes NH, 
Achterberg WP. Geriatric rehabilitation for patients with advanced COPD: programme char-
acteristics and case studies. International journal of palliative nursing. 2013;19(3):141-146.
 12. Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Stahl E, van der Molen T. Health status 
measurement in COPD: the minimal clinically important difference of the clinical COPD 
questionnaire. Respiratory research. 2006;7:62.
 13. Collin C, Wade DT, Davies S, Horne V. The Barthel ADL Index: a reliability study. Interna-
tional disability studies. 1988;10(2):61-63.
 14. Hsieh YW, Wang CH, Wu SC, Chen PC, Sheu CF, Hsieh CL. Establishing the minimal 
clinically important difference of the Barthel Index in stroke patients. Neurorehabilitation 
and neural repair. 2007;21(3):233-238.
 15. ATS statement: guidelines for the six-minute walk test. American journal of respiratory and 
critical care medicine. 2002;166(1):111-117.
Responsiveness of the CCQ 69
4
 16. Puhan MA, Chandra D, Mosenifar Z, et al. The minimal important difference of exercise 
tests in severe COPD. The European respiratory journal. 2011;37(4):784-790.
 17. Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, Schunemann HJ. Interpretation of 
treatment changes in 6-minute walk distance in patients with COPD. The European respira-
tory journal. 2008;32(3):637-643.
 18. Schunemann HJ, Griffith L, Jaeschke R, et al. A comparison of the original chronic respira-
tory questionnaire with a standardized version. Chest. 2003;124(4):1421-1429.
 19. Damato S, Bonatti C, Frigo V, et al. Validation of the Clinical COPD questionnaire in Italian 
language. Health and quality of life outcomes. 2005;3:9.
 20. Papadopoulos G, Vardavas CI, Limperi M, Linardis A, Georgoudis G, Behrakis P. Smoking 
cessation can improve quality of life among COPD patients: validation of the clinical COPD 
questionnaire into Greek. BMC pulmonary medicine. 2011;11:13.
 21. Kocks JW, van den Berg JW, Kerstjens HA, et al. Day-to-day measurement of patient-
reported outcomes in exacerbations of chronic obstructive pulmonary disease. International 
journal of chronic obstructive pulmonary disease. 2013;8:273-286.

 5A prospective cohort study on the eff ects of geriatric rehabilitation following acute 
exacerbations of COPD








JAMDA; accepted on 12-02-2019.
72 Chapter 5
Abstract
Objectives: Older patients with COPD, hospitalized for an acute exacerbation, 
often do not receive recommended postacute pulmonary rehabilitation. This 
underuse might be related to the impaired clinical and functional status of these 
patients, who are more likely to present with frailty, comorbidities, and disability. 
Having developed and implemented a geriatric rehabilitation program for these 
patients (GR_COPD), the primary aim of this study was to investigate the effective-
ness of this program. Design and intervention: A prospective cohort study with a 
three-month follow-up period. Patients who declined the GR_COPD program were 
considered as controls. Setting and participants: The study was conducted at the 
pulmonary department of two hospitals. Patients were eligible when hospitalized 
due to an acute exacerbation of COPD and indicated for the GR_COPD program 
based on standardized criteria. Methods: Primary outcome was defined as change 
in disease-specific health status measured with the clinical COPD questionnaire 
(CCQ), secondary outcome as the exacerbation rate ratio during follow-up. To bal-
ance potential confounders between the intervention and control group, propensity 
score-based weighted linear regression analyses were performed. Results: Of 
the 158 included patients [78 (49.4%) male, mean age 70.8(±8.1) years, mean 
forced expiratory volume in 1 s: 35.5 (±12.8) as % of predicted], 78 received the 
GR_COPD program. The results of the CCQ showed a significant and clinically 
relevant treatment effect of -0.56 points (CI -0.89 to -0.23; p=0.001). Patients in the 
control group had 2.7 times more exacerbations compared with the intervention 
group [CI 2.13 to 3.58; p<0.001]. Conclusion and implications: This study shows 
a clinically relevant effect of the GR_COPD program on disease-specific health 
status and exacerbation rate. Implementation of the program for older patients with 
severe COPD hospitalized for an acute exacerbation is recommended.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a preventable, treatable, but 
often progressive chronic disease that is characterized by persistent airflow limita-
tion and a chronic inflammation of the airways.1 COPD is an increasing problem as 
it is becoming the third leading cause of morbidity and mortality worldwide.2 This 
trend is especially true in older adults, since prevalence and disease severity of 
COPD are both strongly related to age.2 Acute exacerbations of COPD represent 
a major health care burden. They are the most frequent reason for hospital admis-
sions and death and negatively influence quality of life and prognosis in patients 
with COPD.3-6
Pulmonary rehabilitation in the early postacute period of an exacerbation (post-
acute PR) is an effective intervention to counteract deteriorating health status 
caused by acute hospital admission.3 However, referral, motivation and adherence 
to postacute PR are difficult and it remains unclear how postacute PR can best 
be organized for specific groups of patients.3,7 For example, aging populations 
change the demographics and characteristics of hospitalized patients with COPD, 
i.e. multimorbidity and frailty often interfere with postacute PR.8 Secondly, older 
patients with COPD are often (temporarily) care-dependent after hospital admis-
sion. This care-dependency requires a specific setting for postacute PR and a fluid 
transition from hospital to rehabilitation setting. Lastly, many older patients with 
COPD require palliative care and advance care planning.9 However, palliative care 
is seldom offered to patients with COPD, and integration of palliative care aspects 
into rehabilitation is still not optimal.10
Geriatric rehabilitation is an interesting option for these COPD patients and is 
defined as “evaluative, diagnostic and therapeutic interventions whose purpose is 
to restore functional ability or enhance residual functional capability in older people 
with disabling impairments”.11 Furthermore, integration of palliative care methods 
into geriatric rehabilitation programs is already considered standard care.12,13 Ge-
riatric rehabilitation can be provided in hospitals, intermediate care facilities, or at 
skilled nursing facilities. These latter facilities are usually situated within nursing 
homes, and organized as structured care pathways in collaboration with several 
departments of adjacent hospital(s).
The systematic review of Bachmann et al. showed that geriatric rehabilitation can 
improve outcomes related to function, admission to nursing homes, and mortality.13 
However, their review only included studies on general and orthopedic geriatric 
rehabilitation and lacked studies on the effectiveness of programs in other clinical 
specialties (e.g. pulmonary, cardiac or stroke) specifically designed for geriatric 
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patients. This lack of evidence indicates the need for other types of geriatric reha-
bilitation programs.13
In 2009 we developed and implemented a postacute geriatric rehabilitation program 
for older patients with COPD, called the GR_COPD program. Published clinical 
data and preliminary evaluation of patients’ responses showed that the program 
was feasible and likely to offer substantial improvements in health- and functional 
status.12,14 However, since the feasibility study was not a regular effectiveness trial 
and lacked a control group, the efficacy of the program could not be determined.
Therefore, the GR_COPD study was conducted with the aim to investigate ef-
fectiveness of the GR_COPD program on health status (primary outcome) and 
exacerbation rate and functional status (secondary outcomes); the results of the 
latter study are presented here.
Methods
Design
This was a prospective cohort study conducted in the pulmonary department of 
two hospitals. Data were collected during hospital stay (i.e. at start of the study; 
T0) and during a hospital visit at 3-month follow-up (T1). Patients were included 
between January 2015 and January 2018. The Medical Ethics committee of Leiden 
University Medical Centre approved the study (P14.248), which was registered in 
the Netherlands National Trial Register (NTR6261).
Study population
All patients admitted to hospital with an acute exacerbation COPD, according to 
the Global Initiative for chronic Obstructive Lung disease (GOLD) standards, were 
eligible for this study.1 Patients also needed an indication for rehabilitation based 
on standard inclusion/exclusion criteria (Box 1). When diagnosis and indication 
for rehabilitation were present, patients were invited to participate and the motiva-
tion for the GR_COPD program was assessed. All participants signed a written 
informed consent. 
Randomization for the GR_COPD program was considered unethical as rehabilita-
tion after an acute exacerbation has proven benefits and the program was already 
implemented in practice. Therefore, all patients included in the study were offered 
the GR_COPD program; however, those patients who declined the program were 
considered as controls. Treatment and control participants were recruited in both 
hospitals.
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Box 1. Criteria for the GR_COPD program.
Major inclusion criteria:
1. Decline of functional status (ADL)
2. Health status is severely impaired, as measured by CCQ, score ≥ 2.0
3. Frequent exacerbations; ≥ 2 in the last 6 months (excluding the present 
exacerbation)
Minor inclusion criteria:
1. Hypoxemia (excluding pre-existent chronic respiratory failure)
2. Impaired nutritional status: BMI < 21 kg/m2 and/or FFMi depletion
3. Patients at risk for clinically relevant anxiety disorder or depression; HADS 
≥ 8 on either subscale
Indication for the GR_COPD program: 2 major OR 1 major AND 2 minor criteria
Exclusion criteria:
1. Conditions interfering with rehabilitation, such as end-stage of disease
2. Major psychiatric or cognitive disease
Abbreviations: ADL: activities of daily living; CCQ: Clinical COPD questionnaire; BMI: body 
mass index; FFMI: fat-free mass index; HADS: Hospital anxiety and depression scale.
GR_COPD program
The complete GR_COPD program has been described in detail elsewhere and 
is available in appendix 1; briefly, it consisted of a six-week inpatient multidisci-
plinary rehabilitation program delivered immediately after hospital admission.12 
The program is organized as an integrated care pathway and contains multiple 
standard modules, e.g. daily physiotherapy sessions, occupational therapy, and an 
extensive self-management education program. Patients followed a standardized 
daily program, individually tailored to the patient’s needs and possibilities, based 
on a comprehensive assessment. 
Measurements
The following information was collected: age, sex, spirometry (according to the 
GOLD guidelines),15 co-morbidity [Charlson Comorbidity Index (CCI); with a total 
score of ≥2 (excluding COPD) indicating major co-morbidity],16 smoking status 
(current smoker/non-smoker) and the use of oxygen therapy (yes/no). Symptoms 
of anxiety and depression were measured using the Hospital Anxiety and Depres-
sion Scale (HADS); a score of ≥8 on either subscale indicates a high risk for the 
presence of an anxiety disorder or depression.17 Nutritional status was measured 
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by calculating body mass index (BMI; kg/m2); and was divided into underweight 
(<21 kg/m2), normal weight (21-30 kg/m2), and obesity (>30 kg/m2).18
Primary outcome
The primary outcome was defined as change in disease-specific health status as 
measured with the clinical COPD questionnaire (CCQ).19 The CCQ is a validated, 
reliable, 10-item self-administered questionnaire (appendix 2). Items are scored on 
a scale ranging from 0-6; the final score is the sum of all items divided by 10, result-
ing in a total-score ranging from 0-6. The CCQ is sensitive to change in response to 
rehabilitation in these patients and the minimal clinical important difference (MCID) 
of the CCQ total score is ±0.4.20-22
Secondary outcomes
Exacerbation rate and change in functional status were defined as secondary out-
comes. Exacerbation rate during follow-up was assessed using a standard ques-
tion: “How many acute exacerbations (periods of acute worsening of respiratory 
symptoms that resulted in additional therapy [corticosteroids and/or antibiotics) 
and/or hospital admission] did you have in the previous three months?” In case of 
missing data, information was retrieved from the patient’s file.
Functional status was measured with the Barthel index (BI) for activities of daily liv-
ing (ADL); the BI is a valid, reliable instrument to assess ADL during rehabilitation 
with a MCID of ± 1.85.23,24 Total score ranges from 0-20, with 20 representing com-
plete functional independence, 15-19 mild, 10-14 moderate and <10 severe care 
dependency, respectively.24 Exercise capacity was measured with the six-minute 
walking test (6MWT), assessed according to the ERS guidelines.25 The 6MWT is a 
widely used instrument to measure exercise capacity in patients with COPD with 
a MCID of ±30 meter.26 Scores are measured in number of meters walked in six 
minutes and range from zero to the maximum amount. A score of zero indicates 
that the patient is unable to walk or perform the test.
Effect evaluation
General statistical analysis
All data were processed using the SPSS, version 23. Descriptive analyses were 
used for baseline patient and disease characteristics (at T0). Categorical variables 
are described as frequencies; continuous variables were tested for normality and 
are presented as mean and standard deviation (SD), or median and interquartile 
range (IQR) in case of skewed data.
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Propensity score
To balance potential confounders between the intervention (GR_COPD) group 
and the controls, the propensity score (PS) was estimated and PS analyses was 
performed. PS estimation and analysis were based on recently published recom-
mendations that were obtained from a research method symposium of the Ameri-
can Geriatrics Society.27 To estimate the PS, potential confounders were identified 
based on published data and included the following variables: age, sex, marital 
status, lung function, oxygen therapy, exacerbation rate, co-morbidity score, smok-
ing status, ADL status, BMI, HADS and hospital location. These variables were de-
termined prior to data lock and specified in the Dutch Trial Register (NTR6261). All 
variables included in the PS were measured before treatment initiation. Continuous 
variables were transformed into categorical variables (when appropriate) according 
to literature.16-18 Then, the PS (probability of receiving rehabilitation) was estimated 
for all individuals included in the dataset using a logistic model encompassing 27 
parameters. The PS model was then evaluated using the standardized mean dif-
ference (SMD) to assess the balance in potential confounders between the two 
groups. An SMD of <0.1 was considered acceptable.28,29 Overlap in the distribution 
of the PS between the two groups was examined using a graphical presentation.
The primary outcome measure was the mean change in health status as measured 
by the CCQ_delta during follow-up (CCQ at T1 minus CCQ at T0) adjusted for the 
CCQ score at T0. The adjusted treatment effect (ATE) was estimated with a weighted 
linear regression, using PS-based weights defined as the inverse of the probability 
of receiving the treatment that the patients actually received. Thus, the weight (w) 
to estimate ATE is w=1/PS for the intervention group and w=1/(1-PS) for the control 
patients. The CCQ score at T0 was added to the model as a second covariate.
Secondary outcomes (analyzed in a similar way) were mean change in ADL status 
and functional exercise capacity (also controlled for baseline values). Poisson 
regression analysis was used for the exacerbation rate during follow-up as a de-
pendent variable (since exacerbation rate is a count outcome). Data were visually 
assessed for the required model assumptions. The following sensitivity analyses 
were made: we calculated the PS and weight (w) for the dataset with complete 
CCQ results at T1 that were used for the primary analysis (n=125) and explored the 




During the inclusion period, 394 patients were hospitalized for an acute exacerba-
tion (Figure 1); of these, 275 met the inclusion criteria and were eligible for this 
study. Of this latter group, 81 refused participation and 36 patients could not be 
included due to other reasons (i.e. most were already discharged).
Finally, 158 patients were included: 78 (49.4%) male, mean age 70.8 (±8.1) years, 
and mean forced expiratory volume in 1 s (FEV1) as % of predicted value: 35.5 
(±12.8). Of these, 78 patients received the GR_COPD program and the remaining 
80 patients served as controls.
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-missing CCQ_delta (N=2) 




-missing CCQ_delta (N=2) 
Lost  (N=36) 
Abbreviations: COPD: chronic obstructive pulmonary disease; CCQ: Clinical COPD question-
naire;
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No differences in age, sex, CCQ and HADS scores were found between the 
included patients and those that declined participation or were lost before they 
could be included. Table 1 presents baseline data on the participants before and 
after weighting. Before weighting, patients in the intervention group had worse 
lung function and a higher percentage of current smokers, higher HADS and lower 
co-morbidity scores, compared with the controls. After PS weighting, the FEV1 
% predicted was still higher in the controls; however, when classified into GOLD 
stages no differences were found, indicating sufficient balance in lung function as a 
potential confounder between the two groups. Although the percentage of current 
smokers was lower in the controls after PS weighting (SMD 0.10), we considered 
this difference acceptable, also taking into account the expected negative influence 
of smoking on outcome measures.
During follow-up, eight patients died, 18 resigned from the study and three were 
lost for other reasons. In four other patients, the primary outcome measure (CCQ_
delta) was missing. Patients that dropped out of the study [n=21; 9 (43%) male] 
were slightly older [73.3 (± 6.8) years] with slightly better lung function [FEV1 38.2 
(±13.5) % predicted] at baseline compared to participants that completed follow-up. 
No other differences at baseline were found.  Eight patients died during follow-up 
[sex: 75% male; mean age 75.5 (±7.9); mean FEV1 32.5 (±14.5) % predicted; mean 
CCQ_T0: 3.7 (±1.1)].
Estimation of treatment effect
Table 2 shows the treatment effect for the primary and secondary outcome mea-
sures. During follow-up, the intervention group improved (on average) 1.42 CCQ 
points compared with 0.75 points in the controls (unadjusted values); this differ-
ence represents a significant and clinically relevant adjusted treatment effect of 
-0.56 points (p=0.001). Effect analysis of the exacerbation rate during follow-up, 
showed that the control group 2.7 times more frequently had an acute exacerbation 
compared with the intervention group [rate ratio 2.7 (CI 2.13 to 3.58); p<0.001]. 
Regarding functional status, the BI showed a clinically relevant improvement in 
the intervention group; however, when adjusted for baseline data, the difference 
between the two groups was no longer significant (p=0.56). The 6MWT showed 
a clinically relevant improvement in both groups, with no significant differences 
between the groups on the 6MWT_delta [adjusted treatment effect +89 (±99) vs 
+50 (±114); p=0.76].
Sensitivity analysis
A secondary PS and weight (w) was calculated for the dataset including only those 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(change in CCQ) was repeated using weighted linear regression. Results showed 
a very similar adjusted treatment effect (beta -0.53; CI -0.85 to -0.20; p=0.002). 
Also, only small differences were found in treatment effect when truncating maxi-
mum weights to five (beta -0.53; CI -0.86 to -0.20; p=0.002) and to ten (beta 0.56; 
CI -0.89 to -0.23; p=0.001).
Discussion
The main finding of this study is a significant and clinically relevant effect of the 
GR_COPD program on health status and on exacerbation rate during follow-up.
These are the first reported data on the effects of geriatric rehabilitation for patients 
with severe COPD. When comparing these data with the results of our feasibility 
study, several similarities emerge.14 First, patients’ characteristics, such as age 
[68.9 (±9.9) years], sex (51% male), marital status (46% living alone) and lung 
function [FEV1 32.9 (±10.8) % predicted] are similar. More interestingly, the present 
results confirm the outcomes of our feasibility study on the preliminary evaluation 
of patients’ response to the program [mean CCQ score improved from 3.5 (±0.9) to 
2.2 (±1.0)], showing that these results are robust and reproducible.
Our data are in with line others who reported positive effects of rehabilitation in 
the early postacute phase of an exacerbation.3 The systematic review of Puhan 
et al that investigated the effect of short-term hospital based and outpatient or 
home-based programs, described only one study with an extensive postacute 
PR program similar to our program.3,30 In this latter study, 46 patients [mean age 
64.0 (±1.9)(intervention); 68.0 (±2.2)(controls); mean FEV1, 36 (±7) % predicted] 
hospitalized for an exacerbation received either usual care or a 10-day hospital 
based training, followed by a 6-month program of supervised walking training at 
home and education.31 The authors reported sustained improvements in quality of 
life and exercise capacity, but no data on co-morbidity and functional status were 
presented, making comparison to our data difficult. One study in the review of 
Puhan et al also reported on exacerbation rate as outcome and showed a trend in a 
reduction of exacerbation rate in the intervention group; however, only 26 patients 
were included and the effect was not significant (p=0.06).32 Furthermore, the in-
tervention consisted of a home-based program and patients were slightly younger 
[mean age 67 y (±9.7) (intervention); 65.0 y (±11.0) (controls)] with less severe 
airflow obstruction [mean FEV1, 38 (±12) and 42(±12) % predicted, intervention and 
controls respectively] compared with our population. Thus, although the usefulness 
of this comparison is debatable, the effect we found on exacerbation rate seems 
relatively large. Hypothetically, this might also be an effect of the inpatient setting, 
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as the GR_COPD program offered a relatively safe and proactive environment 
with 24/7 medical care for (on average) the first six weeks follow-up. In conclusion, 
although our novel results are broadly in line with others, due to the heterogeneity 
in patient characteristics, setting and intervention, comparison is somewhat limited.
Strengths and limitations
Our study design encompasses both strengths and limitations. Conducting trials on 
the effects of postacute PR is challenging.3 For example, recruitment of patients is 
problematic and randomization is considered unethical given the poor health status 
of most of these patients and the proven benefits.3 As these difficulties probably 
apply even more to geriatric patients, more observational studies are required as 
they are an important source of data when evaluating treatment benefits and harms 
in older adults.3,27 Because lack of comparability in outcome risk factors between 
the treatment and control group could lead to confounding, we chose to use the 
recommended PS weighting techniques.27 Nevertheless, confounding is still pos-
sible and cannot be fully excluded. Because this was a prospective observational 
cohort-study and lenient exclusion criteria were applied, generalizability within this 
group and setting is high. However, selection bias is possible due to the criteria 
applied and because 36 eligible patients were not included since they were already 
discharged. Moreover, patients willing to participate might have been a selective 
group, even though no differences were found in demographics, CCQ and HADS 
scores between included and not included patients.
There was no effect of the GR_COPD program on functional status. Although the BI 
improved in the intervention group, this effect was not significant when controlling 
for baseline data. This lack of treatment effect is probably partly due to the ceiling 
effect of the BI, i.e. at baseline 47 (29.8%) patients already had the maximum 
score of 20. This questions the validity of the BI as a suitable outcome measure 
in this specific group of patients and setting. Also, no treatment effect was found 
on the 6MWT, which is unexpected considering earlier studies on postacute PR 
on exercise capacity. Explanations for this finding could be the wide range of the 
6MWT in both our groups, the amount of missing data (40%) leading to limited 
power, and/or more room for improvement in the treatment group considering their 
lower baseline values. Furthermore, in our patients, baseline 6MWT values were 
relatively low compared with others.30,33,34 These results reflect the poor functional 
status of our patients, and also question the relevance of the 6MWT as an outcome 
measure in these patients.
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Conclusion and implication
This study shows beneficial effects of the GR_COPD program on disease-specific 
health status and exacerbation rate. The results indicate that geriatric rehabilitation 
for older patients with severe COPD hospitalized for an acute exacerbation is effec-
tive and could be implemented in clinical practice. Future research may establish 
whether these results can be maintained for a longer period and whether more 
suitable and relevant outcome measurements on functional status are required for 
this specific group of older patients.
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Appendix 1 Chapter 5: The GR_COPD program
The GR_COPD program was developed as a structured-care pathway. The program 
offers multidisciplinary patient-centred rehabilitation that also integrates palliative 
care aspects, to older patients with COPD who have been hospitalised for an acute 
exacerbation. The program aims to counteract or stabilise the gradual decline in 
health status, achieve sustainable improvements in functional status, quality of 
life and self-management, and prevent hospital readmissions. The multidisciplinary 
team that offers the GR_COPD program consists of an elderly care physician, 
a skilled nurse, a physiotherapist, a psychologist, an occupational therapist, a 
speech and language pathologist, a dietician, and a social worker. The GR-COPD 
program contains several modules concerning different aspects of rehabilitation 
and palliative care, categorized into three domains: i) body structure and function, 
ii) functional status and iii) self-management. These three domains encompass 
several standard treatment modules, all targeted at improving disease-specific 
health status as the ultimate goal of the program. 
Improvement in body structure and function is achieved through treatment modules 
that focus on a) optimizing pharmacological treatment, inhalation techniques and 
oxygen use, b) prevention and treatment of co-morbidities, c) optimizing nutritional 
status and/or treatment of undernourishment, and d) improving symptom burden.
To improve functional status, patients receive endurance and strength training, 
inspiratory muscle training, relaxation techniques, breathing regulation skills, 
mucus evacuation techniques and occupational therapy. If endurance and strength 
training is not feasible, due to limited training capacity, rehabilitation is aimed at 
decreasing care dependency, home adaptation, medical aids and providing profes-
sional support at home.
Improvement of self-management, as the third domain of the GR_COPD program, 
is pursued by the following treatment modules: education on COPD, peer-group 
support, smoking cessation support, training of energy saving techniques, gen-
eral advice concerning healthy aging (e.g. nutrition, exercise), and assessment of 
compliance and coping responses (e.g. patients compliance with care recommen-
dations, adaptive coping responses). Furthermore, the needs of informal/family 
caregivers are addressed and advance care planning is discussed.
The treatment program (including goal setting) is tailored to the individual patient, 
based on a comprehensive assessment (GA) that is conducted within the first week 
after admission. The program is weekly evaluated and adjusted (as needed) by 
the multidisciplinary team and the pulmonologist, who makes monthly visits to all 
patients. All patients follow a standardized 4-6 weeks program and assignment to 
therapies is stringent. The program contains a minimum of six 40-min physiotherapy 
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sessions per week, usually three endurance- and three strength training sessions. 
Group sessions are combined with individual training. Furthermore, training of 
breathing-, huffing- and relaxation techniques is offered once a week. Occupational 
therapy is given once or twice a week in 30- to 45-min sessions and analysis and 
evaluation of nutritional status is done by the dietician every week. Patients partici-
pate in weekly group sessions, which are supervised by the psychologist, and are 
aimed at education of patients and relatives on self-management strategies and 
peer support contact.
The GR_COPD study 87
5
Appendix 2 Chapter 5 
 
Clinical COPD Questionnaire 
Please circle the number of the response that best describes how you have been feeling during the past week 
(only one response for each question) 
On average, during the past week, 














1. Short of breath at rest? 
 
0 1 2 3 4 5 6 
2. Short of breath doing 
physical activities? 
0 1 2 3 4 
 
5 6 
3. Concerned about getting a 
















4. Depressed (down) because 
of your breathing problems? 
0 1 2 3 4 5 6 
In general, during the past week, 
how must of the time: 
0 1 2 3 4 5 6 
5. Did you cough? 
 
0 1 2 3 4 5 6 
6. Did you produce phlegm? 
 
0 1 2 3 4 5 6 
On average, during the past week, 
how limited were you in these 




















7. Strenuous physical activities 
(such as climbing stairs, 















8. Moderate physical activities 
(such as walking, 















9. Daily activities at home 
















10. Social activities 
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6Pain in patients with COPD: a systematic review and meta-analysis










Objectives: To systematically investigate the prevalence of pain, factors related 
with pain and pain management interventions in patients with chronic obstructive 
pulmonary disease (COPD). Design: Systematic review and meta-analysis. Data 
sources and study eligibility criteria: PubMed (MEDLINE), EMBASE, CINAHL and 
PsychINFO from 1966 to December 2013. Studies were included if they presented 
clinical data on pain or symptom burden in patients with COPD, or pain as a domain 
of quality of life (QoL). All types of study designs were included. Results: Of the 
1571 articles that were identified, 39 met the inclusion criteria and were included 
in this review. Fourteen studies focused on pain and symptom burden (including 
pain) in patients with COPD and 25 studies focused on QoL using a questionnaire 
that included a separate pain domain. Reported pain prevalence in high-quality 
studies ranged from 32 to 60%. Included studies report that pain is more prevalent 
in patients with COPD compared to participants from the general population. Co-
morbidity, nutritional status, QoL and several symptoms were related to pain. None 
of the included studies reported a significant relationship between lung function 
and pain prevalence or severity. However, studies investigating pain in patients 
with moderate COPD reported higher pain prevalence compared to studies in 
patients with severe of very severe COPD. Conclusions: Although literature on this 
topic is limited and shows substantial heterogeneity, pain seems to be a significant 
problem in patients with COPD and is related to several other symptoms, comor-
bidity and QoL. Data synthesis suggests that pain is more prevalent in patients 
with moderate COPD compared to patients with severe or very severe COPD. 
Further research is needed and should focus on determining a more accurate pain 
prevalence, investigating the relationship between pain prevalence, disease sever-
ity and comorbidity and explore implementation and efficacy of pain management 
interventions in patients with COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a chronic, usually progressive 
airway disease. Both the prevalence and disease severity of COPD are strongly 
related to age and worldwide, the rate of related morbidity and mortality is rising.1 
COPD represents a major burden for individual patients, healthcare systems and 
societies in terms of healthcare costs.2 As the disease progresses, health status 
becomes increasingly impaired. Especially in advanced COPD, patients suffer 
from high symptom burden, impaired functional capacity and poor quality of life 
(QoL).3,4 Well-known symptoms in COPD are dyspnoea, cough and wheezing, 
whereas other symptoms such as fatigue, nausea and insomnia are also frequently 
reported.5 Recent literature indicates that pain is also a significant symptom in 
patients with COPD. Two systematic reviews on patients with end-stage COPD6,7 
reported prevalences of pain of 21–77%. Both these reviews reported only on stud-
ies including patients with advanced or terminal disease or studies on palliative 
care in patients with very severe COPD. Less is known about pain in patients 
with mild-to-moderate disease. In a cross-sectional study on pain in patients with 
moderate-to severe COPD, HajGhanbari et al8 reported that pain is more preva-
lent among individuals with COPD compared with healthy adults. Bentsen et al9 
found similar results, reporting pain in 45% of the patients with moderate COPD 
compared with 34% in the general population. Other questions remain about pain 
in COPD. For example, the relationship with disease severity and comorbidity 
remains unclear and information on the causes and characteristics of pain, and 
how pain influences functional capacity and QoL, is scarce.8,9 There are several 
factors related to COPD that may contribute to a higher pain prevalence in patients 
with COPD. The systemic inflammatory process, which activates cytokines, may 
generate chronic and neuropathic pain. Musculoskeletal disorders and comorbidi-
ties (including mechanical limitations of chest wall movement due to hyperinflation 
and osteoporosis) are also considered possible causes of pain in patients with 
COPD and inactivity may aggravate common age-related comorbidities such as 
osteoarthritis and low back pain.8 Improving knowledge on aetiology, character-
istics, correlations and impact of pain is important and necessary to improve pain 
recognition and pain treatment in patients with COPD. It is likely that adequate pain 
recognition and treatment is important in improving QoL, exercise tolerance and 
lifelong adherence to physical activity in patients with COPD. Thus, pain seems to 
be a relevant but poorly understood problem in patients with COPD. Therefore, the 
aim of this review is to systematically describe and investigate pain in patients with 
COPD. More specifically, to examine the prevalence of pain and factors related 




We conducted a systematic search using MEDLINE/PubMed (from 1966 to De-
cember 2013), EMBASE (from 1980 to December 2013), CINAHL (from 1981 to 
December 2013) and PsychINFO (from 1980 to December 2013) using the follow-
ing groups of keywords:
1. Pain, pains, Pain Measurement, Analgesics, analgesic (PubMed), pain, pain 
assessment, analgesia, analgesic (EMBASE), Pain, analgesia, analgesic (CI-
NAHL), Pain, Aphagia, Back Pain, Chronic Pain, Headache, Myofascial Pain, 
Neuralgia, Neuropathic Pain, Somatoform Pain Disorder, Analgesia, analgesic 
(PsychINFO).
2. Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive, 
chronic bronchitis, chronic obstructive airway disease, chronic airway obstruc-
tion, chronic airway obstructions, COAD, chronic airflow obstruction, chronic 
airflow obstructions, Pulmonary Emphysema.
Keywords were entered using controlled terms (eg, Medical Subject Headings in 
Medline) and as free-text word. Within each group the keywords were combined 
using ‘OR’ and the two groups were combined using ‘AND’ (supplementary file). No 
language or other restrictions were applied. Reference lists from included studies 
and reviews were searched by hand to identify additional articles. All articles that 
were identified by the electronic search were put into a reference database (Refer-
ence Manager V.12.0).
Selection of studies
Articles that reported original data on pain in patients with COPD, or assessed pain 
as a domain of QoL in patients with COPD, were considered eligible. We included 
all types of study designs (cross-sectional, longitudinal, prospective/retrospective, 
qualitative/quantitative design). Articles without an (English) abstract, reviews, 
editorials, conference abstracts and case reports were excluded. Two members 
of the review team (EFvDvI and KG) independently assessed the titles and ab-
stracts of all potentially relevant publications that were identified from the search. 
Decisions of the two reviewers about inclusion/exclusion were compared and, in 
case of disagreement, were resolved by asking a third reviewer (DJAJ) to achieve 
consensus. Subsequently, the same two reviewers evaluated the full text of all 
potentially eligible articles. Decisions about inclusion and exclusion were again 
compared and, in case of disagreement, resolved by asking the third reviewer in 
order to achieve consensus.
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Data extraction and quality assessment
Details on study design, patients, setting and outcome were recorded by two 
independent reviewers (EFvDvI and KG). For each study the following items 
were recorded: author, journal, year of publication, country of origin, design and 
aim of the study, setting, inclusion and exclusion criteria, response rate, number 
of patients, patient characteristics [age, forced expiratory volume in 1 s as % of 
predicted value (FEV1% predicted), Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) grade, and gender], pain and QoL instrument used, reported pain 
prevalence or mean score on the pain domain of the QoL instrument, correlations, 
limitations and conclusions.
All included articles were ranked for quality according to the Mixed Method Ap-
praisal Tool (MMAT).10 The MMAT has recently been developed for the appraisal 
stage of systematic literature reviews that include quantitative, qualitative and 
mixed methods studies. The MMAT has proven to be an effective and practical 
quality assessment tool for mixed method review studies.10 The MMAT consists 
of four criteria for the appraisal of quantitative (descriptive, randomised and non-
randomised) and qualitative studies. Hence, each study design is judged within 
its methodological domain (Table 1). The MMAT scores range from 100% (all four 
criteria are met) to 25% (one criterion is met). In the present review, quality as-
sessment scores were calculated for all included studies. Ranking according to the 
MMAT was conducted by two independent reviewers (EFvDvI and KG) and any 
disagreement in the MMAT scores was resolved by discussion or by asking a third 
reviewer (DJAJ) for advice to reach consensus.
Data synthesis and meta-analysis
A meta-analysis was performed concerning the Short-Form health survey (SF)-
36_Bodily Pain data. The SF-36 is a widely used, self-administered, reliable and 
valid instrument to assess generic health-related QoL.11 The SF-36 consists of 36 
items divided into eight subdomains. The score of each subdomain ranges from 0 
to 100, with 100 representing the best quality of life. The questionnaire contains 
two questions related to pain: the SF-36 bodily pain subdomain (SF-36_BP): ‘How 
much bodily pain have you had during the past (4) week(s)?’ [score from 0 (no pain) 
to 6 (very severe pain)] and ‘During the past (4) week(s), how much did pain inter-
fere with your normal work (including both work outside the home and housework)?’ 
[score from 0 (not at all) to 5 (extremely)] We performed a meta-analysis with a 
Forest plot using a Microsoft Excel spreadsheets, as developed by Neyeloff et al.12 
They showed that this method produces a statistically adequate but graphically 
appealing forest plot summarising descriptive data. We assumed a random-effects 
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heterogeneity was assessed with the Q statistic and the I2 index. Meta-analyses 
and Forest plots using a Microsoft excel spreadsheet were conducted by step-by-
step guide focusing on descriptive data analysis.12 To determine the strength of the 
linear correlations between lung function (FEV1% predicted) and pain prevalence 
and the SF-36_BP score, we calculated the correlation coefficient between these 
variables. In case of normally distributed data, Pearson correlation coefficient was 
calculated. In case of non-normally distributed data a non-parametric test (Spear-
man’s test) was used. We defined statistical significance at p≤0.05 (two-sided level 
of significance). In studies that presented only the GOLD grade distribution the 
mean GOLD grade was calculated and converted into a mean FEV1%-predicted.
Results
Study selection and characteristics
The electronic systematic search identified 1571 eligible citations (PubMed 1067, 
EMBASE 379, CINAHL 71, PsychINFO 54). Eight studies were identified using 
other sources. A total of 1491 citations were excluded based on title and abstract. 
In total, 88 articles were reviewed in detail. Reasons for exclusion are reported in 
the PRISMA flowchart (Figure 1). Thirty-nine studies met the inclusion criteria and 
were included in the review (Tables 2 and 3).
Fourteen studies focused on pain and symptom burden (including pain) in 
COPD5,8,9,13-23 and 25 studies focused on QoL using a questionnaire that included 
a separate pain domain4,24-47 (Table 2 and 3). The included studies were published 
between 1995 and 2013. All included studies on symptom burden in COPD were 
published in the past decade (2000–2013) and studies with a specific focus on pain 
in COPD were published in the last 5 years (Figure 2).
Of the 14 articles on pain and symptom burden in COPD, three reports from Bent-
sen et al9,21,22 and two reports from Borge et al18,20 were based on the same original 
research study. Ten studies were conducted at the outpatient pulmonary depart-
ment of a hospital (secondary and tertiary care), one in primary care and three 
were population-based studies. Most studies on pain and symptom burden (n=10; 
71%) had a cross-sectional design. The majority of the included studies on pain as 
a domain of QoL also used a cross-sectional design (n=17; 68%), seven studies 
used a prospective design [observational (n=3) and interventional (n=4)] and one 
study used a retrospective design. Almost all studies (n=21) on pain as a domain of 
QoL included patients with COPD recruited from an outpatient pulmonary depart-
ment or hospital/intensive care unit setting (secondary and tertiary care).
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Quality assessment
Of the 14 studies on pain and symptom burden in COPD, 10 had a MMAT score 
of 100%, three scored 75% and one study scored 50% (Table 2). Shortcomings 
in quality included insufficient response rate,13,14,18,20 or insufficient comparability 
between participants.13 Of the 25 studies on pain as a subdomain of QoL, 20 had 
a score of 75% (n=14) or 100% (n=6). The most frequent shortcoming in quality 
assessment was an insufficiently or not reported response rate (n=19; Table 3).




Potentially relevant records identified from 


























Additional records identified 






Records excluded (n=581) 
- not concerning pain in COPD (229) 
- no original data (124) 
- no (English) abstract (12) 
- conference abstract (16) 
- case report (60)  
- doubles (12) 
- adverse drug reaction (94) 
- pain during acute bronchitis (7) 
- anaesthetic management in COPD (27) 
Full-text articles excluded (n=49) 
- not concerning pain in COPD (12) 
- pain domain outcome of the QoL instrument      
not reported (13) 
- no disease stratification (11) 
- data also reported in another included study (2) 
- reported data included outcomes of patients 
with asthma (11) 
Studies included in 
qualitative synthesis 
(n=39) 




Records excluded: not 
concerning COPD 
(n=910) 
Abbreviations: COPD: chronic obstructive pulmonary disease; PRISMA: preferred reporting 
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Pain measurement
Pain was measured using diff erent instruments. Five studies on pain and symptom 
burden in COPD used the Brief Pain Inventory (BPI), or the body outline diagram of 
the BPI.48 The BPI is a self-administered questionnaire used to assess the severity 
of pain [scale 0–10; cut-off  points: mild pain (0–4), moderate pain: (5–6) and severe 
pain (7–10)] and the impact of pain on daily functioning (scale 0–10) in patients with 
chronic diseases or conditions. The BPI also contains a body diagram on which pa-
tients can indicate the location on which they experienced the most pain.20,48 In fi ve 
studies pain was not measured with a specifi c pain or symptom questionnaire, but 
a screening question was used, such as: ‘Are you generally bothered with pain?’9 
or ‘Are you usually free of pain and discomfort?’15 Other instruments used were: 
the McGill Pain Questionnaire (MPQ), the Memorial Symptom Assessment Scale 
(MSAS), the VOICES questionnaire and the London and Leeds Pain Survey. One 
study measured pain using a Visual Analogue Scale (VAS).5 Pain as a subdomain 
of QoL was measured using fi ve diff erent instruments: the SF-36 (n=19), the Eu-
roQol-5 Dimensions (EQ-5D; n=3), the Nottingham Health Profi le (NHP; n=3), the 
Health Status Questionnaire (HSQ; n=1) and the Duke Health Profi le (DHP; n=1).
Figure 2. Number of publications on ‘pain’ and ‘symptom burden including pain’ in patients with 




























Of the 14 studies on pain and symptom burden, 11 reported the prevalence of 
pain: range from 21% to 72.1% (Figure 3). Studies on prevalence of pain differed 
in design, setting and patient characteristics. Mean age ranged from 57.9 to 76.8 
years and mean FEV1% predicted ranged from 21% to 48%. Three studies did not 
report the mean FEV1% predicted or the GOLD grade of the included patients. 
The MMAT scores of the studies that reported pain prevalence ranged from 50% 
to 100%. The reported pain prevalence of the studies with a MMAT score of 100% 
ranged from 32.4% to 59.8% (Figure 3). Five studies investigated the prevalence of 
pain in patients with COPD compared to participants from the general population,8,9 
patients with other chronic diseases,5,23 or patients with lung cancer.13 Bentsen et 
al9 found a pain prevalence in patients with COPD of 45% compared to 34% in 
the general population (p=0.02) and HajGhanbari et al8 reported that patients with 
COPD reported 2.5 times more pain and 3.7 times more interference of pain with 
daily activities, compared to healthy people. Roberts et al23 also reported a higher 
pain prevalence in patients with COPD compared to patients with other chronic 
diseases (59.8% vs 51.7%; p=0.001), but in the study conducted by Janssen et 


















◆ prospective cohort study; ● cross-sectional study; ■ mixed method; ▲ retrospective 
post-bereavement study.  Green: Mixed Method Appraisal Tool (MMAT)-score of 100%; Or-
ange: MMAT-score of 75%; Red: MMAT-score of 50%.
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al,5 patients with chronic heart failure reported more pain than patients with COPD 
(48.8% vs 32.4%, p=0.05).
Of all included studies, 19 used the SF-36, the SF-20 or the SF-8. Of these, 17 
reported scores on the bodily pain domain as a mean score (SD). In four of these 
studies, the SF-36_BP was measured in two separate groups of patients with COPD 
(cases and controls). A random-effects meta-analysis on the SF-36/20/8_BP data 
of the 21 studies and groups of patients with COPD, showed a mean score on the 
SF-36_BP of 66.7 (CI 95% 61.2; 72.2; Figure 4). The three studies that used the 
EQ-5D showed that 45%,40 46%4 and 56%41 of the patients with COPD reported 
having any problems on the subdomain pain/discomfort of the EQ-5D, respectively.
Characteristics of pain
Five studies measured pain intensity and interference using the BPI. Mean pain 
intensity scores ranged from 2.8 to 5.4 points (mild to moderate pain) and mean 
interference scores ranged from 3.6 to 5.8 points (mild to moderate interference) 
on a scale from 0 to 10 (higher scores indicating more pain intensity/interference). 
Three studies used the body outline diagram of the BPI to investigate the most 
prominent locations of the experienced pain.9,17,20 Most frequently reported loca-
tions of pain were the shoulders and neck: 33% (n=15),9 36.4% (n=56)20 and 50% 
(n=8)17; lumbar region: 29.2%(n=45)20 and 47% (n=21)9 and chest: 17.5% (n=27),20 
36% (n=16)9 and 38% (n=6).17 None of the included studies investigated the type 
of pain (eg, neuropathic or nociceptive pain) or conducted a comprehensive pain 
assessment.
Factors related to pain
Of the 14 studies on pain or symptom burden, seven reported factors related to 
pain or correlations between pain and several variables, such as lung function, 
comorbidity and other symptoms (Table 4). Four of these studies reported from the 
same two original studies.18,20-22 None of the studies on pain or symptom burden 
reported a significant relationship between lung function (FEV1% predicted, GOLD 
grade) and pain prevalence or pain severity. Several studies reported a significant 
correlation between pain and comorbidity.8,21,23 Bentsen et al21 reported that co-
morbidity was a risk factor for pain in patients with COPD; patients with COPD and 
pain were more likely to report the presence of comorbidity and had a significantly 
higher number of comorbidities. However, the study from Borge et al20 found no 
significant difference in the number of comorbidities between patients with COPD 
with and without pain. These conflicting results are also found for the correlation 
between pain severity and the number of comorbidities (Table 4).8,18 Other vari-
ables that showed a significant correlation with pain presence or pain severity are: 
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Figure 4. Random eff ects meta-analysis of studies that examined the mean score on Short-
Form health survey-36 (SF-36_BP) in patients with chronic obstructive pulmonary disease. 
The Forest plot shows the mean scores with 95% CIs for included study populations. The Q 
statistic was 19.32 with df=20 (p>0.10) and I2 was 0%. The MMAT scores are shown using 
diff erent colours: green: MMAT-score: 100%; orange: MMAT-score: 75%; red: MMAT-score: 
50%; purple: MMAT-score: 25%.
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QoL, breathlessness, insomnia, fatigue, anxiety, depression and nutritional status 
(Table 4). Of the included studies on pain as a subdomain of QoL, none reported 
correlations between the SF-36_BP score and variables of interest. Two studies 
using other QoL instruments, that is, the EQ-5D40 and the NHP27 concluded that 
their analysis showed no significant correlation between pain as a subdomain of 
QoL and lung function.
Pain management interventions
None of the included studies aimed to investigate the effect of a specific intervention 
on pain in patients with COPD. Bentsen et al9 reported that 49% of the participants 
with pain received treatment with analgesics and 16% received physiotherapy. In 
a cross-sectional study in patients with advanced COPD, Janssen et al5 found that 
47% of the patients with pain (VAS score >30 mm) reported that their symptoms 
were addressed. Furthermore, if symptoms were treated, patients reported only 
moderate satisfaction with symptom treatment. One study on symptom burden in 
patients with severe COPD in primary care reported that all patients who suffered 
from ‘pain every day’ or ‘pain on most days’, were on prescribed analgesics.19 
Three studies investigated the effect of a pulmonary rehabilitation programme on 
health status.32-34 All reported no effect of the intervention on the pain domain of the 
health status instrument used (two studies used the SF-36, one used the HSQ).
Overall relationship between pain prevalence and disease severity
To determine the relationship between lung function and pain prevalence, we 
calculated the correlation coefficient between these variables. Of the 11 studies 
that reported on pain prevalence, seven also reported the mean FEV1% predicted 
and one study reported the GOLD grade distribution,23 which was converted to a 
weighted mean GOLD grade (Figure 5). There was a strong correlation between 
lung function (FEV1% predicted) and pain prevalence; Spearmans r=0.79 (p=0.021). 
Table 4. Factors related to pain (presence and severity)
Significant relation No relation Conflicting results






Nutritional status20  
Abbreviations: HRQoL: health-related quality of life
118 Chapter 6
Of the 21 studies and groups that reported SF-36/20/8 scores on the pain domain, 
18 reported the mean FEV1% predicted. In three groups of patients only the GOLD 
grade was reported,34-37 which was converted to a weighted mean GOLD grade. No 
significant correlation was found between the SF-36_BP score and lung function: 
Pearson’s correlation coefficient=0.21 (p=0.37; Figure 6).
Figure 5. Relationship between lungfunction (forced expiratory volume in 1 second; FEV1) and 










R2 Linear = 0,707











The first main finding of this systematic review is that pain seems to be a significant 
clinical problem in patients with COPD, with a reported prevalence in high qual-
ity studies ranging from 32% to 60%. Second, literature on pain in patients with 
COPD is limited; only a few studies with a specific focus on pain in patients with 
COPD have recently been published. Still, little is known about the causes and 
characteristics of pain, factors that are related to pain and literature on the effect 
of interventions aimed at reducing pain in patients with COPD is lacking. Third, our 
data synthesis showed that studies investigating pain in patients with moderate air-
flow limitation reported a higher pain prevalence compared with studies in patients 
with severe airflow limitation. This finding could suggest that pain is more prevalent 
in patients with moderate COPD compared to patients with severe or very severe 
COPD. However, confounding and selection bias are likely to occur and much 
remains unclear about the relation between pain and disease severity. Fourth, our 
Figure 6. Relationship between lungfunction (forced expiratory volume in 1 second; FEV1) 
and Short Form health survey-36_Bodily Pain (SF-36_BP) score. Each data point represents 
a separate study. Increasing units on the y-axis (e.g. higher SF-36_BP scores) refer to less 
severe pain and better quality of life. Pearson’s correlation coefficient=0.21 (p=0.37).
FEV1% predicted
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results suggest a correlation between pain and several other symptoms, such as 
dyspnoea, insomnia, fatigue, anxiety and depression, QoL and comorbidity.
Strengths and limitations
To our knowledge, this is the first systematic review study on pain in patients with 
COPD. One strength of this study is that we included all types of studies and used 
a broad search method. Therefore, it seems unlikely that the search strategy we 
used failed to identify relevant published studies. Second, the selection strategy 
was objective, as it was performed by two, and in case of disagreement, by three 
individual members of the review team. Third, we were able to conduct a meta-
analysis on the SF-36_BP data. Some limitations also need to be discussed. First, 
as literature on this topic is scarce, only 14 studies on pain and symptom burden 
in patients with COPD were included. Moreover, these studies showed substantial 
heterogeneity in design, setting, patient characteristics and pain measurement 
instruments used. Selected studies included patients with relatively severe COPD; 
mean FEV1% predicted ranged from 21% to 48%. These differences in study 
methods might have influenced the reported pain prevalence and also limit the 
generalisability of the results. Furthermore, there were differences between the 
studies in patient selection criteria and the healthcare setting from which the pa-
tients were recruited, although most of the studies were conducted in a secondary 
(outpatient) care setting. Second, the appropriateness of including the SF-36_BP 
scores in this review is debatable. As our search strategy did not include ‘QoL’ as a 
keyword, we included only those studies on QoL that mentioned the keyword ‘pain’ 
in the abstract. This implies that our data on pain as a subdomain of QoL may not 
be complete. Nevertheless, we feel that the reported results do provide important 
information on this subject.
Interpretation of findings and relation to other literature
The wide range in pain prevalence can be explained by the heterogeneity in study 
design, setting, patient characteristics and instruments and definitions used to 
measure pain. We were interested in chronic and/or recurrent pain in patients with 
COPD. However, as we wanted a broad search method, we used ‘pain’ instead of 
‘chronic pain’ as a major key word in our search strategy, as many studies do not 
clearly define pain as being ‘chronic’ or ‘acute’. We did however exclude studies that 
concerned ‘pain during acute bronchitis’ (Figure 1). Different studies used different 
definitions of pain and none of the included studies presented longitudinal data 
on the course of pain. The wide range in pain prevalence can also be explained 
by differences in the quality assessment score. Three of the studies on pain and 
symptom burden that reported the prevalence of pain, had quality limitations as 
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identified with the MMAT. Furthermore, in the study conducted by Elkington et al14 
pain prevalence was based on reports of informants of the deceased participants. 
Agreement between the patient’s and the proxy perception of pain is only moder-
ate.14,49 This by-proxy reporting of symptoms and the fact that the study included 
only patients in the terminal phase of their disease, could explain the relatively high 
level of reported prevalence of pain (72%). Claessens et al13 reported a relatively 
low prevalence of pain (21%). However, pain was defined as ‘moderately severe or 
extremely severe pain at least half of the time’. Borge et al20 found a relatively high 
prevalence (72%) but used a much lower threshold, as pain was considered to be 
present in all patients that shaded pain on the body diagram of the BPI. Roberts et 
al23 also reported a relatively high pain prevalence of 60%. In their cross-sectional 
study, recurrent pain-related healthcare utilisation (diagnosis and treatment) was 
considered evidence of chronic pain; data were received from the managed care 
claims database and from the outpatient pharmacy. Although evidence of chronic 
pain based on diagnosis and management can be reliable, it should be noted that, 
in the latter study, 28.6% patients with COPD used short-acting or long-acting 
opioids, compared with 17% in the control group (patients with other chronic 
diseases).23 However, as the reason for prescribing opioids was not stated it is de-
batable whether opioid prescription was indeed aimed at treating pain, especially 
as it is also prescribed for chronic dyspnoea in patients with COPD.50 Therefore, 
the reported prevalence of chronic pain in the study of Roberts et al23 might have 
been an overestimation. The reported prevalence of pain should be interpreted in 
relation to pain prevalence in the general population, as well as in patients with 
cancer and other chronic diseases. Recent population-based surveys showed that 
25–35% of the adults report chronic pain.51 In patients with cancer this percent-
age is higher, as 50% of all patients with cancer experience chronic pain.51 Thus, 
literature indicates that the prevalence of pain in patients with COPD is higher 
compared with the general population. Results from our meta-analysis on the SF-
36_BP data also show that patients with COPD experience more pain compared 
to the general population: mean score of the SF-36_BP domain in the general US 
adult population is 75.2 (SD 23.7),11 which is higher than the mean score we found 
in our random-effects meta-analysis of the SF-36_BP data in patients with COPD. 
A higher score on the SF-36_BP domain refers to less pain and better QoL.
We were not able to perform a meta-analysis on the results of the included studies 
that used other QoL instruments, because of the very small numbers of studies that 
used the same instrument (EQ-5D: n=3;NHP: n=2; HSQ: n=1; DHP: n=1). Results 
from the random-effects meta-analysis of the SF-36_BP scores showed substan-
tial heterogeneity. It is very likely that parts of the heterogeneity is explained by 
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research setting, population, study design, cultural diversity and other, unknown 
variables.
None of the included studies on pain or symptom burden reported a significant 
relationship between lung function (measured as FEV1% predicted or GOLD grade) 
and pain prevalence or pain severity. Interestingly, when we investigated the cor-
relation between lung function and pain prevalence over all included studies on 
pain and symptom burden in patients with COPD, a strong correlation was found 
between lung function and pain prevalence. Studies that investigated prevalence of 
pain in patients with moderate COPD reported a higher pain prevalence compared 
with studies in patients with severe and very severe COPD. This might suggest that 
pain is more prevalent in patients with moderate COPD compared with patients 
with severe or very severe COPD. This finding has not previously been reported 
in literature on pain in patients with COPD. An explanation for this might be found 
in the hypothesis that when investigating the relationship between lung function 
and pain, confounding and selection bias are very likely to occur. Possible selec-
tion bias and confounding in the included studies might be an explanation for the 
observed relation between lung function and pain prevalence in the present study. 
For example, the number and severity of comorbidities may have caused selection 
bias: patients with very severe COPD and many comorbidities (cardiovascular 
and musculoskeletal such as osteoporosis) might have already died, or were not 
able to participate in the studies due to severely limited functional capacity. The 
number and severity of comorbidities might also have acted as a confounder in the 
relationship between pain prevalence and disease severity in the included studies. 
Furthermore, our results can be interpreted in line with a growing body of evidence 
showing that the correlation between FEV1, symptoms and impairment of a patient’s 
health status is weak.52 Hence, in the recently updated GOLD Global Strategy 
for Diagnosis, Management and Prevention of COPD (GOLD strategy, 2014) the 
classification of patient’s disease severity requires assessment of symptoms and 
exacerbation history, in addition to the degree of airflow obstruction. Our results 
show some evidence for a relationship between pain and comorbidity, although the 
included studies are not entirely consistent on this topic. Musculoskeletal disorders 
and comorbidities (including mechanical limitations of chest wall movement due to 
hyperinflation and osteoporosis) are considered possible causes of pain in patients 
with COPD.8,9 However, due to the heterogeneity in the study designs we were 
unable to conduct a meta-analysis on pain prevalence and lung function control-
ling for comorbidity. In conclusion, much remains unclear about the relationship 
between disease severity, pain and comorbidity in patients with COPD and further 
research on this topic is needed.
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We were unable to identify a study that investigated a specific intervention aimed at 
reducing pain in patients with COPD. The lack of literature on this topic is probably 
due to the fact that, in general, literature on pain in patients with COPD is scarce 
and pain seems to be a symptom that is often overlooked; this applies to daily 
practice and to research on the effect of comprehensive interventions, such as 
pulmonary rehabilitation (PR) and integrated disease management (IDM). In sys-
tematic reviews on PR and IDM in patients with COPD, pain is not mentioned as a 
patient-centred outcome in the field of symptom management.53,54 Also, in national 
and international COPD guidelines there is almost no discussion of pain as part of 
a comprehensive symptom assessment. For example, the GOLD Global Strategy 
for Diagnosis, Management, and Prevention of COPD (GOLD guideline 2014) does 
not mention chronic pain and discusses opioids only in the context of the relief of 
dyspnoea. Also, the combined statement on PR of two major international medical 
societies does not mention pain as a problem in COPD management.55 Moreover, 
in the Institute for Clinical Systems Improvement (ISCI) guidelines for management 
of COPD, pain is not discussed. Only the American Thoracic Society (ATS) clinical 
policy statement on palliative care for patients with respiratory diseases and critical 
illness includes a separate section on pain management; however, this addresses 
only dying patients with respiratory diseases and critical illnesses in general.56
Conclusion and implications
Pain in patients with COPD is a significant problem with an estimated prevalence of 
32–60%. Literature on this topic is scare, and studies specifically focusing on pain 
in patients with COPD have only recently been published. Little is known about the 
factors associated with pain and no literature is available on the effect of interven-
tions aimed at reducing pain in patients with COPD. Studies that investigated pain 
in patients with moderate airflow limitation reported a higher pain prevalence com-
pared with studies in patients with severe and very severe airflow limitation. This 
finding might suggest that pain is more prevalent in patients with moderate COPD 
compared with patients with severe or very severe COPD. However, there was a 
substantial heterogeneity in patient characteristics and outcome assessment tools. 
More research on this topic is needed. Standardisation of assessment tools of pain 
in patients with COPD is needed. Future studies should focus on determining a 
more accurate prevalence of pain in patients with COPD, also in relationship to 
disease severity and comorbidity. Research should also pay more attention to the 
causes, course and characteristics of pain and clinical intervention trials are war-
ranted. Furthermore, adequate pain recognition and treatment in clinical practice is 
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important and pain assessment should be incorporated into regular comprehensive 
symptom assessment in the clinical care of this group of patients. Finally, pain 
prevalence and its possible impact on QoL should be discussed in guidelines on 
COPD in order to raise awareness and recognition of this topic.
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Appendix Chapter 6
Electronic search systematic review pain in patients with COPD
Pubmed:
(“Pain”[Mesh] OR “pain”[all fields] OR “pains”[all fields] OR “Pain 
Measurement”[Mesh] OR “Analgesics”[Mesh] OR “analgesic”[all fields]) AND (“Pul-
monary Disease, Chronic Obstructive”[Majr] OR “chronic obstructive pulmonary 
disease”[tiab] OR COPD[tiab] OR “Lung Diseases, Obstructive”[Majr:NoExp] OR 
“chronic bronchitis”[tiab] OR “chronic obstructive airway disease”[tiab] OR “chronic 
airway obstruction”[tiab] OR “chronic airway obstructions”[tiab] OR “COAD”[tiab] 
OR “chronic airflow obstruction”[tiab] OR “chronic airflow obstructions”[tiab] OR 
“Pulmonary Emphysema”[Majr])
EMBASE:
(exp *pain/ OR pain*.ti,ab. OR exp *pain assessment/ OR exp *analgesia/ OR an-
algesic.ti,ab.) AND (exp *chronic obstructive lung disease/ OR “chronic obstructive 
lung disease”.ti. OR “chronic obstructive pulmonary disease”.ti. OR COPD.ti. OR 
“obstructive lung disease*”.ti. OR “chronic bronchitis”.ti. OR “chronic obstructive 
airway disease”.ti. OR “chronic airway obstruction*”.ti. OR “COAD”.ti. OR “chronic 
airflow obstruction*”.ti. OR exp *lung emphysema/)
CINAHL
(MH “Pain+” OR TX pain* OR MH “analgesia+” OR TX analgesic) AND (MM 
“Pulmonary Disease, Chronic Obstructive+” OR MM “Bronchitis, Chronic” OR TI 
“chronic obstructive pulmonary disease” OR TI COPD OR TI “obstructive lung 
disease*” OR TI “chronic bronchitis” OR TI “chronic obstructive airway disease” OR 
TI “chronic airway obstruction*” OR TI COAD OR TI “chronic airflow obstruction*” 
OR MM emphysema)
PsycINFO
(DE “Pain” OR DE “Aphagia” OR DE “Back Pain” OR DE “Chronic Pain” OR DE 
“Headache” OR DE “Myofascial Pain” OR DE “Neuralgia” OR DE “Neuropathic 
Pain” OR DE “Somatoform Pain Disorder” OR TX pain OR DE “Analgesia” OR TX 
analgesic) AND (DE “Chronic Obstructive Pulmonary Disease” OR DE “Bronchial 
Disorders” OR DE “Pulmonary Emphysema” OR TX “chronic obstructive pulmo-
nary disease” OR TX COPD OR TX “obstructive lung disease” OR TX “chronic 
bronchitis” OR TX “chronic obstructive airway disease” OR TX “chronic airway 
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obstruction” OR TX “chronic airway obstructions” OR TX COAD OR TX “chronic 
airflow obstruction” OR TX “chronic airflow obstructions” OR TX emphysema)
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7Pain in patients with chronic obstructive pulmonary disease indicated for post-acute 
pulmonary rehabilitation









Objective: Pain is a significant problem in stable chronic obstructive pulmonary 
disease (COPD) and is associated with other symptoms, worse health status and 
lower functional status. Not much is known about pain in unstable disease. The 
primary aim of the present study is to investigate prevalence, characteristics and 
relationships of pain in patients with COPD hospitalized for an acute exacerbation 
(AECOPD) and indicated for post-acute pulmonary rehabilitation (PR). Methods: 
This cross-sectional observational study included 149 patients [mean age 70,8 
(±7,9) years, 49% male, mean FEV1 % predicted 35,3 (±12,6)]. Pain was assessed 
using the Brief Pain Inventory. Functional status and health status were measured 
using the six-minute walking test (6MWT), the Barthel index (BI) and the clinical 
COPD questionnaire (CCQ), respectively. Results: Pain was prevalent in 39,6% of 
all patients. Symptom burden was high, especially in patients with pain. Although 
we found no difference in objective measurements of functional status (6MWT, 
BI), patients with pain had clinically relevant lower health status (CCQ), attributed 
to the functional domain. Conclusion: Pain in patients hospitalized for AECOPD 
and indicated for post-acute PR is a relevant problem and needs more attention. 
Incorporation of standard pain assessment during exacerbations and post-acute 
PR is recommended.
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Background
Pain is a clinically relevant symptom in chronic obstructive pulmonary disease 
(COPD) with prevalences ranging from 32-85%, depending on setting, sample 
and measurements used.1,2 Pain is negatively associated with health-related 
quality of life (HRQoL).1-5 Many symptoms are associated with pain, of which 
dyspnoea, anxiety, depression and insomnia are the most frequent.1 Furthermore, 
these symptoms cluster and aggravate each other. Lohne et al first described this 
process of multiple concurrent symptoms reinforcing each other and called it the 
“vicious COPD circle”.6 In this concept, derived from a qualitative study on pain in 
patients with severe COPD, pain was described as “tying up the body”, which made 
breathing difficult, leading to breathlessness and more pain. Pain also induced 
anxiety, depression and insomnia, causing more pain and psychological problems.6 
Recently, Lee et al reported similar results on the negative interaction between 
several symptoms and pain.7
Pain in COPD is also associated with diminished physical activity and lower func-
tional exercise capacity,8,9 often worsened by pain-related fear of movement.4,7 The 
relationship between pain, symptoms and physical activity is important, since lifelong 
adherence to physical activity is essential to improve HRQoL and prognosis in COPD.
Acute exacerbations in COPD (AECOPD) play a key role. They represent a major 
burden for individual patients,10 are the most frequent reason for hospital admis-
sions and deaths among patients with COPD,11 and negatively influence HRQoL 
and functional capacity,10,11 often leading to re-hospitalizations, further decline of 
health status and high mortality rates.12,13 The prevalence of pain and its relation-
ship with other symptoms, functional capacity and HRQoL in unstable disease is 
however unknown, as data on pain during AECOPD are lacking.1,2 Hypothetically, 
pain in patients with AECOPD might be aggravated compared to the stable state 
due to the mentioned vicious circle of symptoms, since acute exacerbations are 
defined as in increase in symptoms such as dyspnoea and cough. Post-acute 
pulmonary rehabilitation (PR) is an effective and safe intervention to counteract 
the adverse effects of hospital admission for AECOPD on symptom burden and 
physical functioning.10 From this viewpoint post-acute PR could be an effective 
non-pharmacological intervention to reduce pain in unstable COPD, as it might 
counteract the pain-related vicious circles in COPD.14 Also, as pain management 
is preferably undertaken using multi-domain strategies (e.g. psychological, physi-
cal, behavioural and pharmacological)9, it might be a separate goal in post-acute 
PR by means of improving muscle strength, exercise capacity and coping. On the 
other hand, pain might negatively influence outcomes of post-acute PR in terms of 
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HRQoL and functional status. However, as far as we know, no studies on the role 
of pain in post-acute PR are available in literature.
Recently, Harrison et al did report on the role of pain in PR and concluded that a pain 
intervention, as part of a PR education program, seems warranted, as high pain 
prevalence and intensity, in combination with under-diagnosis and under-treatment, 
might negatively influence adherence to and outcomes of PR. Furthermore, as PR 
can aggravate pain in the short term, education of health care professionals and 
patients is important to optimize adherence to PR.14
In summary, pain is a relevant problem in patients with COPD, with relationships 
to several symptoms and diminished physical activity, causing several pain-related 
vicious circles. Furthermore, pain might negatively influence adherence to and out-
comes of PR. However, literature on pain in unstable COPD and in relation to post-
acute PR is lacking. Therefore, the primary aim of the present study is to investigate 
prevalence and characteristics of pain in patients with COPD hospitalized for an 
acute exacerbation and indicated for post-acute PR. Secondary aim is to investigate 
the relationship between pain, other symptoms, functional status and health status.
Methods
Study design
This cross-sectional observational study is part of a larger real-life prospective co-
hort study, conducted in the pulmonary department of two local hospitals to investi-
gate the effects of a post-acute PR program on patients with COPD. Data collected 
during the hospital stay (the start of the study) were used. The Medical Ethics com-
mittee of Leiden University Medical Centre approved the study (P14.248) and the 
study design was registered in the Netherlands National Trial Register (NTR6261).
Participants
Patients were eligible when diagnosed with COPD and hospitalized with an acute 
exacerbation and indicated for post-acute PR based on standard criteria (Box 1). 
All participants signed a written informed consent. Patients were included in the 
study from January 2015 through December 2017.
Measurements
The following patient and disease characteristics were accessed from the patient’s 
file: age, sex, spirometry [according to the Global Initiative for Chronic Obstructive 
Disease (GOLD) guidelines],15 co-morbidity [Charlson Comorbidity Index (CCI)]16 
and smoking status (yes/no). Nutritional status was measured by calculating body 
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mass index (BMI; kg/m2) and assessing the fat-free mass index (FFMI; kg/m2) by 
electrical bio-impedance. Impaired nutritional status was defined as FFMI <16 
(men) or <15 (women) kg/m2, or in case of missing FFMI data, BMI <21 kg/m2.17
Pain
Pain was measured using the Dutch version of the brief pain inventory (BPI).18 
The BPI is a valid, reliable, comprehensive and widely used pain questionnaire in 
COPD studies and clinical practice.19 First, patients are asked to indicate whether 
they are generally bothered by pain in the past week (yes/no), and if so, they 
then completed the full BPI, which consists of nine items subdivided into three 
components; (i) pain location using the body outline diagram on which patients can 
mark the location(s) of their pain, (ii) pain intensity which consists of four items that 
ask about pain intensity “now”, “worst level”, “least level” and “on average”, using 
a numeric rating scale (NRS) ranging from zero (no pain) to ten (worst pain) and 
(iii) pain interference with seven items evaluating how pain interferes with seven 
activities of daily life using a NRS ranging from zero (no interference) to ten (com-
Box 1. Criteria for post-acute PR
Major criteria:
1. Decline of functional status
2. Disease-specific health status is severely impaired, as measured by the 
CCQ, score ≥ 2.0
3. Frequent exacerbations; ≥ 2 in the last 6 months (excluding the present 
exacerbation) 
Minor criteria:
1. Hypoxemia (excluding pre-existing chronic respiratory failure)
2. Impaired nutritional status: BMI <21 kg/m2 and/or FFMI depletion
3. Patients at risk for clinically relevant anxiety disorder or depression; HADS 
>7 on either subscale
Indication for post-acute PR: 2 major criteria OR 1 major AND 2 minor criteria
Exclusion:
1. End-stage of COPD
2. Major psychiatric or cognitive disease
3. Lack of fluency in Dutch language
Abbreviations:  CCQ: Clinical COPD questionnaire; BMI: body mass index; FFMI: fat-free 
mass index; HADS: Hospital anxiety and depression scale
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plete interference). In addition, two items address pain treatment and pain relief by 
treatment, ranging from 0%(no relief) to 100% (complete relief). 
Pharmacologic pain treatment was also assessed using the medical charts of all 
patients. Categories were based on the pain ladder of the World Health Organisa-
tion; 1) non-opioid, 2) weak opioid, and 3) strong opioid.20 All prescriptions were 
coded as ‘daily use’ and/or ‘as needed’.
Symptom burden
In addition to pain, the following symptoms were measured: dyspnoea was mea-
sured using the modified Medical Research Council (mMRC) dyspnoea scale 
(scores range from zero to four); moderate to severe dyspnoea was defined as 
having a score of ≥ two,15 fatigue, insomnia, muscle weakness and anorexia were 
measured using a numeric rating scale (NRS) (scale 0-100) and were considered 
to be moderate to severe with a score of ≥ 40.21,22 Symptoms of anxiety and depres-
sion were measured using the Hospital Anxiety and Depression Scale (HADS). A 
score of > seven points on either subscale indicates moderate to severe symptoms 
of anxiety or depression.23 
Functional status
Activities of daily living (ADL) were measured using the Barthel index (BI).24 The 
BI is a valid and reliable instrument to assess ADL. Total score ranges from 0 to 
20, with 20 representing complete functional independence, 15-19 mild-, 10-14 
moderate- and <10 severe care dependency, respectively.25 Exercise capacity was 
measured with the six-minute walking test (6MWT), according to ERS guidelines. 
The 6MWT is a reliable, practical and widely used instrument to measure exercise 
capacity in patients with COPD.26 
Disease-specific health status
Disease-specific health status was measured using the clinical COPD question-
naire (CCQ).27 The CCQ is a validated and reliable 10-item self-administered 
questionnaire with three subdomains; symptoms, function and mental status. Items 
are scored on a Likert scale ranging from zero to six. The final score is the sum of 
all items divided by 10 and a score of  ≥ 2.0 indicates impaired health status. The 
minimal clinical important difference (MCID) of the CCQ total score is ± 0.4.28
Statistical analysis
All data were processed using the SPSS (IBM SPSS Statistics for Windows version 
23.0). Categorical variables are described as frequencies, while continuous vari-
ables were tested for normality and are presented as mean and standard deviation 
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(SD) or median and interquartile range (IQR) in case of skewed data. Differences 
between patients with and without pain were tested with independent sample t-test 
or chi-square test where appropriate. In case of skewed data, non-parametric tests 




In total, 158 patients participated in the original study. Of these, nine patients 
(5.7%) had not completed the BPI and were excluded from the current analyses. 
Hence, the data of 149 patients [mean age 70.8 (±7.9) years, 49% male, mean 
FEV1 % predicted 35.3 (±12.6)] were analysed (Table 1). Pain was prevalent in 
59 patients (39.6%). No differences in demographic data (age, sex) and disease 
characteristics (FEV1, FEV1% predicted, co-morbidity score, nutritional status, 
smoking status) were found between patients with and without pain. Considering 
the functional status, results of the BI showed only mild care-dependency [BI:18 
(15-20)], but exercise capacity was considerably limited [6MWT: 200.3(10.8)]. 
Table 1. Characteristics of the study population
Total group 
(N=149)
Patients with pain 
(N=59)
Patients without pain 
(N=90)
p-value
Male*** 73 (49) 25 (42.4) 48 (53.3) 0.24
Age in years * 70.8 (7.9) 69.5 (7.3) 71.7 (8.2) 0.08
FEV1(L) 0.88 (0.35) 0.92 (0.37) 0.86 (0.33) 0.28
FEV1 % predicted* 35.3 (12.6) 37.3 (12.6) 33.9 (12.5) 0.11
Smoking*** 45 (30.2) 19 (32.2) 26 (28.9) 0.72
CCI** 2 (1-3) 2 (1-3) 2 (1-3) 0.75
BMI* 24.8 (5.4) 25.3 (6.1) 24.5 (4.9) 0.33
FFMI* 16.2 (2.6) 16.4 (2.7) 16.1 (2.5) 0.63
Impaired nutritional status*** 52 (34.9) 21 (35.6) 31 (34.4) 0.89
BI** 18 (15-20) 18 (16-20) 18 (15-20) 0.34
6MWT* 200.3 (1108) 212.0 (111.5) 201.9 (114.4) 0.42
*Mean values (SD), **median (IQR), or ***counts with percentage are indicated. Level of sig-
nificance: p <0.05
Abbreviations: FEV1% predicted: forced expiratory volume in one second as percentage of 
predicted value; CCI: Charlson Comorbidity Index; BMI: body mass index; FFMI: fat-free mass 
index; BI: Barthel index; 6MWT: six-minute walking test;
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No differences in functional status were found between the two groups (p=0.34; 
p=0.42 respectively).
Characteristics of pain and pain treatment
In total, 94 marks were placed on the body outline diagram by 44 patients. In 15 
patients with pain, the body outline diagram was blank. Pain was most frequently 
located in the trunk region (Figure 1). More than half (57%) of the patients with pain 
indicated two or more locations of pain on the body outline diagram. 
Mean pain intensity scores on the BPI ranged from 2.7 (±2.3) (least pain) to 6.4 
(±2.5) (worst pain). ‘Average pain’ and ‘pain right now’ showed mean scores of 4.3 
(±2.3) and 4.1 (±3.1), respectively. Interference domain scores were highest for 
interference with normal work [5.9 (±3.3)], walking ability [5.6 (3.1)] and general ac-
tivity [5.5 (3.0)]. Patients experienced the least interference with mood [3.6 (±2.9)] 
and relations with others [3.3 (±2.9)].
Figure 1. Reported pain locations, N(%) 
 
 


























Pain in patients with COPD indicated for GR_COPD 141
7
Patients with pain were asked which treatment they received for their pain. In 14 
patients this item was blank, three patients indicated they did not know the name of 
the treatment and eight patients wrote ‘no treatment’. In total, 27 patients (45.7%) 
reported use of analgesic medication and 43 treatment items were scored: 23 non-
opiod, 4 weak opioid,  8 strong and 8 other [antibiotics (n=2), corticosteroids (n=5) 
and physiotherapy (n=1)]. Patients were also asked to score the effect of treatment 
on pain relief on a scale ranging from 0-100%; the mean score was 43.5% (±32.1), 
indicating a mean moderate relief of pain due to pain treatment. 
Data on pain prescriptens were collected from the medical files of all patients. 
In the total group (patients with and without pain), 67 patients (45.0%) had one 
or more analgestic prescription (daily use); most frequently prescibed were non-
opioid analgesics: paracetamol (25.4%) and non steroidal anti-inflammatory drugs 
(15.9%). Analgestic prescription (daily use) was more frequent in patients with 
pain compared with those without pain (64% versus 38%; p=0.01). Analgestics ‘as 
needed’ were prescibed in 25.6% of the patients, with no differences between the 
two groups. 
Differences in symptom burden (prevalence and intensity) in patients with 
and without pain
Almost all patients (91.3%) experienced moderate to severe dyspnoea with no dif-
ferences between patients with and without pain (p=0.37).  After dyspnoea, fatigue, 
muscle weakness and symptoms of anxiety and/or depression were most prevalent. 
Patients with pain suffered more often from fatigue (p=0.004), muscle weakness 
(p=0.01), anorexia (p=0.02) and symptoms of anxiety and/or depression (p=0.04), 
(Table 2). Considering symptom intensity, patients with pain had significantly higher 
scores for all symptoms except for dyspnoea (Table 3).
Differences in health status in patients with and without pain
Patients with pain had significantly and clinically relevant worse disease specific 
health status compared to patients without pain (Table 4).  When analysing the dif-
ferences in the scores on the three subdomains of the CCQ, only the CCQ_function 
subdomain showed significant and clinically relevant higher scores in patients with 
pain, compared to patients without pain. 
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Table 2. Prevalence of symptoms in patients with and without pain
Symptoms, N(%) N Patients with pain Patients without pain p-value
Dyspnea 149 52 (88.1) 84 (93.3) 0.37
Fatigue 137 52 (94.5) 62 (75.6) 0.004
Muscle weakness 136 44 (80.0) 47 (58.0) 0.01
Insomnia 136 37 (67.3) 43 (53.1) 0.11
Anorexia 136 31 (56.4) 29 (35.8) 0.02
Anxiety and/or depression 147 41 (70.7) 47 (52.8) 0.04
Notes: Moderate to severe fatigue, insomnia, muscle weakness, and anorexia was defined 
as having a NRS score of ≥ 40. Moderate to severe symptoms of anxiety or depression was 
considered to be present with a score of >7 on either subscale of the HADS, moderate to se-
vere dyspnea was considered present with a score of ≥2 on the mMRC dyspnea scale. Level 
of significance: p <0.05
Abbreviations: mMRC: modified Medical Research Council Dyspnea Scale; NRS: numerical 
rating scale; HADS: Hospital Anxiety and Depression Scale
Table 3. Symptom intensity in patients with and without pain
Total group 
(N=149)*
Patients with pain 
(N=59)*
Patients without pain 
(N=90)*
p-value
mMRC_Dyspnea (range 0-4) 3.1.(1.0) 3.1 (1.1) 3.1 (1.0) 0.60
NRS_Fatigue (range 0-100) 63.1 (24.8) 72.6 (20.4) 56.8 (25.7) <0.001
NRS_Muscle weakness (range 
0-100)
50.0 (27.7) 56.7 (25.9) 45.4 (28.1) 0.02
NRS_Insomnia (range 0-100) 41.8 (31.0) 49.8 (33.5) 36.3 (28.0) 0.01
NRS_Anorexia (range 0-100) 35.2 (22.4) 46.1 (22.9) 27.8 (20.0) 0.001
HADS_Anxiety (range 0-21) 7.8 (4.5) 8.9 (4.5) 7.2 (4.4) 0.03
HADS_Depression (range 0-21) 7.5 (4.2) 8.3 (4.6) 6.9 (3.8) 0.07
*Mean (SD). Level of significance: p <0.05
Abbreviations: mMRC: modified Medical Research Council Dyspnea Scale; NRS: numerical 
rating scale; HADS: Hospital Anxiety and Depression Scale
Table 4. Health status in patients with and without pain
Total group 
(N=149)*
Patients with pain 
(N=59)*
Patients without pain 
(N=90)*
p-value
CCQ_total (range 0-6) 3.6 (1.1) 3.9 (1.0) 3.4 (1.1) 0.04
CCQ_symptoms (range 0-6) 3.6 (1.1) 3.8 (1.1) 3.5 (1.1) 0.10
CCQ_function (range 0-6) 4.1 (1.3) 4.4 (1.1) 3.9 (1.3) 0.04
CCQ_mental (range 0-6) 2.4 (1.7) 2.6 (1.7) 2.2 (1.7) 0.14
*Mean (SD). Level of significance: p <0.05
Abbreviations : CCQ: clinical COPD questionnaire




The present study is the first to measure pain in patients hospitalized for AECOPD 
and indicated for post-acute PR and shows that 39.6% of these patients reported 
pain with moderate to severe intensity and interference scores. These findings 
indicate that pain is also a relevant problem in this specific group of patients. Pa-
tients with pain also experienced a worse disease specific health status, compared 
to patients without pain, which was predominantly caused by more experienced 
limitations in functional status. 
Interpretation of findings and relation to literature
In recent literature, two systematic reviews investigated pain prevalence in patients 
with stable COPD.1,2 Prevalences varied widely, from 32 to 88%, with a pooled 
prevalence of 66%.2 Compared to these results, we found a relatively low preva-
lence of pain. When comparing our results to individual studies that investigated 
pain in patients with similar characteristics (age, sex and lung function) that also 
used the BPI, more similarity was found. Lee et al conducted a cross-sectional 
study in 64 patients [mean age 71(±10) years; mean FEV1 % predicted 37.9(±14.9)] 
with stable COPD (outpatient clinic) and reported a pain prevalence of 41%.9 In two 
other studies,4,29 pain prevalence was 50 and 45% in patients with similar mean age 
[70.0(±6.7) and 65.0(±9.2) years] but slightly better lung function [mean FEV1 % 
predicted 44.7(±19.2) and 48(±16)%], respectively.  However, in the cross-sectional 
study of Christensen et al,30 61% of 258 COPD patients [mean age 63.4(±9.4) 
years, mean FEV1 % predicted 40.9(±19.2)] reported pain. Interestingly, the authors 
concluded that lower stages of COPD were associated with (more) pain and more 
interference. The apparent paradoxical relationship between pain and lung function 
was also reported in our earlier review.1 This inverse relationship, probably also 
caused by selection bias, could be explained by the hypothesis that, in more se-
vere COPD, other symptoms like dyspnoea are more distressing than pain, leading 
to more focus on dyspnoea and less on pain, also causing patients to be reluctant 
to spontaneously report pain.6,14 Furthermore, patients with more severe disease 
and worse health status might experience a ‘response shift’ in their perception of 
pain, as they may have had pain for a longer period of time. Response shift refers 
to the phenomenon that patients suffering from chronic diseases change their in-
ternal standards as their disease progresses.31 In summary, evidence from recent 
research together with the above outlined hypotheses indicate that our prevalence 
could have been an underestimation.
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Our data showed no difference in co-morbidity between patients with and without 
pain. Other studies reported co-morbidity as a risk factor for pain,32 and correla-
tions were shown between pain and the number of co-morbidities,4 but data are 
conflicting. Janssen et al reported a high prevalence of thoracic pain (53,7%), but 
no correlation between the CCI and thoracic pain was found.5 A reason for this 
could be that the CCI measures co-morbidities in relation to mortality.
Regarding nutritional and functional status, several studies concluded that pain in 
COPD is associated with lower functional exercise capacity and higher BMI.8,9,33 
Our results show no differences in functional and nutritional status between pa-
tients with and without pain. Explanation for this finding could be that exacerbations 
and hospital admissions cause deterioration of functional and nutritional status.10 
Furthermore, in the present study, decline of functional and nutritional status were 
part of the selection criteria for indication of post-acute PR. The effect of the exac-
erbation and hospital admission on functional and nutritional status was probably 
dominant in comparison with the effect of pain.
In the present study, mean pain intensity and interference scores were relatively 
high compared to other reports in similar patients,4,9,29,30 but within the range of the 
mean scores reported in our review.1
Pain treatment was assessed by the self-reported BPI and by collecting prescription 
data from the medical files of all patients. Relief from pain treatment or medication 
provided was 43.5% (±32.1), which is comparable to the result of Christensen et 
al [41.6%(±33.0].30 Not many other studies on pain in COPD elaborated on pain 
treatment. In the study of Bentsen et al,29 48.9% of the patients with pain received 
analgestics (patient reported), also similar to our results. When comparing this 
pecentage with prescription data derived from the patient’s file, patient reported 
analgestic use seems to cause a considerable underestimation. However, still 36% 
of the patients with pain did not have any analgestic prescription. Results from 
recent literature on this topic, together with our data, indicate that pain treatment is 
probably suboptimal in terms of pain relief and prescription of analgetics in patients 
with COPD.
In patients with pain, total symptom burden was higher compared to patients with-
out pain; they experienced more symptoms with worse intensity of which fatigue, 
muscle weakness and symptoms of anxiety and depression were most frequent 
and most severe. This is in line with earlier studies showing correlations between 
different symptoms and pain prevalence.3,6,9,30,34
We found no difference in prevalence or severety of dyspnoea beween patients 
with and without pain. This is an interesting result, as many studies in stable COPD 
found a relation between pain and dyspnoea.1 However, this finding can probably 
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be explained by the overall high prevalence of dyspoea in our study population, 
due to the acute state our patienst were in.
The present study is in line with earlier studies reporting that pain is negatively 
associated with HRQoL and health status in stable COPD,4,5,9,33,35 as patients with 
pain in our study had a significantly and clinically relevant higher score on the 
CCQ. Interestingly, when looking at the mean scores on the subdomains of the 
CCQ, only the CCQ_function domain showed higher mean scores. However, no 
differences in more objective measurements of functional status (6MWT, BI) were 
found. Literature on the relation between pain and disease specific health status 
measured with the CCQ is scarce. Two studies did not find an association between 
pain and outcomes of (subdomains of) the CCQ.22,36 The CCQ_function domain is 
known to correlate well with objective measurements of functional status in patients 
with COPD with similar age, lung function and functional status,37 but literature on 
this relationship in COPD patients with pain is completely lacking. Therefore, inter-
pretation of this particular finding is difficult but could generate new hypotheses on 
this subject. First, when patients with pain experience more limitations than they 
objectively have, this might negatively influence their motivation for rehabilitation. 
Furthermore, rehabilitation might be more effective in these patients when specifi-
cally addressing pain- experience, management and implications, also in relation 
to individual coping style. The study of Harrison et al on the role of pain in PR from 
a qualitative perspective, provides evidence that is in line with these hypotheses.14
Strengths and limitations
To our knowledge, this is the first study to investigate pain in patients with COPD 
hospitalized for AECOPD and indicated for post-acute PR. Furthermore, as this 
was a real-life study, almost no exclusion criteria were applied, indicating good 
generalizability within this group and setting. However, generalizability beyond 
this specific group and setting is limited, as only 149 patients from two hospitals 
were included. Selection bias may have occurred, as all patients in this group 
were indicated for post-acute rehabilitation. As this is a cross-sectional study and 
no comparison to patients within the stable state of COPD was made, it remains 
unclear if pain is worse following an AECOPD, only that people do experience pain 
during AECOPD. We also cannot determine case and effect, i.e. does pain affect 
HRQoL or does having poor HRQoL mean people have heightened sensitivity to 
the experience of pain.
Conclusions and implications
Pain in patients hospitalized for AECOPD and indicated for post-acute PR is a rel-
evant problem. Patients with pain experience more severe limitation in the function 
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domain of their health status (CCQ) but no differences in objective measurements 
of functional status (6MWT, BI) were found. Pain in this specific group of patients 
needs more attention, as our study suggests that pain treatment is suboptimal. The 
reported prevalence of pain in patients hospitalized for AECOPD and indicated 
for post-acute PR is comparable to the prevalence of pain in the stable state. 
Therefore, incorporation of standard pain assessment in stable COPD and during 
exacerbations and post-acute PR is recommended, and patient education on pain 
in COPD and its possible implications is important. Further research should focus 
on assessing longitudinal data on pain in relation to exacerbations and post-acute 
PR as well as developing multi-domain pain treatment interventions that can be 
tested in (post-acute) PR programs.
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Aim and outline of of this thesis
The central aim of this thesis is to investigate whether developing and implementing 
a specific geriatric rehabilitation program for older patients with severe COPD that 
also integrates palliative care aspects, the GR_COPD program, is both feasible 
and effective.
With this goal in mind, four studies were performed that included two different study 
populations, as well as a systematic review and meta-analysis of the literature.
First, the feasibility study (that included a retrospective case series of 61 consecu-
tive patients with COPD that followed the GR_COPD program) investigated feasi-
bility in terms of patient characteristics, suitability, safety and preliminary evaluation 
of patient response to the GR_COPD program. Furthermore, in this specific group 
and setting, the responsiveness of the clinical COPD questionnaire (CCQ) was 
examined in order to determine if the CCQ could be used as a primary outcome in 
the subsequent GR_COPD study. 
Second, the GR_COPD study (that included a prospective cohort of 158 patients, 
hospitalized for an acute exacerbation and indicated for the GR_COPD program), 
investigated the effect of the GR_COPD program on disease-specific health status 
(measured with the CCQ), functional status and exacerbation frequency.  
Third, a systematic review of the literature was made, including a meta-analysis, 
that examined the prevalence of pain, factors related to pain and pain management 
interventions in patients with COPD. 
Fourth, cross-sectional data from the GR_COPD study were used to examine the 
prevalence, characteristics and relationships of pain in patients hospitalized for an 
acute exacerbation and indicated for the GR_COPD program.
Results
Main findings 
Part one: The GR_COPD program
Chapters 3 and 4 present the feasibility study. The results show that patients admit-
ted to the GR_COPD program had complex health issues: i.e. all patients suffered 
from advanced COPD (GOLD stage 3 or 4), co-morbidities were frequent, health 
status was severely impaired, and exercise capacity was limited. Furthermore, 
undernourishment was prevalent and many patients were at risk for an anxiety dis-
order or depression. These results confirm that patients admitted to the GR_COPD 
program have specific and complex problems and needs that can be explained by 
the co-occurrence of disease- and age-related problems. This underpins the need 
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for a suitable program that addresses these complex health issues. Preliminary 
evaluation of patient response to the GR _COPD program showed a clinically 
relevant improvement in both functional status and health status. Moreover, adher-
ence to the program was good, there were no unexpected adverse events and over 
90% of these patients were discharged home after a median length of inpatient re-
habilitation of 35 days. Thus, we concluded that geriatric rehabilitation for patients 
with advanced COPD is feasible and is likely to offer substantial benefits.
The study in Chapter 4 evaluated outcomes of the CCQ in relation to lung function, 
degree of dyspnoea and (change in) functional status. Results showed that, in 
this specific group of patients, the CCQ is sensitive to change in response to the 
GR_COPD program. 
Chapter 5 presents the results of the GR_COPD study and shows that, during 
a three-month follow-up period, the GR_COPD program had a significant and 
clinically relevant treatment effect on disease-specific health status (measured 
with the CCQ) and exacerbation rate. This allowed us to conclude that geriatric 
rehabilitation, for older patients with severe COPD and hospitalized for an acute 
exacerbation, is effective. However, a longer follow-up period is needed to reveal 
whether these results can be maintained for a longer period of time. Nevertheless, 
we also concluded that the GR_COPD program should be implemented in clinical 
practice, as no alternative rehabilitation programs for this specific group of patients, 
are available.
Part two: Pain in patients with COPD
Chapters 6 and 7 present two studies that focused on pain in COPD. Overall 
symptom burden is one of the most important determinants of disease-specific 
health status and, therefore, adequate symptom control is of major importance, 
from the perspective of both palliative care and rehabilitation medicine. Patients 
with COPD suffer from many different symptoms, of which the most commonly 
known are dyspnea, cough and sputum production. We decided to focus on pain, 
since pain is also highly relevant but an often unrecognized, underestimated and, 
therefore, undertreated symptom in patients with COPD; moreover, pain has a 
negative impact on quality of life and possibly also on functional status.
The results of our systematic review (Chapter 6) confirm that pain is prevalent in 
patients with COPD, with moderate to severe scores on intensity and interference. 
Furthermore, the results show that pain is related to many other symptoms (e.g. 
dyspnea, insomnia, fatigue, anxiety and depression) and that pain is negatively as-
sociated with health-related quality of life. Nevertheless, much remained unknown 
due to the relatively few studies on pain in COPD and the considerable amount of 
heterogeneity in the design of the included studies. 
Summary and general discussion 155
8
The cross-sectional study (Chapter 7) on the prevalence and characteristics of 
pain in patients indicated for the GR_COPD program, shows that pain was also a 
prevalent and significant symptom in this specific population, as 40% of all patients 
suffered from pain, with moderate to severe scores on intensity and interference. 
Furthermore, compared to patients without pain, patients with pain had an overall 
higher symptom burden and a more impaired disease-specific health status. Al-
though we found no difference in objective measurements of activities of daily living 
and exercise capacity, patients with pain experienced more limitations in functional 
status, as measured with the functional domain of the CCQ. Results from this study 
also indicate that pain treatment was probably suboptimal in terms of pain relief 
and prescription of analgetics. These results tend to confirm that, in patients with 
COPD, pain is often unrecognized, underestimated and undertreated. Thus, we 
concluded that, in this group of patients and setting, pain needs more attention and 
standard assessment of pain should be implemented into daily practice, together 
with patient education on this subject.
Reflection
To further discuss the outcomes of the work presented in this thesis, the postacute 
rehabilitation (PAC) quality framework of Jesus and Hoenig was used as a theoreti-
cal context and translated to the GR_COPD program and study.1 
The PAC quality framework was based on the structure, process, outcome (SPO) 
model of Donabadian and the International Classification of Functioning, Disability 
and Health (ICF) model of the World Health Organization (WHO). It was developed 
in order to clarify what constitutes ‘quality of care’ in postacute rehabilitation, and to 
provide a sound and evidence-based framework that can be used for quality of care 
evaluation and improvement (Figure 1). The PAC quality framework was therefore 
used as a model to evaluate the results of the present work, and to develop a 
broader and more generic view on geriatric rehabilitation for patients with chronic 
diseases, in terms of implications for clinical practice and recommendations for 
research. Below, we discuss the different elements of the framework in a stepwise 
reverse order, i.e. we start with the outcomes, because these reflect what really 
matters: namely, benefit for our patients.
Outcomes of the GR_COPD program
Macro level
The primary outcome measure of the GR_COPD study was change in disease-
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Our results show a clinically relevant effect of the GR_COPD program on disease-
specific health status. Choosing disease-specific health status as primary outcome 
is important, as it reflects the patient’s personal experience of disease severity and 
covers other domains beyond the functional domain, such as symptoms and mental 
status. This is also in line with literature and guidelines on pulmonary rehabilitation 
and palliative care in COPD, which also state that improvement of (health-related) 
quality of life should always be the ultimate aim of any intervention or treatment 
program within these domains.2-5
Exacerbation rate was defined as secondary outcome. Results from the GR_COPD 
study show a relevant effect on exacerbation rate during a three-month follow-up 
period: i.e. patients in the control group had an exacerbation rate of 2.7 as com-
pared to 1.0 in the GR_COPD group. Exacerbation rate can be related to several 
macro outcomes. First, in patients with COPD, exacerbations are strongly related 
to diminished health-related quality of life and have a negative impact on functional 
performance and prognosis.6,7 Second, exacerbation rate can be seen as a deriva-
tive of healthcare utilization, because exacerbations are the most frequent reason 
for hospital admission in these patients.8 However, secondary analysis with a lon-
ger follow-up period that also focuses on other outcome measures more strongly 
related to healthcare utilization (i.e. cost-effectiveness), such as rehospitalizations 
and preventable follow-up care, is needed.
In the ICF-based construct of functional performance, social participation and the 
extent to which patients can perform tasks of daily living in their own environment 
(i.e. activity) are considered the primary outcomes of rehabilitation. Both activity 
and participation are complex concepts, not only determined by individual factors 
but also by the dynamics of social roles and the direct environment in which they 
take place. However, measurement of participation was not part of the primary 
analysis of the GR_COPD study. Although validated and widely used instruments 
are available that measure activity [e.g. functional independence measure (FIM)], 
no internationally used and validated tool that includes the complexity of participa-
tion in this domain is available.1 In the Netherlands, the Utrecht scale for evalua-
tion of rehabilitation-participation (USER-p) was developed and appears to be a 
valid measure to rate participation in persons with physical disabilities.9 Integrating 
personal goals on the level of participation into geriatric rehabilitation programs is 
important, as was recently stated in the Dutch Position Paper on geriatric reha-
bilitation, and has already been confirmed in stroke survivors aged 70 years and 
older.10,11 Therefore, validating the USER-p as outcome measure on a macro level 
could prove important for research in geriatric COPD rehabilitation.
It should be mentioned that the patients’ and caregivers’ actual experience with the 
program was not measured. This can be seen as an important shortcoming of our 
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study, as the patient’s perspective is an important outcome measure that directly 
reflects the degree of patient centeredness and, thus, the quality of healthcare.1 In 
addition to the relevance of the patient’s perspective, it is also important to note 
that the construct of ‘experience’ was preferred to ‘satisfaction’, the latter being 
more expectancy-dependent and more subjective.12 
Intermediate/immediate level
Intermediate outcomes of the GR_COPD program can be categorized into three 
domains: i) body structure and function, ii) functional status and iii) self-manage-
ment. These three domains encompass several standard treatment modules, all 
targeted at improving disease-specific health status as the ultimate goal (on a 
macro level) of the program (Figure 2). These three domains are very similar to 
the immediate/intermediate outcomes defined in the PAC quality framework (body 
structure & function; functional capacity; psychosocial & behavioural), although the 
third domain (i.e. self-management) needs additional clarification and elaboration 
(further discussed below). 
Improvement in body structure and function was achieved through treatment 
modules that focussed on a) optimizing pharmacological treatment, inhalation 
techniques and oxygen use, b) prevention and treatment of co-morbidities, c) op-
timizing nutritional status and/or treatment of undernourishment, and d) improving 
symptom burden. There is considerable evidence to support the important role 
of symptoms in COPD driving the burden of the disease.13 Therefore, optimal 
symptom control is considered to be a key target in COPD treatment and of major 
importance for improving health status, also from a palliative care perspective.14 
Figure 2. Three-domain-model of the GR_COPD program.
Body structure & function
Functional status Self-management
Health Status
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Symptom burden in patients with advanced COPD is known to be high: this is also 
confi rmed by our data (Chapters 3, 4 and 7). Participants of the GR_COPD study 
suff ered from many symptoms, the most prevalent being dyspnoea, fatigue, muscle 
weakness and pain (Chapter 7). Furthermore, in patients with COPD, symptoms 
(including pain) seem to cluster, thereby aggravating each other, causing several 
‘vicious circles in COPD’ (Figure 3). In this concept, originally based on the study 
of Lohne et al, and further developed based on the results from our systematic 
review (Chapter 6), cross-sectional data from the GR_COPD study (Chapter 7) 
and (more recently) studies on pain in COPD, physical deconditioning is seen as 
the underlying process that could explain the observed co-occurrence of pain and 
many other symptoms. This process is mediated by diminished physical activity 
and pain-related fear of movement, and is often aggravated by co-morbidities and 
poor nutritional status.15-18
The central role of symptoms in the burden of COPD emphasizes that standard 
systematic assessment and follow-up of symptom burden should be part of clini-
cal care for patients with COPD during the stable phase of the disease, and also 
during exacerbations and rehabilitation (Chapter 7). This requires a valid multidi-
mensional symptom assessment instrument and specifi c interventions aimed at 
optimal control of several symptoms, such as pain, fatigue, dyspnoea, insomnia, 
anxiety and depression. 
The GR_COPD study could not establish any treatment eff ect on functional status 
(Chapter 5). Considering the fact that postacute rehabilitation in general primarily 
focusses on functional recovery and functional performance, this result is some-
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what surprising and might even be concerning. Functional status as intermediate 
outcome refers to the ability of the patients to function (i.e. perform. activities of 
daily living such as washing, getting dressed, going to the bathroom, walking and 
eating) regardless of social roles or environmental variables.1 We defined functional 
recovery as improvement in two functional domains: 1) change in the level of care 
dependency concerning activities of daily living, as measured with the Barthel Index 
(BI), and 2) change in exercise capacity, as measured with the six-minute walking 
test (6MWT). When analysing the results of the BI and 6MWT we concluded that, 
although both outcome measures had improved to a clinically-relevant extent, the 
BI is probably less suitable as an outcome measurement in this specific group 
of patients because of (amongst other reasons) its ceiling effect. Results of the 
6MWT showed a high amount of missing data and a wide range, leading to limited 
statistical power. Based on these results, the relevance of the BI and the 6MWT as 
outcomes in geriatric COPD rehabilitation can be questioned, also because of the 
possible limited correlation of these instruments to activity and participation. When 
the GR_COPD study was designed, choosing these instruments to measure (im-
provement in) functional status was based on international literature and guidelines 
on pulmonary rehabilitation (6MWT) and generic geriatric rehabilitation (BI). Thus, 
we conclude that, based on our results, together with the construct of activity and 
participation from the PAC framework, additional instruments are needed.
For this, the Utrecht scale for evaluation of rehabilitation (USER) and the USER-
participation (USER-p), might be a more suitable choice for measuring functional 
status and participation, and improvement of these outcomes in response to geriat-
ric COPD rehabilitation. The USER was developed in the Netherlands, and is a valid 
and reliable instrument to measure immediate/intermediate outcomes of rehabilita-
tion on an individual level, and can also be used to measure the effectiveness of 
specific rehabilitation programs.10 The USER consists of several domains including 
activities of daily living, mobility, cognition, psychosocial functioning and several 
symptoms (including fatigue and pain). The USER is also part of the Standard 
Measurement Plan for Geriatric rehabilitation, developed at the University Network 
for the Care Sector South Holland (UNC-ZH) that is currently being implemented 
and tested in several geriatric rehabilitation units.
Improvement of self-management, as the third intermediate outcome of the 
GR_COPD program, was pursued by the following treatment modules: educa-
tion, peer-group support, smoking cessation support, training of energy saving 
techniques, general advice concerning healthy aging (e.g. nutrition, exercise), and 
assessment of compliance and coping responses (e.g. patients compliance with 
care recommendations, adaptive coping responses). Motivation for the program 
and psychological status, expressed by symptoms of anxiety and depression and 
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cognitive impairment, are also known to affect macro outcomes of postacute reha-
bilitation.1 Furthermore, the interaction between motivation and psychological sta-
tus is of interest and importance. For instance, symptoms of depression can predict 
uptake and non-completion of rehabilitation, and cognitive impairment  increases 
the risk for dropout during pulmonary rehabilitation.19,20 From a broader perspec-
tive, research questions should move from focussing on effectiveness of postacute 
rehabilitation for patients with COPD to how referral, uptake and adherence can be 
improved, also in relation to patients’ motivation and preferences in terms of setting 
and timing.6,21 In the GR_COPD study, indication for the program was based on a 
set of standard criteria, probably resulting in a relatively high referral rate (although 
evaluation of the referral rate was not part of the study). Also, the feasibility study 
showed good adherence, as only one patient dropped out due to lack of motivation. 
However, uptake of the program can be interpreted as being relatively low: of the 
158 included patients only 78 were motivated for the GR_COPD program. This 
finding again raises the important discussion concerning which variables influence 
and constitute patients’ motivation for rehabilitation, and how to improve uptake.
The GR_COPD study was not aimed at measuring the direct effects of the program 
on self-management, or one or more of its individual components. Also, we did 
not investigate the relationship between (components of) self-management and 
psychological status as independent variables and health status as a dependent 
primary outcome measure, nor did we investigate the effect of specific self-
management and psychological treatment modules on an intermediate or macro 
outcome level. However, more knowledge on the effectiveness of these specific 
elements of the GR_COPD program (also in relation to motivation and uptake) is 
important since improvement of self-management is a key component of treatment 
in general for chronic conditions, such as COPD.1,5 The PAC quality framework 
does not present an evidence-based conceptual understanding and approach for 
definitions and quality evaluation of self-management; this emphasizes the need 
for the development of concepts that describe and explain the complex interactions 
between motivation, psychological status and self-management in this specific 
group of patients and setting.
Patient care process: evaluation of the GR_COPD program
The GR_COPD program was developed as a structured care pathway, in close 
collaboration with the pulmonary department of the adjacent hospital. Coordination 
of care across settings enables smooth transitions and helps to synchronize the 
care provided by different healthcare providers interfacing with the patients. The 
resultant synergies are known to have a positive effect on patients’ outcomes.1 
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The GR_COPD program was based on (inter)national guidelines on comprehensive 
evidence-based pulmonary rehabilitation.5,22 Implementation and dissemination of 
these guidelines into clinical practice was assured by repeated knowledge transi-
tion from the pulmonary department to the multidisciplinary rehabilitation team, and 
vice versa. Furthermore, the feasibility study (Chapters 3 and 4) was developed 
to evaluate the program and the results were also used for quality improvement.
Although guidelines should direct practice, rehabilitation should always be tailored 
to patients’ needs and possibilities and, therefore, programs need to be individual-
ized. This also applies to the treatment plan of the GR_COPD program, which is 
based on an individual comprehensive assessment. Outcomes from this assess-
ment, combined with the experience of the rehabilitation team, are used as input 
for the complex process of individualized clinical reasoning about the wide variety 
of variables that constitute a patient’s disabilities and limitations. At the next level, 
individualization should be part of the process of defining specific rehabilitation 
goals, i.e. use patient-centred goal setting and shared decision-making. Structured 
goal setting in rehabilitation has the potential to improve macro outcomes via 
higher levels of motivation and self-efficacy.23 Although patient-centred goal setting 
does take place within the GR_COPD program, this is not done in a formalized way 
[e.g. by using an instrument that facilitates the goal-setting process, such as the 
Canadian Occupational Performance Measure (COPM) or Goal Attainment Scale 
(GAS)] and, therefore, implementation cannot be guaranteed. In the Standardized 
Measurement Plan for Geriatric Rehabilitation, the COPM is one of the core instru-
ments. Preliminary results of pilot studies show that the COPM is feasible in this 
population.24
The GR_COPD program was developed as a modular program that combines 
specific interventions of rehabilitation medicine and palliative care. The program 
is aimed at restoring patients’ health status to the level before hospital admission 
or, in other patients, to counteract or stabilize the gradual decline in health status 
that preceded hospital admission and prevent hospital readmissions (Chapter 2). 
The GR_COPD program consists of several standard treatment modules within 
the three domains (Figure 2). Using standardized treatment modules that specify 
exactly what kind of treatment is provided, facilitates quality monitoring and pre-
sumably improves outcomes.1 However, the complexity of most disabilities, and the 
rehabilitation process itself, challenge the use of standardized treatment modules. 
Nevertheless, using a modular program (categorized into the three domains) seems 
to be a suitable and workable structure for this specific group of patients. Moreover, 
it can be argued that geriatric rehabilitation after an acute exacerbation of a chronic 
(‘acute-on-chronic’) disease (e.g. heart failure, renal failure, Parkinson’s disease, 
oncological diseases) is different from geriatric rehabilitation after an acute event, 
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such as a hip fracture or stroke. Besides focussing on functional recovery and 
improvement of body structures and body functions, rehabilitation after an ‘acute-
on-chronic’ event should also be aimed at improving self-management strategies 
(i.e. educate the patient how to live well with a chronic disease) and should also 
integrate palliative care aspects into the rehabilitation plan.
In Chapter 2 we described the palliative care aspects of the GR_COPD program. 
The palliative care needs of patients with advanced chronic organ failure can be 
divided into five domains: 1) symptoms, 2) care dependency, 3) family caregiving, 
4) co-morbidities. and 5) advance care planning.25 Although all of these domains 
were implemented into the structure of the GR_COPD program, this was not car-
ried out in a standardized systematic way in daily practice. Implementation of a 
more standardized systematic assessment of the five palliative care needs defined 
by Janssen et al might be beneficial to patients and could improve outcomes of 
the GR_COPD program. Therefore, a validated instrument for the assessment of 
multidimensional symptom burden, and specific interventions aimed at optimal 
control of specific symptoms (such as pain, fatigue and insomnia), are needed. 
An intervention that facilitates implementation of advance care planning into daily 
practice was recently developed and evaluated, and should be implemented into 
practice.26
Interprofessional processes
Interprofessional processes support the care process and outcomes, and encom-
pass team functioning and improvement processes. However, since evaluating the 
quality of the interprofessional process of the GR_COPD program was beyond the 
aims of this research project, this element is not addressed in detail. Nevertheless, 
the design of the GR_COPD program does meet all the conditions that define 
good quality of team functioning in postacute rehabilitation, such as deliberate care 
planning (e.g. multidisciplinary treatment plans), care coordination (e.g. weekly 
interdisciplinary team meetings), team leadership (e.g. coordination of interdisci-
plinary care by the elderly care physician) and sociologic factors (e.g. rehabilitation 
climate as part of organizational culture). 
Structure of the GR_COPD program
Organizational management
When the GR_COPD program was first developed, geriatric rehabilitation was part 
of a government-guided long-term care reimbursement system without financial 
incentive for efficient or high-quality geriatric rehabilitation. In 2011, a bundled 
payment system was introduced to improve the quality of service delivery and, 
ultimately, the quality of care. Considering the process of service delivery, develop-
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ing structured care pathways was one of the main goals. However, this requires 
effective collaboration between different stakeholders, e.g. nursing homes with 
specialized nursing facilities (SNF), specialized rehabilitation centres and hospitals. 
Although the GR_COPD program was developed in close collaboration with the 
pulmonary department of the adjacent hospital (secondary care), structural collabo-
ration with a pulmonary rehabilitation centre (tertiary care) or general practitioners 
and other primary care stakeholders was not part of the developmental process. 
Moreover, structural cooperation in daily practice on a patient, outcome and quality 
level was only present between the SNF and the adjacent hospital. Developing 
and implementing cooperation on a large scale with multiple healthcare providers 
and stakeholders from different domains of the healthcare system is challenging, 
especially in a changing external healthcare environment.27,28 Nevertheless, from a 
patient’s and evidence-based perspective, integrated care pathways that cover all 
domains of healthcare should always be pursued, as they improve quality of care 
and contribute to deliverance of the right type of care, at the right moment, in the 
right setting, for the right patient.
Patient centeredness
In the PAC quality framework, patient-focussed quality definitions are considered to 
be of key importance and, therefore, the patient is placed in the centre of the frame-
work. First, a patient-centred rehabilitation process, with alignment with patients’ 
care needs, values and perspectives, is crucial, Second, patients can be seen 
as co-creators of their own rehabilitation process and directly influence outcomes 
and quality of care. Therefore, involvement of the patient (and family/caregiver) in 
the rehabilitation process, mediated by individual goal setting, shared decision-
making, improvement of self-management and context-based care, is needed.11 
This process should be fostered by healthcare providers. Recently, patients are 
increasingly involved in the development of patient- reported outcome measures 
(PROMs), also in line with value-based healthcare.29,30 The GR_COPD program 
was developed as a patient-centred program. The treatment plan is based on a 
thorough individual assessment that includes the patient’s preferences, needs and 
goals, also in the context of psychosocial status and participation. Furthermore, 
the program is aimed at improving self-management and disease-specific health 
status, using a disease-specific PROM (i.e. the CCQ) as outcome. Nevertheless, 
processes that actually constitute patient centeredness were not yet transparent 
and, thus, the quality of implementation cannot be objectively measured and evalu-
ated. This calls for implementation of innovative techniques that, ideally, facilitate 
and foster patient centeredness (e.g. goal setting and self-management), improve 
the quality of the process (i.e. ensure that patient centeredness was indeed part 
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of daily practice) and improve (macro) outcomes (i.e. are (cost)-effective). An in-
novative technique that has the potential to combine these outcomes, is eHealth.31 
eHealth can be defined as the use of information and communication technologies 
for health and can, when integrated into usual care (i.e. blended eHealth), improve 
self-management in patients with chronic diseases, such as COPD.32 Developing 
and implementing blended eHealth interventions aimed at improving, facilitating 
and monitoring patient centeredness in geriatric rehabilitation, can be seen as 
a new and important field of interest, both from a practice and evidence-based 
perspective.
Methodological consideration
When interpreting the results of this thesis, some important limitations should be 
considered. We discuss these limitations in relation to the three study designs that 
were used. 
Limitations of the feasibility study
The first and most important limitation of the feasibility study (designed as a real-life 
study describing a consecutive series of patients all receiving the GR_COPD pro-
gram, but with no control group) is population bias due to the selection procedure, 
which was not based on strict inclusion criteria and might negatively affect gener-
alizability. The lack of a control group, although self-evident when considering the 
design and aims of this study, can be seen as a second limitation: it is plausible that 
those that received usual care also experienced significant improvement. Thirdly, 
when considering the guidelines on conducting feasibility studies, one important 
recommended objective was not incorporated into this study: we could not report 
on recruitment rate, as data from patients that were indicated but not motivated for 
the program, were not collected. 
Limitations of the systematic review and meta-analysis
First, because our review was the first systematic review study on pain in patients 
with COPD, at the time of performing the search strategy the literature on this topic 
was scarce; only 14 studies on pain and symptom burden in patients with COPD 
could be included and, of these, only 11 reported on the prevalence of pain in 
COPD. Also, because the included studies showed considerable heterogeneity in 
design, setting, patient characteristics and pain measurement instruments used, 
this probably affected the validity and reliability of our results. As a consequence, 
the estimated prevalences of pain in patients with COPD showed a large range (21-
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72% overall; 32-60% in high-quality studies). Furthermore, the appropriateness of 
including data from quality of life instruments that included a separate pain domain 
is debatable. Because our search strategy did not include ‘quality of life’ as a key-
word, we included only those studies on quality of life that mentioned the keyword 
‘pain’ in the abstract. This implies that our data on pain as a subdomain of quality of 
life are probably incomplete. However, there has been a recent increase in studies 
specifically focussing on pain in COPD; this allows to more accurately determine 
the prevalence of pain in COPD, and helps the development and implementation of 
treatment interventions that specifically target pain in patients with COPD.
Limitations of the GR_COPD study
The design of the GR_COPD study is an important limitation. Because random-
ization was considered unethical, lack of comparability in outcome risk factors 
between the GR_COPD and control group might have led to confounding. There-
fore, we chose to use propensity scores (PS) analysis and included sensitivity 
analysis for unmeasured confounding. PS analysis is recommended when con-
ducting observational real-life studies that evaluate treatment benefits and harms 
in older adults. Although an additional sensitivity analysis showed similar results, 
confounding cannot be fully excluded as we did not perform other recommended 
strategies to address unmeasured confounding (e.g. active comparator design). 
Another important limitation is the generalizability to other patients with COPD; 
although positively influenced by the fact that this was a real-life study and lenient 
exclusion criteria were applied, this influence may have been limited due to selec-
tion bias caused by the indication criteria applied. Moreover, patients willing to 
participate might have been a selective group, even though no differences were 
found in demographics and baseline CCQ and HADS scores between the included 
and not included patients. Finally, results from both the feasibility study and the 
GR_COPD study question the appropriateness and relevance of the instruments 
used to measure functional status (i.e. the Barthel Index and the 6MWT). This 
limitation was mainly reflected in the observed ceiling effect of the Barthel Index 
and the wide range in values of the 6MWT combined with a relatively high amount 
of missing data (40%). Furthermore, since no valid set of outcome measures for 
this group of patients and setting is available, this makes it difficult to compare our 
results on functional status with other studies in general. 
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Conclusion, implications and recommendations
Based on the results of the work in this thesis we conclude that a disease-specific 
geriatric rehabilitation program that integrates rehabilitation with palliative care 
aspects (the GR_COPD program) is needed, is feasible, and shows beneficial 
effects on disease-specific health status and exacerbation rate, in older patients 
with COPD hospitalized for an acute exacerbation. These results imply that the 
GR_COPD program should be available to all patients within this specific group. 
We used the PAC quality framework to structure implications for daily practice 
and recommendations for research. First, considering the macro outcomes of the 
program, it is recommended to use the CCQ as primary patient-related outcome 
measure (PROM), in clinical practice and in research. PROMs related to activity and 
participation (macro outcome) and to functional recovery (intermediate outcome) 
for this specific group of patients are needed, because integration of personal goals 
on the level of activity, participation and functional recovery into the treatment plan 
is important. There is evidence that using the USER and USER-p as outcome mea-
sures on an intermediate and macro level is promising, and further research should 
focus on evaluating the validity, reliability and responsiveness of these instruments 
in geriatric rehabilitation. Furthermore, measurement of patients’ and caregivers’ 
experience with the program is important and should be implemented into practice 
and used as an outcome measure in studies on geriatric rehabilitation.
Second, within the process-outcome interface, it is recommended to use the 
three-domain model with a specific focus on self-management (Figure 2) in 
disease-specific geriatric rehabilitation programs for patients that suffer from acute 
exacerbations of chronic (‘acute-on-chronic’) diseases. Furthermore, palliative 
care aspects should be integrated into the treatment plan by incorporating stan-
dardized symptom assessment and advance care planning methods. Research 
should focus on developing a valid multidimensional symptom assessment 
instrument for patients with COPD or, more generally, for patients with chronic 
organ failure. Specific interventions aimed at optimal symptom control (e.g. pain, 
fatigue and insomnia) and facilitating implementation of advance care planning 
into practice, should be developed and tested. Third, research should focus on 
obtaining more knowledge about the effectiveness of specific interventions of the 
GR_COPD program, especially concerning self-management and palliative care. 
This requires development of a conceptual approach to the complex interaction be-
tween motivation, psychological status and self-management in this specific group 
of patients and setting. Fourth, on an organizational level, models of cooperation 
between multiple healthcare providers and stakeholders that cover all domains of 
rehabilitation medicine (community and hospital care, tertiary (pulmonary) reha-
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bilitation centres) on a patient, outcome and quality level, should be developed 
and implemented into practice. Finally, eHealth is a novel but promising field of 
interest with considerable potential in terms of improving patient centeredness, 
quality of care and saving costs. Therefore, future research should also focus on 
development, implementation and evaluation of blended eHealth interventions in 
geriatric rehabilitation.
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Deel I: Het GR_COPD zorgpad
Gezien de wereldwijde vergrijzing en stijging van het aantal kwetsbare ouderen 
met chronische aandoeningen en multimorbiditeit, is er in toenemende mate be-
hoefte aan revalidatieprogramma’s die specifiek gericht zijn op deze groeiende 
groep ouderen met vaak complexe problematiek, lage belastbaarheid en beperkte 
prognose. Geriatrische revalidatiezorg heeft zich de laatste jaren sterk ontwikkeld 
en geprofessionaliseerd. Hierbinnen past het ontwikkelen en wetenschappelijk 
evalueren van doelgroep specifieke revalidatie programma’s. Eén van de patiën-
tengroepen waarvoor dit zinvol kan zijn betreft oudere patiënten met chronisch 
obstructief longlijden, ofwel COPD. COPD is de afkorting van de Engelse term 
Chronic Obstructive Pulmonary Disease, en wordt gekenmerkt door een chroni-
sche, meestal progressieve, luchtwegobstructie die niet volledig reversibel is. De 
belangrijkste symptomen van COPD zijn kortademigheid, hoesten en het opgeven 
van sputum. COPD is een wereldwijd groeiend probleem met stijgende prevalen-
tie-, morbiditeits- en mortaliteitscijfers, met name onder ouderen. Het beloop en de 
prognose van COPD wordt voor een groot deel bepaald door acute exacerbaties, 
welke gedefinieerd zijn als een acute toename van de respiratoire symptomen 
waarvoor behandeling en/of ziekenhuisopname geïndiceerd is. Exacerbaties heb-
ben belangrijke klinische gevolgen, waaronder een negatief effect op de kwaliteit 
van leven, de functionele status en de prognose van patiënten. 
Onderzoek laat zien dat revalidatie direct na een ziekenhuisopname vanwege een 
acute exacerbatie COPD (postacute longrevalidatie) een effectieve en veilige be-
handeling is en de negatieve effecten van een exacerbatie (deels) kan herstellen. 
Echter, laag belastbare, kwetsbare oudere patiënten met vaak ernstig COPD en 
multimorbiditeit, opgenomen in het ziekenhuis vanwege een acute exacerbatie, 
ontvangen in de dagelijkse praktijk vaak geen postacute longrevalidatie. Reden 
hiervoor is vaak diezelfde matige belastbaarheid en kwetsbaarheid, waardoor 
deze patiënten vaak niet in staat zijn deel te nemen aan intensieve revalidatie 
programma’s, die bovendien vaak niet in de buurt van hun eigen woonomgeving 
beschikbaar zijn. Daar komt bij dat er bij deze doelgroep vaak ook sprake is van 
tijdelijke zorgafhankelijkheid en dat, mede gezien de beperkte prognose, het inte-
greren van palliatieve zorg aspecten in het revalidatieprogramma geïndiceerd is 
maar in de praktijk maar moeizaam tot stand komt.
In 2009 heeft Zorggroep Solis, in samenwerking met de longafdeling van het De-
venter Ziekenhuis, het ketenprogramma “Geriatrische revalidatie voor patiënten 
met ernstig COPD” (het GR_COPD zorgpad) ontwikkeld. Doel van dit revalida-
tieprogramma is het verbeteren van de kwaliteit van leven van oudere patiënten 
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met (zeer) ernstig COPD, na een ziekenhuisopname in verband met een acute 
exacerbatie. Tevens wordt gestreefd naar een betere functionele status en het 
voorkomen van complicaties, zoals een progressieve achteruitgang van de alge-
hele gezondheidsstatus en recidiverende ziekenhuisopnames. Om deze doelen te 
behalen worden revalidatie- en palliatieve zorg aspecten geïntegreerd aangeboden 
in het behandelprogramma.
Het centrale doel van dit proefschrift is om te onderzoeken of het GR_COPD 
zorgpad haalbaar en effectief is. Met dit doel voor ogen werden vier studies ont-
worpen en uitgevoerd met twee verschillende onderzoekspopulaties, evenals een 
systematische review en meta-analyse van de literatuur.
Hoofdstuk 2 beschrijft het GR_COPD zorgpad zoals dat is ontworpen en geïm-
plementeerd. Het GR_COPD zorgpad is een multidisciplinair patiënt-georiënteerd 
revalidatieprogramma en wordt aangeboden binnen de setting van de geriatrische 
revalidatiezorg (GRZ). Het zorgpad bestaat uit een modulair behandelprogramma 
dat gebaseerd wordt op een individueel breed assessment bij opname. De ver-
schillende behandelmodules kunnen worden gecategoriseerd in de volgende drie 
domeinen: 1) somatische status, 2) functionele status en 3) zelfmanagement. Het 
uiteindelijke doel van het behandelprogramma is het verbeteren van de algehele 
gezondheidsstatus van de patiënt. Aan de hand van drie case-studies wordt ge-
illustreerd hoe het programma in de praktijk is opgezet en wat de meerwaarde 
van het GR_COPD zorgpad kan zijn voor individuele patiënten. Hierbij wordt ook 
verduidelijkt hoe de integratie van revalidatie en palliatieve zorg in de praktijk wordt 
toegepast.
Hoofdstuk 3 presenteert de resultaten van een retrospectieve pilot studie van 61 
patiënten met COPD die het GR_COPD zorgpad volgden. De studie onderzocht de 
haalbaarheid van het zorgpad, waarbij met name gekeken werd naar de volgende 
vragen: 1) patiëntkenmerken: Worden de juiste patiënten in het GR_COPD zorg-
pad opgenomen?, 2) beloop: Laten geselecteerde uitkomstmaten een verbetering 
op patiënten-niveau zien gedurende het zorgpad? 3) ontslagbestemming: Lukt 
het in voldoende mate om patiënten terug naar huis te ontslaan? De resultaten 
van deze studie laten zien dat er bij patiënten die werden opgenomen voor het 
GR_COPD zorgpad sprake was van complexe problematiek: alle patiënten had-
den ernstig of zeer ernstig COPD, multimorbiditeit kwam frequent voor, bij veel 
patiënten was er sprake van een slechte voedingsstatus en overall was de inspan-
ningscapaciteit ernstig beperkt. Bovendien was er gemiddeld genomen sprake van 
een verhoogd risico op het voorkomen van een angststoornis en/of depressie en 
was de ziekte-specifieke gezondheidsstatus ernstig verminderd. Deze resultaten 
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bevestigen dat patiënten opgenomen voor het GR_COPD zorgpad specifieke en 
complexe problemen hebben die kunnen worden verklaard door het naast elkaar 
voorkomen van COPD en leeftijdsgebonden aandoeningen, zoals multimorbiditeit 
en lage belastbaarheid. Deze uitkomsten bevestigen de behoefte aan een doel-
groep-specifiek programma dat deze complexe gezondheidsproblemen aanpakt. 
Het beloop van een aantal relevante uitkomstmaten van het GR_COPD zorgpad 
toonde een klinisch relevante verbetering van zowel de functionele status als de 
ziekte-specifieke gezondheidsstatus. Bovendien was de adherence goed, waren 
er geen adverse-events en kon meer dan 90% van de patiënten naar huis na een 
gemiddelde opnameduur van ongeveer 5 weken. Conclusie van de pilot studie 
was dan ook dat het GR_COPD zorgpad haalbaar is en waarschijnlijk substantiële 
verbetering voor patiënten kan bieden.
In hoofdstuk 4 wordt dieper ingegaan op het in de pilot studie gebruikte meetin-
strument voor de ziekte-specifieke gezondheidsstatus, de Clinical COPD Questi-
onnaire (CCQ). Het meten van de gezondheidsstatus vanuit het perspectief van de 
patiënt wordt in toenemende mate gezien als een belangrijke maat voor de ernst 
van een aandoening, zowel in de dagelijkse praktijk als in wetenschappelijk onder-
zoek. De CCQ is ontwikkeld als ziekte-specifieke maat voor de gezondheidsstatus 
van patiënten met COPD. Het is een eenvoudige 10-item vragenlijst en bestaat uit 
drie domeinen: symptomen, functionele status en mentale status. Bij patiënten met 
mild tot matig ernstig COPD correleert de CCQ goed met de functionele status en 
heeft een goede voorspellende waarde voor wat betreft exacerbaties en mortaliteit. 
Er was echter nog weinig bekend over het gebruik en uitkomsten van de CCQ bij 
oudere patiënten met multimorbiditeit en (zeer) ernstig COPD, en over de uitkom-
sten van de CCQ bij deze groep in relatie tot uitkomsten van postacute revalidatie. 
Doel van de aanvullende analyse van de pilot studie was dan ook het onderzoeken 
van uitkomsten en de responsiviteit van de CCQ in deze specifieke groep en 
setting om zo te bepalen of de CCQ als een primaire uitkomstmaat gebruikt kan 
worden in de daaropvolgende GR_COPD studie. De resultaten laten zien dat, in 
deze specifieke groep patiënten, een verbetering op de CCQ goed correleert met 
verbeteringen in de functionele status en het inspanningsvermogen. Op basis van 
deze resultaten hebben wij geconcludeerd dat de CCQ in deze groep patiënten 
gevoelig is voor verandering in reactie op het GR_COPD zorgpad en gebruikt kan 
worden als primaire uitkomstmaat in de vervolgstudie.
Hoofdstuk 5 presenteert de resultaten van de GR_COPD studie, een prospec-
tieve vergelijkende cohortstudie naar de effecten van het GR_COPD zorgpad 
op de ziekte-specifieke gezondheidsstatus als primaire uitkomstmaat. Secun-
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daire uitkomstmaten waren de functionele status en de exacerbatie-frequentie. 
De studie werd uitgevoerd op de longafdeling van twee ziekenhuizen, namelijk 
het Deventer Ziekenhuis en het Isala Ziekenhuis in Zwolle. In beide regio’s is het 
GR_COPD zorgpad beschikbaar voor patiënten. Alle patiënten die in aanmerking 
kwamen voor deze studie waren opgenomen in het ziekenhuis vanwege een acute 
exacerbatie COPD en hadden een indicatie voor het GR_COPD zorgpad. Deze 
indicatie werd gesteld op basis van een aantal standaard criteria. Vervolgens werd 
bepaald of patiënten ook gemotiveerd waren voor het zorgpad. Uit de pilotfase van 
het onderzoek was al gebleken dat ongeveer de helft van de patiënten met een 
indicatie voor revalidatie niet gemotiveerd was voor deelname aan dit specifieke 
programma. In de vervolgstudie werden deze patiënten beschouwd als controle. 
Randomisatie voor het GR_COPD zorgpad zou op basis van wetenschappelijke 
inzichten wellicht de voorkeur hebben gehad, maar was in de praktijk niet haalbaar. 
Veel van deze patiënten verkeren na ziekenhuisopname wegens een acute exacer-
batie in een dusdanig slechte algehele gezondheidsstatus dat het onthouden van 
revalidatie niet ethisch zou zijn geweest. In de gekozen onderzoeksopzet moest 
echter wel gecorrigeerd worden voor confounding, aangezien het te verwachten 
is dat de groep met motivatie voor het zorgpad zou verschillen van de groep 
zonder motivatie. Op basis van de literatuur hebben we er daarom voor gekozen 
om hiervoor te corrigeren middels de propensity-score. De propensity-score geeft, 
op basis van een aantal van tevoren vastgestelde mogelijke confounders, zoals 
leeftijd, geslacht, de ernst van de aandoening en functionele beperkingen, de kans 
weer dat een bepaalde patiënt kiest voor het zorgpad. Correctie voor confounding 
vindt vervolgens plaats door het wegen van de onderzoekspopulatie op basis 
van de propensity-score. In totaal konden158 patiënten worden geïncludeerd in 
deze studie, van wie er 78 gemotiveerd waren voor het GR_COPD zorgpad en 
de resterende 80 patiënten de controlegroep vormden. Tijdens de analyse bleek 
dat de twee groepen in veel opzichten van elkaar verschilden, zoals in leeftijd, 
geslacht, longfunctie, voorgeschiedenis, rookgedrag en exacerbatiefrequentie. Na 
correctie met de propensity-score waren er geen significante verschillen meer tus-
sen de twee groepen, voor wat betreft gemeten confounders. Hierna kon met een 
propensity-score gewogen lineaire regressie het behandeleffect worden bepaald. 
De resultaten hiervan tonen aan dat het GR_COPD zorgpad een significant en 
klinisch relevant behandeleffect heeft op de ziekte-specifieke gezondheidsstatus, 
gemeten met de CCQ, en de exacerbatie-frequentie, gedurende een follow-up 
periode van drie maanden. Op basis van de resultaten van dit onderzoek hebben 
wij geconcludeerd dat het GR_COPD zorgpad, voor oudere patiënten met ernstig 
COPD, opgenomen in het ziekenhuis vanwege een acute exacerbatie, effectief 
is. Er is echter vervolgonderzoek nodig om vast te stellen of deze resultaten ook 
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gedurende een langere periode kunnen worden behouden, en ook is onderzoek 
nodig naar de kosteneffectiviteit van het zorgpad. Bovendien lieten de resultaten 
geen significant effect zien van het zorgpad op de functionele status. Dit kan deels 
verklaard worden door de kenmerken van de gebruikte uitkomstmaten, zoals het 
bestaan van het plafond-effect bij de Barthel Index, de gebruikte maat voor het 
meten van de zelfstandigheid. Daarnaast bleek de gebruikte test voor het meten 
van het inspanningsvermogen, de zes-minuten-wandeltest, een grote spreiding te 
vertonen en bovendien voor een deel van de patiënten een te grote belasting te 
zijn, waardoor het aantal missing waarden voor deze uitkomstmaat relatief groot 
was. Desalniettemin hebben we geconcludeerd dat het GR_COPD zorgpad breder 
geïmplementeerd kan worden in de klinische praktijk, mede gezien het feit dat 
er geen alternatieve revalidatieprogramma’s voor deze specifieke groep patiënten 
beschikbaar zijn. Vervolgonderzoek naar geschikte uitkomstmaten van de func-
tionele status die bij deze specifieke doelgroep goed correleren met doelen op 
participatie en activiteiten- niveau, is van belang.
Deel II: Pijn bij patiënten met COPD
Binnen het onderzoek van dit proefschrift is een specifiek focus aangebracht op 
pijn bij patiënten met COPD. Achtergrond hiervan is dat in de literatuur in toe-
nemende mate gepleit wordt voor betere integratie van revalidatie en palliatieve 
zorg voor deze groep patiënten met een chronisch progressieve aandoening. 
Veel oudere patiënten met (zeer) ernstig COPD hebben een hoge symptoomlast, 
slechte kwaliteit van leven en een beperkte prognose. Inzet van palliatieve zorg 
is dus geïndiceerd, maar blijft in de praktijk vaak uit, mede doordat het indivi-
dueel voorspellen van de prognose moeilijk is en revalidatie en palliatieve zorg 
vaak als aparte domeinen zijn georganiseerd in de gezondheidszorg. Optimale 
symptoomcontrole wordt beschouwd als een belangrijk doel van de behandeling, 
zowel vanuit het perspectief van revalidatie als palliatieve zorg. Het is bekend dat 
patiënten met COPD last hebben van veel symptomen, waarvan dyspneu, hoesten 
en sputumproductie het meest bekend zijn. Uit de recente literatuur kwam naar 
voren dat pijn ook een relevant, maar vaak niet herkend, onderschat en daardoor 
vaak onder-behandeld symptoom lijkt te zijn bij patiënten met COPD. Bovendien 
zou pijn gecorreleerd zijn aan veel andere symptomen en deze mogelijk kunnen 
verergeren. Dit fenomeen wordt de ‘vicieuze COPD-cirkel’ genoemd. In dit concept 
bemoeilijkt pijn de ademhaling, wat leidt tot meer kortademigheid, verkramping van 
spieren en daardoor nog meer pijn. Via deze weg kan pijn ook leiden tot inactiviteit, 
of angst voor bewegen, met een verdere achteruitgang van conditie en spierkracht 
tot gevolg. Pijn lijkt ook angst, depressie en slapeloosheid te veroorzaken, of te 
verergeren, en deze symptomen hebben op zichzelf vaak weer een negatief effect 
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op pijn. Pijn lijkt ook samen te hangen met een verminderde kwaliteit van leven en 
hypothetisch zou pijn de uitkomsten van (postacute) longrevalidatie negatief kun-
nen beïnvloeden, maar mogelijk kan revalidatie juist bijdragen aan het verminderen 
van pijn, mits hiervoor voldoende aandacht is binnen het behandelprogramma. 
Veel was echter nog onduidelijk over pijn bij COPD, zoals een preciezere preva-
lentie, ook in relatie tot de ernst van de COPD en de setting, de oorzaken van pijn 
en de relatie met co-morbiditeit, en de relatie tussen pijn en andere symptomen. 
Tevens was onduidelijk welke interventies pijn bij patiënten met COPD kunnen 
verminderen en of er interventies bekend zijn die mogelijk ook effectief zouden 
kunnen zijn in het verminderen van de negatieve gevolgen van pijn bij COPD.
In hoofdstuk 6 worden de resultaten gepresenteerd van onze systematische 
review en meta-analyse van de wetenschappelijke literatuur naar pijn bij COPD, 
waarbij specifiek gekeken is naar de prevalentie van pijn, factoren gerelateerd 
aan pijn en interventies gericht op het verminderen van (de gevolgen van) pijn bij 
patiënten met COPD. De resultaten van deze systematische review bevestigen dat 
pijn relatief veel voorkomt bij patiënten met COPD. De ernst en belemmeringen 
van pijn zijn gemiddeld genomen matig tot ernstig te noemen. Verder laten de 
resultaten van de systematische review zien dat pijn gerelateerd is aan veel andere 
symptomen, zoals kortademigheid, slapeloosheid, vermoeidheid, angst en depres-
sie en dat pijn negatief geassocieerd is met kwaliteit van leven. De relatie met 
co-morbiditeit blijft onduidelijk, alhoewel sommige studies een duidelijk verband 
lieten zien met het voorkomen en de ernst van pijn. In de onderzochte afzonderlijke 
studies werd geen relatie gevonden tussen pijn en leeftijd, geslacht, roken en de 
longfunctie. Onze meta-analyse toonde wel een negatieve correlatie aan tussen 
de ernst van de luchtwegobstructie, als maat voor de ernst van COPD, en pijn; 
met andere woorden, geïncludeerde studies met patiënten met minder ernstige 
luchtwegobstructie rapporteerden een hogere prevalentie van pijn, in vergelijking 
met studies met patiënten met ernstig en zeer ernstig COPD. Dit zou er op kunnen 
wijzen dat pijn bij patiënten met mild of matig ernstig COPD vaker voorkomt in 
vergelijking met patiënten met (zeer) ernstig COPD. Veel blijft echter ook ondui-
delijk over pijn bij COPD. Zo vonden we geen enkele studie die een interventie, 
gericht op het verminderen van (de gevolgen van) pijn bij COPD, beschreef of 
had onderzocht. Opvallende uitkomst was ook het relatief lage aantal onderzoeken 
dat zich specifiek heeft gericht op pijn bij COPD. Bovendien was er sprake van 
een aanzienlijke heterogeniteit van de geïncludeerde studies in studie opzet en de 
gehanteerde methodes, zoals bijvoorbeeld de gebruikte meetinstrumenten en de 
setting van waaruit patiënten werden gerekruteerd.
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Hoofdstuk 7 presenteert de resultaten van een cross-sectionele studie naar de 
prevalentie, de karakteristieken en de relaties van pijn bij patiënten die waren 
geïncludeerd in de GR_COPD studie. Dit onderzoek laat zien dat pijn ook in deze 
specifieke populatie een veel voorkomend en significant symptoom is, met een 
prevalentie van ongeveer 40% en matige tot ernstige scores voor wat betreft de 
ernst van pijn en belemmeringen als gevolg van pijn. Bovendien hadden patiënten 
met pijn in vergelijking met patiënten zonder pijn een algehele hogere symptoom-
last en een slechtere ziekte-specifieke gezondheidsstatus. Een opvallend resultaat 
van dit onderzoek is dat we geen verschil vonden in objectieve maten van activitei-
ten van het dagelijks leven en inspanningscapaciteit, maar dat patiënten met pijn 
weldegelijk meer beperkingen in hun functionele status ervaarden, in vergelijking 
met patiënten zonder pijn. De resultaten van dit onderzoek wijzen er ook op dat 
de behandeling van pijn zeer waarschijnlijk niet optimaal was. Veel patiënten met 
pijn kregen geen pijnmedicatie voorgeschreven, en patiënten met pijnmedicatie 
rapporteerden een matige effect hiervan op hun pijn. Deze resultaten lijken te be-
vestigen dat pijn bij patiënten met COPD vaak niet wordt herkend en onvoldoende 
wordt behandeld. Conclusie van deze studie is dat pijn ook bij deze patiënten vaak 
voorkomt en meer aandacht behoeft. Het standaard in kaart brengen van pijn, voor, 
tijdens en na een exacerbatie, en als onderdeel van het revalidatieprogramma, 
wordt geadviseerd en zal moeten worden geïmplementeerd in de dagelijkse prak-
tijk. Tevens is vervolgonderzoek nodig naar interventies gericht op het verminderen 
van (de gevolgen van) pijn bij deze groep patiënten, welke ook geïntegreerd zou-
den kunnen worden in het GR_COPD zorgpad.
Conclusies en aanbevelingen
Op basis van de resultaten van de studies beschreven in dit proefschrift is onze 
belangrijkste conclusie dat voor oudere patiënten met ernstig COPD, opgenomen 
in het ziekenhuis vanwege een acute exacerbatie, een ziekte-specifiek geriatrisch 
revalidatieprogramma dat revalidatie integreert met palliatieve zorgaspecten (het 
GR_COPD zorgpad) nodig en haalbaar is. Bovendien heeft het GR_COPD zorgpad 
gunstige effecten op de ziekte-specifieke gezondheidsstatus en de exacerbatie-
frequentie. Deze resultaten impliceren dat het GR_COPD zorgpad beschikbaar 
zou moeten zijn voor alle patiënten binnen deze specifieke doelgroep.
Op basis van de uitkomsten van de CCQ in deze specifieke patiënten groep 
wordt het aanbevolen om de CCQ te gebruiken als primaire patiënt-gerelateerde 
uitkomstmaat, zowel in de klinische praktijk als in wetenschappelijk onderzoek.
Vervolgonderzoek moet zich in de eerste plaats richten op de vraag of de huidige 
resultaten ook op de langere termijn te behouden zijn. Daarnaast is het van belang 
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om de kosteneffectiviteit van het GR_COPD zorgpad te onderzoeken. Ook daar-
voor is een langere follow-up periode noodzakelijk.
Vervolgonderzoek is ook nodig om te bepalen wat relevante uitkomstmaten zijn 
met betrekking tot functioneel herstel en participatie voor deze specifieke groep 
patiënten.
Pijn komt veel voor bij patiënten met COPD en heeft belangrijke klinische conse-
quenties. Dit betekent dat pijn bij COPD meer aandacht behoeft, zowel in de klini-
sche praktijk als in wetenschappelijk onderzoek. Gestandaardiseerd assessment 
van de symptoomlast, in alle fasen en stadia van de aandoening, is van belang. 
Onderzoek moet zich richten op de ontwikkeling van een valide en betrouwbaar 
multidimensionaal instrument voor het meten van de symptoomlast van patiënten 
met COPD. Specifieke interventies gericht op optimale symptoomcontrole (zoals 
pijn, vermoeidheid en slapeloosheid), moeten worden ontwikkeld, geëvalueerd en 
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